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9General introduction
Better health care and advances in prevention and treatment of diseases are some of the most 
important reasons that led to increased health, life-expectancy, and quality of life (QoL) of 
the population of >75-year-olds. But much of what we know about the risks and benefits of 
prevention and treatment is based on evidence from trials that usually exclude these patients. 
Most of those excluded have multimorbidity (two and more chronic diseases), polypharmacy 
(5 or more medication daily) or are frail. Frailty as a concept lacks of a standardized way to 
measure, but there is consensus that physical measurements e.g. hand grip strength or mea-
sures of multiple components that reflect more the impact on daily living (i.e. complex health 
problems) both constitute to frailty [1]. Due to the exclusion of these patients from trials, this 
dearth of evidence puts general practitioners (GPs) and other physicians in a difficult situation 
when deciding what treatments are best in old age.
GPs and their older patients must make a number of decisions, including prioritizing health 
care to meet patient needs, choosing the best preventive strategies for cardiovascular disease 
(CVD), and accounting for multimorbidity and polypharmacy. Cardiovascular prevention 
can serve as a typical example of the dilemmas that GPs face. Since the American Heart As-
sociation (AHA) recently updated its hypertension guidelines [2], and reduced blood pressure 
target values from 140 to <130 mmHg also for older patients, there has been heated debate 
[3]. These new treatment goals for hypertension had an immediate and dramatic effect on 
the general population. In the US, for example, the population in need of antihypertensive 
treatment jumped sharply from 32% to 46% [4].
Mrs s wAnts to know her iDeAL systoLiC BLooD Pressure
Mrs S, a 90-year-old woman, is the kind of patient 
that GPs often see (Figure 1). She enters the exami-
nation room slowly, relying on her walker. She has 
multimorbidity and polypharmacy as she is taking 
eight medications including antihypertensives. 
A myocardial infarction a few years ago left her 
too frail to undergo surgery to relieve her lumbar 
spinal stenosis; this is why she uses a walker and is 
in constant pain, which limits her activities in daily 
life. Measured in the office, her systolic blood pres-
sure (SBP) under treatment is 154 mmHg. Earlier 
measurements taken at home were between 145 and 150 mmHg. Mrs S asks her GP if he is 
satisfied with her current blood pressure measurement. Then, the GP starts thinking. What 
would be her ideal blood pressure? And how do we make that determination?
Figure 1. Portrait of Mrs S (symbolic)
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Mrs S is a typical older patient, who would almost certainly have been excluded from the 
hypertension trials that provide evidence for appropriate treatment. The CVD prevention 
guidelines that depend on the results of those trials are not based on data about patients like 
her. When thinking about her optimal blood pressure, it is unsure what will happen if current 
guidelines would be strictly followed, which suggest lowering her SBP to <150 mmHg, or even 
<130 mmHg. Would she benefit from a lower cardiovascular risk? Would lowering her blood 
pressure make her tired or dizzy and lower her QoL, or increase her risk of falling or even 
dying? Would she suffer from a decline in cognitive function or daily functioning?
Current stAte oF knowLeDGe
This section provides background information on polypharmacy and treating hypertension in 
old age and summarizes what we know about the risks and benefits of treating hypertension 
in that population.
Polypharmacy in old age
Polypharmacy is usually defined as taking >5 long-term prescribed drugs [5-12]. The preva-
lence of polypharmacy in all adults has doubled in the last decades, rising from 11% in 1995 
to 21% by 2010 [6]. As people age, the prevalence of polypharmacy increases dramatically 
(Figure 2). In Scotland, prevalence increased from 30% in those aged 60-69 years to almost 
70% in those >80 years. In the Netherlands, prevalence increased to 60% [13]. We see the same 
trend in individuals who take 10 or more medications.
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Figure 2. Increase of polypharmacy by age category. Solid line = 5 and more medications; dashed line = 10 or 
more medications. Adapted from [6].
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Patients are likely to take more and more medication, the older they get. They, their families, 
GPs, and society meet the growing challenge of adapting to the increase in polypharmacy. 
It is therefore highly needed to determine the safety and efficacy of polypharmacy, and to 
find out which patients will benefit from polypharmacy and which will not. Because negative 
consequences of polypharmacy are well described: poor medication adherence, degraded 
physical and social function, worse health outcomes, higher healthcare costs, and lower QoL 
[11, 14, 15].
Polypharmacy has many causes. Notable among them is the tendency to address chronic 
conditions with disease-specific guidelines that do not take into account that a patient is 
multimorbid [6]. These single-disease guidelines may suggest treatment with medication 
without considering drug-drug and drug-disease interactions [16]. Patients who see multiple 
specialists may be prescribed a variety of drugs that GPs do not feel comfortable to reduce 
the dose or stop (also known as deprescribing) [17]. Preventive medication for CVD strongly 
contributes to polypharmacy, since guidelines advise that patients at increased cardiovascular 
risk combine blood pressure lowering medication, cholesterol lowering medication and plate-
let aggregation inhibitors.
Next to having different chronic conditions that attribute to polypharmacy, also treating one 
condition with multiple medications increases the risk to have polypharmacy. Often multiple 
medications are prescribed to lower blood pressure and achieve tight blood pressure control 
in patients with hypertension [3]. In a global cohort study [18], 16% of younger adults, with 
hypertension were prescribed three or more antihypertensive drugs; this rose to 38% for 
patients aged >75. Many of these older patients are also prescribed statins and anticoagulants, 
pushing them over the threshold of polypharmacy [19]. The effort to prevent CVD by lower-
ing blood pressure with polypharmacy is also very expensive. In the UK, CVD preventive 
medication was the most prescribed medication in the general population, making up 30% of 
all prescriptions and 12% of the total primary care prescribing budget in 2016 [16].
Prevalence of hypertension in old age
In the US population, 32% have been diagnosed with hypertension (applying the threshold 
of SBP >140mmHg [20]. A population-based study showed prevalence of hypertension in-
creased from about 60% in <55-year-olds to >80% in >75-year-olds (Figure 3) [21].
Longer lifespans are shifting our definitions of “old”, with many more >75-year-olds and older 
that are the fastest-growing age group. This population will triple in the next 35 years [22], and 
it is very heterogeneous. Some >75-year-olds are very healthy, but many have multimorbidity 
and are frail. Figure 4 describes the WHO framework on ageing, adding functional capacity 
to the dimension of age. While functional capacity is almost equal for all in early life, a gap 
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in functional capacity opens in adult life and increases over the life-course. In old age, this 
gap crosses the disability threshold for some >75-year-olds, while others continue perform at 
higher levels, with little change in their capacity since early life. Though functional capacity 
varies widely in old age, trials and guidelines tend to treat all old people equally. However, 
hypertension is prevalent in >80% in old age regardless of their individual differences in 
functional capacity and their GPs have to decide on the optimal target blood pressure when 
treating hypertension [21].
A Life Course Appr oach to Active 
Ageing
A life course perspective on ageing recognizes 
that older people are not one homogeneous 
group and that individual diversity tends to 
increase with age. Interventions that create 
supportive environments and foster healthy 
choices are important at all stages of life (see 
Figure 4).
As individuals age, noncommunicable diseases 
(NCDs) become the leading causes of morbid-
ity, disability and mortality in all regions of 
the world, including in developing countries, 
as shown in Figures 5 and 6. NCDs, which 
are essentially diseases of later life, are costly 
to individuals, families and the public purse. 
But many NCDs are preventable or can be 
postponed. Failing to prevent or manage the 
growth of NCDs appropriately will result in 
enormous human and social costs that will ab-
sorb a disproportionate amount of resources, 
which could have been used to address the 
health problems of other age groups. 
*Changes in the environment can lower the disability threshold, thus decreasing the number of disabled people in a given com-
munity.
Functional capacity (such as ventilatory capacity, muscular strength, and cardiovascular output) increases in childhood and 
peaks in early adulthood, eventually followed by a decline. The rate of decline, however, is largely determined by factors related to 
adult lifestyle – such as smoking, alcohol consumption, levels of physical activity and diet – as well as external and environmen-
tal factors. The gradient of decline may become so steep as to result in premature disability. However, the acceleration in decline 
Figure 4. Heterogeneity in maintaining functional capacity over the life course [23].
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Figure 3. Percentage of hypertensive participants by age group. Adapted from [21].
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Current evidence on effects of high blood pressure in old age
Hypertension is the main risk factor and preventable cause of CVD. It is responsible for many 
deaths from stroke, myocardial infarction, and other CVDs [24]. It injures blood vessels, so 
atherosclerotic plaques accumulate in the heart, brain, and other arterial beds, impairing 
perfusion of every major organ. When the plaques rupture, they can cause stroke and myo-
cardial infarction. Antihypertensive treatment can prevent these injuries. However, through 
the 1980s this treatment was commonly withheld from old patients (>60 years) because physi-
cians thought hypertension in old age was a healthy adaptation to arteriosclerotic rigidity [25]. 
In the 1990s, after trials proved that treating those over 60 for hypertension reduced stroke 
rates and myocardial infarction [26-28], this paradigm shifted.
We know antihypertensive treatment is effective in patients >60 years. The earliest trials, in 
the 1990s, studied the effect of antihypertensive treatment in >60-year-olds. The SHEP trial 
included almost 5,000 patients with isolated systolic hypertension (>160mmHg) and found 
antihypertensive treatment significantly reduced risk of stroke by 36%, and myocardial infarc-
tion by 27%. SHEP established a trend for lower mortality in the treated group [28]. Two more 
trials, the Swedish STOP trial [29] and the Syst-Eur trial [26], which included 23 European 
countries, found stroke rate and cardiovascular outcomes were similarly lower after treatment.
However, treating hypertension to prevent cardiovascular disease in >75-year-olds is still 
under discussion. The most influential trials on current hypertension guidelines in the past 
decade have been HYVET and SPRINT. In HYVET, 3,845 patients all aged >80 years were 
invited when their baseline SBP without antihypertensive treatment was >160mmHg. The 
intervention targeted an SBP of <150mmHg. HYVET found that antihypertensive treatment 
reduced death from any cause by 21% and a trend in reduction of stroke by 30%. In SPRINT, 
9,361 non-diabetic persons with an SBP of >130mmHg and increased CVD risk were assigned 
to either intensive blood pressure lowering treatment (<120 mmHg) or standard treatment 
(<140mmHg) [30]. The primary outcome (first occurrence of myocardial infraction, stroke, 
acute coronary syndrome, heart failure, or CV-death) was 25% lower in the intensive-
treatment group; all-cause mortality was about 30% lower. For >75-year-olds, the results were 
similar [31].
HYVET and SPRINT strongly suggest that treating >75-year-olds for hypertension is benefi-
cial, but neither trial can be generalized to all patients in this age group because they excluded 
patients with dementia, living in nursing homes or other frail patients with multimorbidity 
[32]. For example, most participants in HYVET were between 80- and 85-years-old, but the 
median follow-up period was only 1.8 years, so HYVET did not provide much evidence about 
patients >85 years [33]. The only evidence for treating those over >85 years with hyperten-
sion has come from population-based cohort studies. Many of these studies raised concern 
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that lowering SBP too far might have negative effects like increasing mortality or accelerating 
cognitive decline [34-44]. However, it is challenging to draw connections between SBP and 
cognitive decline [45]. High SBP in midlife appears to damage cerebral vessels and impair 
brain function [46], but late in life, and especially in frail subjects, there is an association 
between low SBP and higher risk of cognitive decline [47]. If a patient already has vascular 
injuries, these cannot be reversed. In these patients, antihypertensive treatment may disturb 
hemodynamic regulation of the heart and brain, reducing cognitive function [48-53].
A landmark paper by Mosello et al. in 2015 found that in a cohort of cognitively impaired 
patients (mean age 79), lower SBP was associated with faster cognitive decline [40]. Several 
earlier studies made similar observations and later studies confirmed it [34-39, 43]. But Mo-
sello et al. were the first to show that antihypertensive therapy modified these associations: 
low SBP was associated with cognitive decline only in patients being treated for hyperten-
sion. Their study was limited to patients of an outpatient memory clinic, they did not assess 
mortality risk and patient-related outcomes like QoL, and they did not follow up patients 
long enough to detect long-term protective effects of antihypertensive treatment, so they do 
not offer us a strong enough evidence base for developing guidelines for antihypertensive 
treatment in >75-year-olds.
AiM AnD outLine oF this thesis
The general aim of this thesis is to increase the scientific knowledge about the effects of treat-
ing hypertension in >75-year-olds, especially in those with frailty.
This thesis has three aims:
1. To measure the prevalence of polypharmacy in older patients.
2. To test for an association between low SBP and mortality, cognitive function, daily func-
tioning, and QoL in older patients under antihypertensive treatment.
3. To understand the role that frailty plays in GP decisions about treating hypertension in 
old age across countries and see if those differences can be explained by country-specific 
cardiovascular disease burden and life expectancy.
To address these aims, datasets from four study populations are used that include both pa-
tients and GPs. The studies were conducted in Switzerland, the Netherlands, and, in the case 
of the international comparative study, in 29 mainly European countries, Brazil, Israel, and 
New Zealand.
15
General introduction
Polypharmacy – Part of preventive cardiovascular medication
We set out to measure the prevalence of polypharmacy in university primary care settings, to 
assess the association of polypharmacy with specific comorbidities, including cardiovascular 
prevention, and to identify subgroups of patients at higher risk of polypharmacy.
We analysed the Corif dataset, a Swiss retrospective cohort study that contains data of a 
random sample of 1,002 patients collected 2005-2006, from all four university primary care 
clinics (Basel, Geneva, Lausanne, and Zürich). Data were extracted from medical records of 
50- to 80-year-old patients; of those, 67.5% had multimorbidity.
Our results are presented in Chapter 2.
Low sBP under antihypertensive treatment and the effect on outcomes in old age
We tested for an association between low SBP and mortality, cognitive function, daily func-
tioning, and QoL in older patients under antihypertensive treatment. We analysed data from 
two cohort studies (Leiden-85 plus and ISCOPE).
The Leiden 85-plus Study is a population-based, prospective follow-up study of 599 inhab-
itants of the City of Leiden, the Netherlands, who turned 85 between 1997 and 1999. No 
selection criteria other than reaching the age of 85 years were applied. The study team visited 
all participants at home, at baseline, and yearly thereafter, until they turned 90. Each year, 
the team collected information on sociodemographic characteristics. Participants were inter-
viewed face-to-face, and were given extensive cognitive tests, including the Mini-Mental State 
Examination (MMSE). Mortality data were obtained from the municipal registry.
The Integrated Systematic Care for Older Persons (ISCOPE) trial was conducted about 10 
years after the Leiden 85-plus Study between 2009 and 2014 in Leiden, the Netherlands [54]. 
In ISCOPE, general practitioners (GPs) in and around Leiden recruited 1,921 patients aged 
≥75 years. Nurses performed baseline and one-year follow-up measurements to assess baseline 
and outcome measurements on cognitive function, daily functioning and QoL in this cohort.
Using those data, Chapters 3 and 4 describe the consequences of low SBP in old age under 
antihypertensive treatment. Chapter 3 tests the association of low SBP and antihypertensive 
treatment with all-cause mortality and cognitive function from the general population of 
85-year-olds in the Leiden 85-plus Study, who were followed up for five years. Chapter 4 
tests the association of low SBP and antihypertensive treatment with cognitive function, daily 
functioning, and QoL in the ISCOPE study, and includes patients ≥75 years with a one-year 
follow-up. Both studies further stratify their models for frailty and complex health problems.
Chapter 1
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Variation in antihypertensive treatment in old age, according to GPs
We sought to understand the role that frailty plays in GP decisions about treating hyperten-
sion in old age across countries and to see if those differences could be explained by country-
specific cardiovascular disease burden and life expectancy.
The Antihypertensive treatment in Very elderly (ATTENTIVE) Study is a collaborative 
research project. The ATTENTIVE Study enrolled GPs from 29 countries (26 European 
countries, and Brazil, Israel, and New Zealand) between March and July of 2016 [55, 56]. 
The only inclusion criteria for ATTENTIVE was that participants had to be practicing GPs. 
All participants were asked to answer an online survey that contained eight case vignettes of 
old patients (80 years) who consulted their GPs for a routine visit. The case vignettes differed 
in three characteristics: SBP of 140 or 160 mm Hg; CVD present or absent; and frailty (yes 
or no). For each case vignette, GPs were asked to decide if they would start antihypertensive 
treatment.
Chapters 5 and 6 focus on decisions GPs across 29 countries made about starting antihyper-
tensive treatment when they were offered case vignettes of old patients. Chapter 5 describes 
the international variation in GP decisions to start antihypertensive treatment in old age, and 
the ways patient characteristics affected this decision. Chapter 6 describes our comparison of 
these countries, and accounts for country-specific CVD burden and life-expectancy at age 60.
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ABstrACt
Background
Polypharmacy is associated with adverse events and multimorbidity, but data are limited on its 
association with specific comorbidities in primary care settings. We measured the prevalence 
of polypharmacy and inappropriate prescribing and assessed the association of polypharmacy 
with specific comorbidities.
Methods
We did a cross-sectional analysis of 1,002 patients aged 50-80 years followed in Swiss uni-
versity primary care settings. We defined polypharmacy as ≥5 long-term prescribed drugs 
and multimorbidity as ≥2 comorbidities. We used logistic mixed-effects regression to assess 
the association of polypharmacy with the number of comorbidities, multimorbidity, specific 
sets of comorbidities, potentially inappropriate prescribing (PIP) and potential prescribing 
omission (PPO). We used multilevel mixed-effects Poisson regression to assess the association 
of the number of drugs with the same parameters.
results
Patients (mean age 63.5 years, 67.5% ≥2 comorbidities, 37.0% ≥5 drugs) had a mean of 3.9 
(range 0-17) drugs. Age, BMI, multimorbidity, hypertension, diabetes mellitus, chronic kid-
ney disease, and cardiovascular diseases were independently associated with polypharmacy. 
The association was particularly strong for hypertension (OR 8.49, 95%CI 5.25-13.73), mul-
timorbidity (OR 6.14, 95%CI 4.16-9.08), and oldest age (75-80 years: OR 4.73, 95%CI 2.46-
9.10 vs.50-54 years). The prevalence of PPO was 32.2% and PIP was more frequent among 
participants with polypharmacy (9.3% vs. 3.2%, p<0.006).
Conclusions
Polypharmacy is common in university primary care settings, is strongly associated with 
hypertension, diabetes mellitus, chronic kidney disease and cardiovascular diseases, and 
increases potentially inappropriate prescribing. Multimorbid patients should be included in 
further trials for developing adapted guidelines and avoiding inappropriate prescribing.
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introDuCtion
With the increasing life expectancy worldwide, a higher proportion of individuals not only get 
older [1], but are also more likely to develop multiple chronic conditions [2-4]. Most chronic 
conditions (comorbidities) are covered by disease-specific clinical guidelines using a single 
disease framework; this leads physicians to recommend drug treatments for each condition 
separately, which may lead to polypharmacy and drug-drug and drug-disease interactions [5]. 
In addition, to lower the risk of developing future medical conditions, research in preventive 
medicine has uncovered multiple risk factors, particularly in cardiovascular medicine, that 
also need treatment, thus increasing the number of people on regular multiple drug therapy [6, 
7]. Furthermore, patients are often seen by multiple specialist physicians who prescribe drugs 
that primary care physicians are often reluctant to stop [8]. Polypharmacy, commonly defined 
as the concurrent use of 5 or more long-term prescribed drugs, is frequent and increasing 
in prevalence [4, 7, 9-14]. The use of multiple drugs is associated with potential unforeseen 
medical consequences, such as adverse drug events, drug monitoring errors, unplanned 
hospitalizations, and sometimes fatal outcomes [5, 15-19]. The risk of drug-drug interaction 
increases with the number of prescribed drugs: 13% of patients on 2 concurrent drugs experi-
ence drug-drug interaction, but this risk rises to 38% for those on 5 drugs and 82% for those on 
≥7 drugs [20]. Moreover, polypharmacy is associated with poor adherence, lower physical and 
social function, higher healthcare costs, and decreased quality of life [13, 16, 19]. Additionally, 
inappropriate prescribing, including both over- (potentially inappropriate prescribing [PIP]) 
and underprescription (potential prescribing omission [PPO]) is also associated with poor 
outcome, such as increase in adverse drug events [21]. While polypharmacy is relatively well 
defined, the definition of multimorbidity is not consistent in the literature; a common defini-
tion is 2 or more comorbidities [3].
Prior epidemiological studies conducted in several other countries found a prevalence of 
polypharmacy ranging from 12 to 48% in patients aged 50 years or older [9, 10, 13, 14, 22], 
but data remain limited on associations between polypharmacy and specific comorbidities, 
like cardiovascular ones [13]. In Switzerland, a country with universal healthcare coverage, 
only one study assessed the prevalence of polypharmacy and PIP, based on claims data from a 
health insurer company without clinical information on diagnosis. Except for this study, data 
on PIP and PPO in Switzerland are limited, with studies including only hospitalized geriatric 
[23] or mentally-ill patients [24].
We therefore aimed to measure the prevalence of polypharmacy, PIP and PPO in university 
primary care settings, and to assess the association of polypharmacy with specific comorbidi-
ties, in order to uncover subgroups of patients at higher risk of polypharmacy.
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MAteriAL AnD MethoDs
study population
We abstracted medical records from 1002 randomly selected patients followed for at least one 
year by primary care physicians in all but one Swiss university primary care clinics (Basel, 
Geneva, Lausanne and Zurich) in a retrospective cohort study, as previously described [25]. 
For this analysis, we used cross-sectional data of the baseline visit. These community-dwelling 
patients were randomly identified from electronic administrative data of all patients aged 50 
to 80 years and followed in 2005-2006. The selection was limited to this age group to ensure 
a high prevalence of cardiovascular risk factors and other conditions that are targeted by 
preventive care and medical treatment. About 90% of the patients were cared for by residents 
in general internal medicine supervised by senior physicians. The remaining 10% were cared 
by senior physicians directly.
We initially identified 1889 patients, among which 54 charts could not be found, probably 
because the patients had left the clinic for another ambulatory practice. We excluded 125 
patients because they had no outpatient visit to a primary care physician, and 117 that were 
followed only in a specialized care setting during this period. In order to ensure adequate time 
and information to assess preventive care, we excluded another 591 patients who had less than 
one-year follow-up in the university primary care setting during the review period.
Definitions of polypharmacy and multimorbidity
We recorded only long-term prescribed drugs at the first visit of the review period; prescrip-
tions for acute conditions, like antibiotics or temporary painkillers, were not taken into 
account. Similarly, to previous studies, we defined polypharmacy as 5 or more long-term 
prescribed drugs [9, 12, 14, 26, 27].
We found no consistent definition to select comorbidities in prior scientific literature [28]. 
The length of comorbidity lists ranged from 7 to 46 different comorbidities [13, 29-31]. We 
therefore established a new list including 17 comorbidities (Appendix table 1), as previously 
described [32], based on a large study by Higashi et al. [33] and on the Charlson index [34]. 
We added psychiatric conditions (e.g. schizophrenia, depression) as an important comorbid-
ity [35], based on a consensus of the above mentioned references and between the authors. 
Additionally, we defined specific subgroups of comorbidities: 1) cardiovascular diseases: his-
tory of transient ischemic attack, cerebral vascular accident, coronary artery disease, angina, 
myocardial infarction, congestive heart failure and/or peripheral vascular disease; 2) chronic 
pulmonary diseases: chronic obstructive pulmonary disease, asthma, sleep apnea syndrome, 
sarcoidosis, pulmonary hypertension, bronchiectases, interstitial pulmonary disease and/or 
global respiratory insufficiency; 3) psychiatric diseases: depression, bipolar disorder, psycho-
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sis, schizophrenia and/or pervasive development disorder. For sensitivity analyses, we used 
subcategories of cardiovascular disease (cerebral vascular disease, ischemic heart disease, 
heart failure). As did others [3, 29], we defined multimorbidity as the presence of 2 or more 
of these comorbidities [32], but also assessed the number of comorbidities as a count variable.
Potentially inappropriate prescribing and potentially prescribing omission
PIP and PPO were measured using the Screening Tool of Older People’s Prescriptions (STOPP) 
and the Screening Tool to Alert doctors to Right Treatment (START) criteria [36]. As the 
criteria were developed for individuals aged ≥65 years, we applied them to this subgroup of 
our patients, and then performed a sensitivity analysis including our whole population. As we 
had detailed clinical information on cardiovascular disease and cardiovascular risk factors, 
we only applied the STOPP/START criteria for cardiovascular and anti-diabetic drugs when 
all detailed clinical information was available. Therefore, we applied 7 STOPP (i.e. A3, B3, B6, 
C1, C7, J1, J2) and 4 START (i.e. A3, A4, A5, A7) criteria related to these drugs. One author 
(CEA) checked the whole database for PIP and PPO. A 5% random sample was checked for 
accuracy by a second author (SS). The agreement between the 2 reviewers was 98.0% and the 
2.0% disagreement was solved by discussion. PIP and PPO were defined as the percentage of 
patients with at least 1 unfulfilled STOPP and START criteria, respectively.
statistical Analyses
We counted the number of drugs as a whole (0, 1, 2, 3, 4, 5, 6, 7, 8, 9, ≥10), as well as stratified 
by 5-year age groups and by the number of comorbidities (0, 1, 2, 3-4, 5-6, ≥7). We compared 
baseline characteristics between patients with and those without polypharmacy using t-test 
and chi-square test where appropriate.
We used a logistic mixed-effects regression model, crude and adjusted for age, gender, 
civil status and occupation, to assess the association of polypharmacy with the number of 
comorbidities, presence of multimorbidity, smoking status, body mass index (BMI), specific 
comorbidities, subgroups of comorbidities (psychiatric diseases, dementia, cardiovascular 
diseases, diabetes mellitus, hypertension, chronic pulmonary diseases, cancer and chronic 
kidney disease), PIP and PPO. Results were presented as odds ratio (OR) with 95% confidence 
intervals (CI).
We used a multilevel mixed-effects Poisson regression model, crude and adjusted for the same 
parameters, to assess the association between the number of drugs as a count variable with 
the same variables as in the previous model. Results were presented as incidence rate ratios 
(IRR) with 95% CI.
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We used the mixed-effects models to account for the clustering of patients within the dif-
ferent treating physicians and treatment centres. We performed all statistical analyses using 
STATA release 13.1 (StataCorp, College Station, TX). All p-values were 2-sided at a 0.05 level 
of significance.
resuLts
Patients characteristics
Table 1 shows baseline characteristics of the study population by presence or absence of poly-
pharmacy. Mean age (standard deviation [SD]) was 63.5 (8.3) years and 44.4% were women. 
Most patients (55.9%) were Swiss and 37.9% were retired. The majority (67.5%) of patients 
had multimorbidity and the mean number of comorbidities was 2.6, ranging from 0 to 10. 
Almost every patient (91.1%) had at least 1 drug, 37.0% had polypharmacy and 4.1% had at 
least 10 drugs. The maximum number of different drugs taken by a single patient was 17.
table 1. Patient characteristics: overall and by presence or absence of polypharmacy.
Characteristics overall (n=1,002)a
0-4 drugs 
(n=631, 63.0%)a
≥5 drugs
(n=371, 37.0%)a p-value
b
Age, mean (SD) 63.5 (8.3) 62.2 (8.1) 65.7 (8.0) <0.001
Age groups, n (% per column)
50-54 197 (19.7) 156 (24.7) 41 (11.0) <0.001
55-59 193 (19.3) 125 (19.8) 68 (18.3) <0.001
60-64 186 (18.6) 118 (18.7) 68 (18.3) <0.001
65-69 183 (18.3) 106 (16.8) 77 (20.8) 0.03
70-74 128 (12.3) 74 (11.7) 54 (14.6) 0.08
75-80 115 (11.5) 52 (8.2) 63 (17.0) 0.31
Women, n (% per column) 445 (44.4) 297 (47.1) 148 (39.9) 0.03
Civil status, n (% per column)
married 506 (51.0) 314 (50.3) 192 (52.0) <0.001
single 151 (15.2) 101 (16.2) 50 (13.6) <0.001
divorced / separated 233 (23.5) 150 (24.0) 83 (22.5) <0.001
widow/-er 103 (10.4) 59 (9.5) 44 (11.9) 0.14
Occupation, n (% per column)
Employed 285 (29.0) 225 (36.3) 60 (16.6) <0.001
Social aid 109 (11.1) 60 (9.7) 49 (13.5) 0.29
Unemployed 101 (10.3) 51 (8.2) 50 (13.8) 0.92
At home or in education 115 (11.7) 79 (12.7) 36 (9.9) <0.001
Retired 372 (37.9) 205 (33.1) 167 (46.1) 0.049
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table 1. Patient characteristics: overall and by presence or absence of polypharmacy. (continued)
Characteristics overall (n=1,002)a
0-4 drugs 
(n=631, 63.0%)a
≥5 drugs
(n=371, 37.0%)a p-value
b
Legal status, n (% per column)
Swiss 560 (55.9) 362 (59.4) 198 (55.0) <0.001
Resident permit 325 (32.4) 183 (30.2) 142 (39.4) 0.02
Forced migrant 81 (8.1) 61 (10.1) 20 (5.6) 0.002
Number of outpatients visits over 2 years
Median (interquartile range) 10 (7-15) 9 (6-13) 12 (9-17) <0.001
Range, minimum-maximum 2-63 2-41 3-63
Never smoked, n (% per column) 283 (41.0) 194 (44.3) 89 (35.3) 0.02
BMI, mean (SD) 28.8 (5.6) 27.9 (5.3) 30.4 (5.8) <0.001
Comorbiditiesc
mean (SD) 2.6 (1.9) 1.9 (1.4) 3.7 (2.0) <0.001
≥2 comorbidities, n (% per column) 676 (67.5) 346 (54.8) 330 (89.0) <0.001
Specific subgroupsd, n (% per column)
Psychiatric diseasese 294 (29.3) 180 (28.5) 114 (30.7) 0.46
Dementia 24 (2.4) 14 (2.2) 10 (2.7) 0.63
Cardiovascular diseasesf 364 (36.3) 154 (24.4) 210 (56.6) <0.001
Diabetes mellitus 292 (29.1) 113 (17.9) 179 (48.2) <0.001
Hypertension 753 (75.1) 406 (64.3) 347 (93.5) <0.001
Chronic pulmonary diseasesg 261 (26.1) 148 (23.4) 113 (30.5) 0.02
Cancer 142 (14.2) 84 (13.3) 58 (15.6) 0.31
Chronic kidney disease 167 (16.7) 61 (9.7) 106 (28.6) <0.001
Inappropriate prescribing
Patients aged ≥65 yearsa
PIP, n (% per column) 25 (5.6) 7 (3.0) 18 (9.3) 0.006
PPO, n (% per column) 137 (32.2) 80 (34.5) 57 (29.4) 0.26
Whole population
PIP, n (% per column) 67 (6.7) 23 (3.7) 44 (11.9) <0.001
PPO, n (% per column) 275 (27.5) 176 (28.0) 98 (26.4) 0.56
Abbreviations: PIP, potentially inappropriate prescribing; PPO, potentially prescribing omission; SD, standard 
deviation; STOPP, Screening Tool of Older People’s Prescriptions; START, Screening Tool to Alert doctors to 
Right Treatment.
a  For the subset of patients aged ≥65 years that were applied the STOPP/START criteria: total n was 426, with 
194 (45.6% with polypharmacy and 232 (54.5%) without polypharmacy.
b  p-value for comparison between patients with and without polypharmacy.
c  list of 17 comorbidities listed in Appendix 1, full description in [32].
d  record of ever having the listed comorbidity
e  depression, bipolar disorder, psychosis, schizophrenia, pervasive development disorder.
f  history of transient ischemic attack, cerebral vascular accident, coronary artery disease, angina, myocardial 
infarction, congestive heart failure or peripheral vascular disease.
g  chronic obstructive pulmonary disease, asthma, sleep apnea syndrome, sarcoidosis, pulmonary hypertension, 
bronchiectases, interstitial pulmonary disease or global respiratory insufficiency.
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The association between polypharmacy, number of drugs and age
Figure 1 (top) shows the percentage of patients on a particular number of drugs according to 
age group. Patients with polypharmacy were significantly older than patients on less than 5 
drugs (p<0.0001, Table 1). The prevalence of polypharmacy was 20.8% (41/197) in the young-
est age group (50-54 years), 45.6% (194/426) in the patients aged 65 years or older, and 54.8% 
(63/115) in the oldest age group (75-80 years). The oldest age group had the highest odds for 
polypharmacy compared to the youngest age group in adjusted analysis (OR 4.73, 95% CI 
2.46-9.10, Table 2). In the highest age group, the number of drugs was 29% higher than in the 
lowest age group (IRR 1.29, 95% CI 1.07-1.56, Table 3).
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Figure 1. Percentage of patients in ambulatory medicine receiving a particular number of drugs (0 to ≥10), 
stratified by a) age groups; b) number of comorbidities (0, 1, 2, 3-4, 5-6, ≥7), out of a list of 17 selected comor-
bidities, based on a large study by Higashi et al. [33] and the Charlson index [34], as previously defined [32].
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table 2. Multivariate mixed-effects logistic regression analysis for the association between patient characteris-
tics and polypharmacy.
Variable
Polypharmacy (≥5 drugs)
or 95% Ci
Age (years)a
50-54 (reference) 1 -
55-59 2.14 1.31-3.51
60-64 2.16 1.30-3.59
65-69 2.71 1.52-4.84
70-74 2.78 1.46-5.27
75-80 4.73 2.46-9.10
Men 1.28 0.93-1.75
Civil status
married (reference) 1 -
single 0.79 0.52-1.21
divorced / separated 0.95 0.67-1.36
widow/-er 1.01 0.63-1.61
Occupation
Employed (reference) 1 -
Social aid 2.91 1.76-4.81
Unemployed 3.89 2.29-6.61
At home/in education 1.37 0.77-2.44
Retired 1.74 1.07-2.82
Never smoked 0.76 0.52-1.11
BMI (kg/m2), per unit 1.12 1.08-1.16
Comorbiditiesb
Per each comorbidity 1.86 1.68-2.07
≥2 comorbidities versus 0-1 comorbidity 6.14 4.16-9.08
Specific subgroupsc
Psychiatric diseasesd 1.14 0.83-1.59
Dementia 0.83 0.35-2.01
Cardiovascular diseasese 3.74 2.76-5.08
Diabetes mellitus 4.47 3.23-6.20
Hypertension 8.49 5.25-13.73
Chronic pulmonary diseasesf 1.29 0.94-1.76
Cancer 0.97 0.65-1.45
Chronic kidney disease 3.96 2.71-5.80
Inappropriate prescribing
Patients aged ≥65 years
Potentially inappropriate prescription 3.72 1.47-9.44
Potentially prescribing omission 0.75 0.49-1.15
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The association of polypharmacy, number of drugs and comorbidities
The number of drugs increased significantly with the number of comorbidities. In patients 
with 4 or more comorbidities, all but 2 patients (9.2%) had at least 1 drug. Among the patients 
with at least 7 comorbidities, 84.9% had polypharmacy (Figure 1 bottom). This association re-
mained significant in multivariate analyses; even after adjustment for demographics, patients 
with multimorbidity had a far higher odds for polypharmacy (OR 6.14, 95% CI 4.16-9.08, 
Table 2) and an increased number of drugs (IRR 1.91, 95% CI 1.72-2.13, Table 3) compared to 
patients without multimorbidity. For each additional comorbidity, patients were more likely 
to have more prescribed drugs (IRR 1.18, 95% CI 1.15-1.20).
Hypertension had the strongest association with polypharmacy (OR 8.49, 95% CI 5.25-13.73) 
and the number of drugs (IRR 2.10, 95% CI 1.87-2.36). Cardiovascular diseases, diabetes mel-
litus, BMI and chronic kidney disease were also independently associated with polypharmacy 
and the number of drugs (Tables 2 and 3). Chronic pulmonary diseases were weakly associated 
with the number of drugs, but not with polypharmacy (Tables 2 and 3). Psychiatric diseases, 
dementia and cancer were associated neither with polypharmacy nor with the number of 
drugs. The OR (95%CI) for polypharmacy was 2.63 (1.56-4.46) in patients with cerebral vas-
cular disease, 3.96 (2.75-5.71) in patients with ischemic heart disease, and 14.32 (5.75-35.66) 
in patients with heart failure.
table 2. Multivariate mixed-effects logistic regression analysis for the association between patient characteris-
tics and polypharmacy. (continued)
Variable
Polypharmacy (≥5 drugs)
or 95% Ci
Whole population
Potentially inappropriate prescription 3.64 2.07-6.39
Potentially prescribing omission 0.81 0.59-1.11
The model was adjusted for age, gender, civil status, occupation. Random-effects model was used to account 
for treating physician.
Some statistically significant variables in Table 1 lost significance because of the mixed-effects analysis.
Abbreviations: BMI, body mass index; CI, confidence interval; OR, odds ratio.
a  for univariate and multivariate analysis p-value for trend <0.001.
b  list of 17 comorbidities listed in Appendix 1, full description in [32].
c  record of ever having the listed comorbidity.
d  depression, bipolar disorder, psychosis, schizophrenia, pervasive development disorder.
e  history of transient ischemic attack, cerebral vascular accident, coronary artery disease, angina, myocardial 
infarction, congestive heart failure or peripheral vascular disease.
f  chronic obstructive pulmonary disease, asthma, sleep apnea syndrome, sarcoidosis, pulmonary hypertension, 
bronchiectases, interstitial pulmonary disease or global respiratory insufficiency.
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table 3. Multivariate categorical mixed-effects regression analysis for the association with number of drugs as 
a count variable.
Variable
number of drugs (count variable)
incident rate ratio 95% Ci
Age (years)
50-54 (reference) 1 -
55-59 1.27 1.11-1.45
60-64 1.24 1.07-1.44
65-69 1.30 1.10-1.53
70-74 1.29 1.09-1.53
75-80 1.29 1.07-1.56
Male 1.11 1.01-1.22
Civil status
married (reference) 1 -
single 0.94 0.81-1.08
divorced / separated 0.97 0.86-1.08
widow/-er 1.05 0.92-1.19
Occupation
Employed (reference) 1 -
Social aid 1.55 1.30-1.86
Unemployed 1.60 1.37-1.87
At home/in education 1.27 1.07-1.51
Retired 1.37 1.18-1.58
Never smoked 0.91 0.81-1.03
BMI (kg/m2), per unit 1.03 1.02-1.04
Comorbiditiesa
Each comorbidity 1.18 1.15-1.20
≥2 comorbidities versus 0-1 comorbidity 1.91 1.72-2.13
Specific subgroupsb
Psychiatric diseasec 1.11 1.00-1.23
Dementia 1.11 0.85-1.46
Cardiovascular diseased 1.48 1.35-1.63
Diabetes mellitus 1.58 1.45-1.72
Hypertension 2.10 1.87-2.36
Chronic pulmonary diseasee 1.15 1.04-1.26
Cancer 1.01 0.89-1.14
Chronic kidney disease 1.52 1.37-1.69
Inappropriate prescribing
Patients aged ≥65 years
Potentially inappropriate prescription 1.35 1.12-1.64
Potentially prescribing omission 0.94 0.83-1.06
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Polypharmacy, number of drugs and other clinical variables
Being employed was associated with a lower number of drugs when compared with other 
social status (on social aid, unemployed, at home, in education, or retired), and with a lower 
prevalence of polypharmacy when compared with being on social aid or unemployed (Tables 
2 and 3). These associations were less strong after adjusting for the number of comorbidities 
(data not shown). Civil status was associated neither with polypharmacy nor with the number 
of drugs. Finally, male gender was only slightly associated with the number of drugs, but not 
with polypharmacy (Tables 2 and 3).
Potentially inappropriate prescribing and potentially prescribing omission
Table 4 describes the prevalence of each STOPP/START criterion in patients aged ≥65 years 
and in the whole patient population. In patients aged ≥65 years, the prevalence of PIP was 
5.9%; it was higher among patients with polypharmacy (9.3% versus 3.0% in those without, 
p=0.006, Table 1) and strongly associated with polypharmacy (OR 3.72, 95% CI 1.47-9.44, 
Table 2) and with the number of drugs (IRR 1.35, 95% CI 1.12-1.64, Table 3). Almost one third 
(32.2%) of the patients had PPO. PPO was associated neither with polypharmacy nor with the 
number of drugs (Tables 2 and 3). Forty-eight patients had more than 1 PPO. Omitting anti-
platelet (START criterion A3) and statin (START criterion A5) therapies with a documented 
history of coronary, cerebral, or peripheral vascular disease were the 2 most prevalent PPO, 
accounting for 70.7% of the PPOs. We found similar results in the whole study population 
(Tables 2, 3 and 4).
table 3. Multivariate categorical mixed-effects regression analysis for the association with number of drugs as 
a count variable. (continued)
Variable
number of drugs (count variable)
incident rate ratio 95% Ci
Whole population
Potentially inappropriate prescription 1.44 1.26-1.64
Potentially prescribing omission 0.90 0.81-1.00
The model was adjusted for age, gender, civil status, occupation. Random-effects model was used to account 
for treating physician.
Some statistically significant variables in Table 1 lost significance because of the mixed-effects analysis.
Abbreviations: BMI, body mass index; CI, confidence interval.
a  list of 17 comorbidities listed in Appendix 1, full description in [32].
b  record of ever having the listed comorbidity.
c  depression, bipolar disorder, psychosis, schizophrenia, pervasive development disorder.
d  history of transient ischemic attack, cerebral vascular accident, coronary artery disease, angina, myocardial 
infarction, congestive heart failure or peripheral vascular disease.
e  chronic obstructive pulmonary disease, asthma, sleep apnea syndrome, sarcoidosis, pulmonary hypertension, 
bronchiectases, interstitial pulmonary disease or global respiratory insufficiency.
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DisCussion
In this random sample of primary care patients aged 50-80 years, we found that 37% had poly-
pharmacy, and 4% received 10 drugs or more. The prevalence of PIP was significantly higher 
among patients with polypharmacy. Multimorbidity, age, and specific comorbidities, such 
as hypertension, diabetes mellitus, chronic kidney disease and cardiovascular diseases, were 
associated with polypharmacy, while other subgroups of comorbidities (psychiatric diseases, 
dementia, chronic pulmonary diseases, cancer) were not. The association was particularly 
strong for hypertension.
The prevalence of polypharmacy in our study was consistent with prior epidemiological studies 
conducted in other high income countries in patients aged 50 years or older: a large Swedish 
study found a prevalence of polypharmacy of 12-38% in the age group 50-79 years [9], while it 
ranged from 13 to 48% for the same age range in a study using electronic primary care records 
in Scotland [13], and was 29% in patients aged 57-85 years in the USA [14]. When focusing on 
table 4. Number of patients with unfulfilled STOPP/START criteria.
Patients
≥65 years, 
(n=426)
All patients 
(n=1,002)
stoPP criteria
A3. Any duplicate drug class prescription e.g. two concurrent NSAIDs, SSRIs, 
loop diuretics, ACE inhibitors, anticoagulants
5 (1.2) 7 (0.7)
B3. Beta-blocker in combination with verapamil or diltiazem 1 (0.2) 4 (0.4)
B6. Loop diuretic as first-line treatment for hypertension 1 (0.2) 4 (0.4)
C1. Long-term aspirin at doses greater than 160mg per day 8 (1.9) 17 (1.7)
C7. Ticlopidine in any circumstances 0 (0.0) 0 (0.0)
J1. Sulphonylureas with a long duration of action with type 2 diabetes mellitus 12 (2.8) 37 (3.7)
J2. Thiazolidenediones in patients with documented heart failure 0 (0.0) 0 (0.0)
stArt criteria
A3. Antiplatelet therapy (aspirin or clopidogrel or prasugrel or ticagrelor) with 
a documented history of coronary, cerebral or peripheral vascular disease
63 (14.8) 129 (12.9)
A4. Antihypertensive therapy where systolic blood pressure consistently >160 
mmHg and/or diastolic blood pressure consistently >90 mmHg; if systolic 
blood pressure >140 mmHg and /or diastolic blood pressure >90 mmHg, if 
diabetic
15 (3.5) 53 (5.3)
A5. Statin therapy with a documented history of coronary, cerebral or 
peripheral vascular disease, unless the patient’s status is end-of-life or age is 
>85 years.
77 (18.1) 153 (15.3)
A7. Beta-blocker with ischaemic heart disease. 43 (10.1) 72 (7.2)
Abbreviations: STOPP, Screening Tool of Older People’s Prescriptions; START, Screening Tool to Alert doctors 
to Right Treatment. Data are presented as number (%) of patients.
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patients aged 65 years or older, the prevalence of polypharmacy in our study (46%) was also 
consistent with previous data from an Italian community-dwelling population (46%) [22].
The strong association of multimorbidity and the number of comorbidities with polyphar-
macy and the number of drugs is consistent with previous data [13, 14, 31]. This may reflect 
the disease-specific guidelines that are still usually applied for initiating drug treatments. 
However, patients with multimorbidity are often excluded from, and less than 5% explicitly 
included in randomized controlled trials on which these recommendations are based [37]; 
thus, applying them to these patients may be inappropriate [19, 38]. The strong association 
between PIP and polypharmacy is consistent with previous data using the same criteria 
for PIP [23]. This observation highlights the importance to reconsider each prescription in 
patients receiving polypharmacy. For this purpose, the STOPP/START criteria may help [36, 
39]; however, as the application of the whole criteria set is time-consuming and therefore 
difficult to implement in everyday clinical practice, software solutions are under development. 
Finally, physician’s clinical judgment and shared decision making are central in the process of 
prescription.
The United Kingdom Prospective Diabetes Study (UKPDS) in patients with type 2 diabetes 
showed that 29% of the patients needed at least 3 different drugs to reach a blood pressure 
target of <150/85mmHg [40], while the recommended goal in this population is far lower 
(<130/80mmHg) [41]. Additionally, because hypertension, diabetes mellitus and chronic kid-
ney disease are strongly related to cardiovascular diseases, patients with these comorbidities 
often receive additional drugs recommended in both primary and secondary prevention (e.g. 
aspirin, statins) [19, 42-44]. The association of these cardiovascular risk factors and cardio-
vascular diseases with polypharmacy is consistent with previous data [13, 45]. Interestingly, 
we found a stronger association of polypharmacy with hypertension than with cardiovascular 
disease. The interpretation of this finding is limited by our broad classification of cardiovas-
cular disease, which was associated with some heterogeneity (e.g. stronger association of 
polypharmacy with heart failure than with stroke).
Surprisingly, we found no association between polypharmacy and psychiatric disorders. This 
probably reflects the reality of patients cared in ambulatory general internal medicine. Psy-
chiatric conditions that are mostly managed with drugs (e.g. schizophrenia) [46] were indeed 
rather rare (6% of the patients having a psychiatric condition in our study had schizophrenia), 
while more prevalent conditions like personality disorder (25% of the patients having a psy-
chiatric condition in our study) are often managed without any drug as first line therapy. On 
the other hand, patients followed in specialized psychiatric settings may have more severe 
conditions needing multiple medications, thus polypharmacy may be more prevalent among 
them. We also found no association with dementia, but our study included only 24 patients 
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with this condition. Preventive drugs might have been discontinued in these patients with 
formally diagnosed dementia, as dementia is associated with shortened life expectancy and 
decreased quality of life [47].
In our study, there was no significant association between cancer and polypharmacy, which 
is consistent with the study by Payne et al. (12) that found a similar mean number of drugs 
among this subgroup of patients (4 drugs). On the opposite, a review of previous studies in 
patients with advanced cancer showed a high prevalence of polypharmacy among them [48]. 
This discrepancy is probably due to different settings (in-hospital versus ambulatory) and 
study population (advanced versus not advanced cancer).
Patients who were unemployed, receiving social aid, at home, in education or retired, were 
prescribed a higher number of drugs than patients that were employed. Interestingly, this as-
sociation was stronger for patients unemployed or receiving social aid than for patients being 
at home, in education or retired. This finding may be partially explained by a higher number 
of comorbidities, as the association of occupation status and polypharmacy was weakened 
by adjusting for the number of comorbidities. This is consistent with data showing a higher 
prevalence of multimorbidity in the most deprived population, among which multimorbidity 
would occur on average 10 to 15 years earlier [3]. However, as this association didn’t disappear 
after adjustment for the number of comorbidities, we can hypothesize additional explanations 
for this finding: deprived patients may have lower income and/or education, which has been 
associated with polypharmacy [10, 13, 49]; they may also more likely consult with a prescrip-
tion purpose, as suggested previously [49].
Although the community-dwelling individuals in our study differed from older frail nursing 
home residents, those with multimorbidity are at higher risk of polypharmacy as they become 
older. Although the patterns of drugs are different in nursing home and in the community, e.g. 
with a higher number of pain-killers and psychotropic drugs [50-52], optimizing medication 
in the community-dwelling individuals is also central in order to optimize care and reduce 
polypharmacy.
There are some limitations to our study. First, our results are based on retrospective medical 
chart review, with potential underreporting; however, a previous study comparing process-
based quality scores using standardized patients, clinical vignettes and abstraction of medical 
charts found that measurement of quality of care using abstraction of medical charts was 
about 5% lower than using clinical vignettes and 10% lower than using standardized patients 
[53]. Second, we restricted our analyses to patients aged 50 to 80 years and can therefore 
not draw conclusions for younger or older patients. Third, as we could apply a subset of the 
STOPP/START criteria only, we could not compare the prevalence of PIP and PPO with data 
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of other previous studies. Fourth, we conducted only a cross-sectional analysis without as-
sessing the impact of polypharmacy and STOPP/START criteria on patient’s related health 
outcomes Finally, our results may not be totally generalizable to primary care settings in 
general for several reasons: we could not assess other parameters of socioeconomic status, 
such as income and education, because of the lack of reliable information on these variables in 
the medical charts, and, in Switzerland, there are generally more forced migrants and patients 
with lower socioeconomic status in university primary care settings, which has been associ-
ated with an earlier occurrence of multimorbidity [3]. The prevalence of some comorbidities, 
like hypertension, may also be higher in these settings [32]. Furthermore, almost all patients 
were cared by residents at the end of their postgraduate training, who may be more adherent 
to medical guidelines [25].
Conclusions
In this random sample of primary care patients, we found that polypharmacy was highly 
prevalent in university primary care settings and strongly associated with age, multimorbidity, 
the number of comorbidities, and specific comorbidities, particularly hypertension, diabetes 
mellitus, chronic kidney disease, and cardiovascular diseases. This is clinically relevant, given 
the association of polypharmacy with adverse consequences, particularly in patients with 
multimorbidity [5]. Given that the prevalence of polypharmacy and multimorbidity will very 
probably further increase in the coming years, and that PIP is associated with polypharmacy, 
further randomized trials including multimorbid patients are needed in order to develop 
guidelines adapted to this particular population to help avoiding PIP and adverse drug events. 
As polypharmacy, the risk for drug-drug interactions and their associated negative conse-
quences are significantly increased among the oldest old patients because of frailty and their 
higher number of comorbidities [54], future studies should also plan to include oldest old 
patients, i.e. those aged more than 80 years. Waiting for any new specific recommendation 
for multimorbid elderly, specific indications for each drug should be very carefully reviewed, 
particularly in those patients. In the meantime, we suggest that the process of prescription 
relies on the use of criteria developed to avoid PIP and PPO (e.g. the STOPP/START criteria 
[36, 39]), accounting for physician’s clinical judgment, estimated patient’s life expectancy and 
patient’s preferences.
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Appendix table 1. List of 17 selected comorbiditiesa in ambulatory medicine
Condition Prevalence, n (%)
Hypertension 743 (75.2)
Diabetes mellitus 292 (29.1)
COPD, Asthma 261 (26.1)
Depression 197 (19.7)
Coronary artery diseaseb 190 (19.0)
Renal insufficiencec 167 (16.7)
Cancerd 142 (14.2)
Other psychiatric diseasese 97 (9.7)
Stroke (or carotid endarterectomy, hemiplegia) 86 (8.6)
Liver disease (cirrhosis, hepatitis B/C) 63 (6.3)
Gastrointestinal diseasef 52 (5.2)
Connective tissue disease 51 (5.1)
Heart failure 47 (4.7)
Peripheral vascular disease (angioplasty, foot amputation) 37 (3.7)
Major neurologic diseaseg 29 (2.9)
Dementia 24 (2.4)
AIDS 13 (1.3)
a  Based on previous studies [32] and the Charlson index [34].
b  Coronary artery disease, angina, myocardial infarction, other coronary heart disease, coronary angioplasty, 
coronary bypass
c  End-stage renal disease, dialysis, kidney transplant, diabetic nephropathy or hypertensive nephropathy
d  Solid non-metastatic, solid metastatic cancer, leukemia, lymphoma
e  Bipolar disorder, psychosis, schizophrenia, pervasive developmental disorder, spastic paresia
f  Gastric ulcus or pancreatitis or Crohn’s disease or ulcerative colitis
g  Multiple sclerosis, epilepsy,medullary compression, Parkinson, Polio or spastic paresis
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ABstrACt
Background
The appropriateness of lowering systolic blood pressure remains controversial in the oldest-
old. We tested whether systolic blood pressure is associated with all-cause mortality and 
change in cognitive function for patients prescribed antihypertensive treatment and those 
without treatment.
Methods
We studied participants in the population-based Leiden 85-plus cohort study. Baseline systolic 
blood pressure and use of antihypertensive treatment were predictors; all-cause mortality and 
change in cognitive function measured using the Mini-Mental State Examination were the 
outcomes. Grip strength was measured as a proxy for physical frailty. We used Cox propor-
tional hazards and mixed-effects linear regression models to analyse the relationship between 
systolic blood pressure and both time to death and change in cognitive function. In sensitivity 
analyses we excluded deaths within one year and restricted analyses to participants without a 
history of cardiovascular disease.
results
Of 570 participants, 249 (44%) were prescribed antihypertensive therapy. All-cause mortality 
was higher in participants with lower blood pressure prescribed antihypertensive treatment 
(HR 1.29 per 10mmHg lower systolic blood pressure, 95% CI 1.15-1.46, p<0.001). Participants 
taking antihypertensives showed an association between accelerated cognitive decline and 
lower blood pressure (annual mean change -0.35 points per 10mmHg lower systolic blood 
pressure, 95% CI -0.60, -0.11, p=0.004); decline in cognition was more rapid in those with 
lower handgrip strength. In participants not prescribed antihypertensive treatment, no 
significant associations were seen between blood pressure and either mortality or cognitive 
decline.
Conclusions
Lower systolic blood pressure in the oldest-old taking antihypertensives was associated with 
higher mortality and faster decline in cognitive function.
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introDuCtion
Hypertension is the most important preventable cause of cardiovascular disease (CVD), 
including stroke and myocardial infarction [1]. The prevalence of hypertension increases 
sharply with age [2]. It has been clear for at least two decades that older patients (>60 years) 
also benefit from antihypertensive treatment [3, 4], but guidelines may not apply equally to 
everyone over 60 years. For example, we do not know if the effects of treating hypertension are 
similar among individuals aged over 80 years (the oldest-old) – a segment of the population 
that is expected to triple in the next two decades [5].
Hypertension studies have tended to exclude patients with multimorbidity and frailty. These 
criteria disproportionately exclude the oldest-old because this age group are much more likely 
to have multimorbidity or to be frail [6, 7]. At the same time, observational studies have raised 
concerns about associations between low systolic blood pressure (SBP), increased mortality 
and accelerated cognitive decline, especially in the oldest-old living with frailty [8]. Studying 
associations between SBP and cognitive decline is challenging [9]. There is evidence that high 
SBP in midlife damages cerebral vessels and impairs brain function [10], but low SBP in late 
life, particularly in frail subjects, is associated with higher risk for cognitive decline [11]. A 
study by Mosello et al. found that lower SBP was associated with faster cognitive decline in 
individuals who were already cognitively impaired [12]; several other studies had produced 
similar findings [13-19]. Mosello et al. were the first to describe that antihypertensive therapy 
modified these associations: low SBP was associated with cognitive decline only in patients 
under antihypertensive therapy, but not in those who were not prescribed antihypertensive 
therapy. Unfortunately, the follow-up time was too short to detect long-term protective effects 
of antihypertensive treatment, and the population was limited to patients attending a memory 
clinic.
There is therefore a need for rigorous, population-based observational studies with adequate 
follow up time to test the association between antihypertensive therapy, blood pressure, 
mortality and cognitive decline in the oldest-old. We analysed data from a population-based 
cohort study with a five-year follow-up to test if the association between low SBP with all-
cause mortality and cognitive function differs for oldest-old patients under antihypertensive 
treatment and those without treatment, and to test if frailty modifies these associations.
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MethoDs
study design and setting
We analysed data from a prospective, population-based cohort study with a five-year follow 
up - the Leiden 85-plus Study [20, 21]. All inhabitants of the city of Leiden, the Netherlands, 
were invited to join this cohort study if they turned 85 years between 1997-1999. No exclusion 
criteria were applied. The target population was 705 inhabitants. Of these, 14 (2.0%) died 
before being enrolled in the study; 599 (85.0%) provided informed or proxy consent [22]. The 
Medical Ethical Committee of the Leiden University Medical Center approved the original 
study.
Participants
For this analysis, we applied two prespecified exclusion criteria. To lower the risk of reverse 
causality between SBP and mortality risk, we excluded participants who died less than 3 
months after they entered the cohort (n=5). We also excluded participants who had no SBP 
measurements at baseline (n=24).
Procedures and measurements
A history of cardiovascular disease (i.e. previously recorded diagnoses of angina pectoris, 
myocardial infarction, heart failure, intermittent claudication, peripheral arterial surgery, 
transient ischaemic attack, and stroke) was available from General practitioners (GPs) or 
nursing home physicians. At baseline, research nurses visited all participants to administer 
the Mini-Mental State Examination (MMSE) [23]. At baseline, SBP was measured twice with 
a mean time range between measurements of 2 weeks. SBP was measured using a mercury 
sphygmomanometer, in the seated position after at least 5 min of rest and with no vigorous 
exercise in the preceding 30 min. For this analysis, we averaged the two measurements of 
SBP. The research nurses also recorded socio-demographic characteristics (level of education, 
income, living place); current smoking status (yes/no); depressive symptoms if MMSE was 
>18 points using the 15-point Geriatric Depression Scale [24]; and hand grip strength using 
a hand dynamometer. During annual follow-up visits, nurses repeated MMSE measurements. 
All participants were followed for all-cause mortality for 5 years using municipal records.
statistical Analysis
We assessed associations between exposure (baseline SBP and use of antihypertensive medi-
cation) and outcomes (all-cause mortality and annual change in cognitive function) over 5 
years. At baseline, we compared characteristics of participants prescribed and not prescribed 
antihypertensive therapy. The crude and adjusted modelling approaches for all-cause mortal-
ity using Cox proportional hazard models and annual change in MMSE using mixed-effects 
linear regression models are described in detail in Appendix text. Subgroup analyses were 
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performed for the second aim, to test if grip strength (as a proxy for frailty) modified the asso-
ciations of SBP and treatment with the outcomes. We stratified both models for low/high hand 
grip strength to explore effect sizes and directions of effects. However, due to small sample 
sizes, this subgroup analysis was only exploratory. In sensitivity analyses, we firstly excluded 
deaths within 1 year after baseline; secondly restricted the models to participants without a 
history of CVD at baseline; and thirdly recoded participants who could not perform the hand 
grip strength test as missing. A two-sided P-value of 0.05 was taken as statistically significant 
for all analyses. We used STATA 15.0 (StataCorp, College Station, TX, USA) for all analyses.
This work was supported in part by an unrestricted grant from the Dutch Ministry of Health, 
Welfare and Sports; the Swiss National Science Foundation (SNF) (P2BEP3_165353); and the 
Gottfried and Julia Bangerter-Rhyner Foundation, Switzerland.
resuLts
We analysed data from 570 individuals, of whom 249 (43.7%) were prescribed antihyperten-
sive therapy at baseline (Table 1). Participants prescribed antihypertensive therapy and those 
not prescribed antihypertensives were similar in all aspects except for a higher prevalence of 
CVD in those prescribed antihypertensives (61.9% vs. 35.8%, p<0.001). The other cardiovas-
cular, socio-demographic, and functional characteristics at baseline were equally distributed 
among the two groups.
Appendix table 1 describes the sample of 214 participants grouped in lowest/highest SBP 
quintile. In the group prescribed antihypertensive therapy, participants with SBP <140 mmHg 
were more often institutionalized than those with SBP >170 mmHg (33.3% vs. 4.7%, p=0.001), 
and had slightly lower baseline MMSE (median 26 vs. median 27, p=0.021). The same pattern 
was evident in participants not prescribed antihypertensive therapy.
All-cause mortality over time
Figure 1 shows Kaplan-Meier survival curves for participants in the highest and lowest quin-
tiles of SBP. Those prescribed antihypertensive therapy with SBP >170 mmHg had the lowest 
risk of all-cause mortality, and those with SBP <140mmHg had the highest risk (log rank test 
p<0.001).
During the 5-year follow-up, 263 (46.1%) participants died. For those participants prescribed 
antihypertensive therapy, all-cause mortality was significantly higher with decreasing SBP (HR 
1.29 per 10mmHg lower SBP, 95%CI 1.15-1.46, p<0.001) (Table 2). For those not prescribed 
antihypertensives, the effect was smaller and did not reach significance (HR 1.08 per 10mmHg 
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lower SBP, 95% 1.00-1.18, p=0.057). The sensitivity analyses returned similar results in the 
model excluding deaths (n=47) within 1-year after baseline (Appendix table 2) and when the 
model was restricted to participants with no history of CVD at baseline.
Change of cognitive function over time
Figure 2 describes the median annual change in MMSE for those in the highest and low-
est quintiles of SBP, both for those prescribed antihypertensives and those not prescribed 
antihypertensives. In the group prescribed antihypertensives, those with SBP in the lowest 
quintile showed faster cognitive decline compared to those in the highest SBP-quintile (-1.1 
points per year [IQR 1.4] vs -0.1 points per year [IQR 0.6]; p=0.022). For those not prescribed 
table 1. Baseline characteristics of participants at age 85 years by antihypertensive treatment (n=570).
Domains overall(n=570)
Antihypertensive 
treatment (n=249)
no antihypertensive 
treatment (n=321) P-value
a
sociodemographic characteristics
Women, n (%) 380 (66.7) 173 (69.5) 207 (64.5) 0.21
Low educationb, n (%) 358 (64.9) 163 (66.8) 195 (63.3) 0.39
Low incomec, n (%) 280 (50.9) 122 (50.8) 158 (51.0) 0.98
Institutionalized, (%) 102 (18.4) 45 (18.4) 57 (18.3) 0.97
Cardiovascular characteristics
SBP in mmHg, mean (SD)d 155.2 (18.7) 154.8 (16.8) 155.5 (20.0) 0.64
Current Smoker, n (%) 89 (15.7) 33 (13.3) 56 (17.6) 0.16
Diabetes mellitus, n (%) 91 (16.3) 46 (18.9) 45 (14.2) 0.14
CVDe, n (%) 269 (47.2) 154 (61.9) 115 (35.8) <0.001
Functional characteristics
Cognition (MMSE f), median (IQR) 26 (22-28) 26 (21-28) 26 (23-28) 0.094
Depression (GDSg), median (IQR) 2 (1-3) 2 (1-3) 2 (1-3) 0.70
Low hand grip strengthh, n (%) 362 (63.5) 161 (64.7) 201 (62.6) 0.62
a  Chi-square test for categorical variables, t-test for normally distributed continuous and Wilcoxon rank-sum 
test for non-normally distributed data was used
b  defined as primary school only
c  defined as state pension only (about EUR 750 monthly)
d  SBP = systolic blood pressure was measured twice during home visit at baseline in a seated position, two 
weeks apart, and after at least 5 minutes of rest and no vigorous exercise in the preceding 30 minutes. Both 
measurements were averaged.
e  CVD included angina pectoris, myocardial infarction, heart failure, intermittent claudication, peripheral arte-
rial surgery, TIA, and stroke
f  MMSE, possible scores range from 0 to 30 points (worst to best). Missing data in n=7.
g  GDS-15, possible scores range from 0-15 (worst to best). Data not available for participants with Mini-Mental 
State Examination (MMSE) scores <18 (n=97).
h  Participants with hand grip strength below the sex-specific medians or unable to perform the test (n=35)
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antihypertensive therapy, no significant difference between the lowest and highest quintiles of 
blood pressure was evident (-0.7 points per year [IQR 2.2] vs. -0.5 points per year [IQR 1.4]; 
p=0.46).
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Figure 1. Kaplan-Meier survival curves for all-cause mortality grouped by under/without antihypertensive 
therapy and lowest/highest quintile of systolic blood pressure. All participants were aged 85 years when in-
cluded in the study and followed-up to a maximum of 5 years.
table 2. Subgroup analysis for hand grip strength and associations of systolic blood pressure (SBP) and all-
cause mortality per 10 mmHg lower SBP (n=570)
hazard ratio (95% Ci)
per 10 mmhg lower sBP P-value
treatment
Overalla (n=249) 1.29 (1.15, 1.46) <0.001
By hand grip strengthb Low (n=161) 1.24 (1.08, 1.42) 0.002
High (n=88) 1.40 (1.09, 1.80) 0.009
no treatment
Overalla (n=321) 1.08 (1.00, 1.18) 0.057
By hand grip strengthb Low (n=201) 1.10 (1.00, 1.21) 0.060
High (n=120) 0.99 (0.86, 1.15) 0.90
a  Participants during and without antihypertensive treatment, adjusted for sex and cardiovascular disease
b  Participants who were unable to perform the test (n=35) were classified to be low in hand grip strength, ad-
justed for sex and cardiovascular disease
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After accounting for baseline differences, those prescribed antihypertensives showed a faster 
rate of decline in MMSE with lower blood pressure (annual change in MMSE of -0.35, 95% CI 
-0.60 to -0.11 per 10mmHg drop in SBP; p=0.004). For those not prescribed antihypertensive 
therapy, the rate of decline was not significantly faster with lower baseline blood pressure 
(annual change in MMSE -0.14, 95% CI -0.39 to 0.11 per 10mmHg drop in SBP; p=0.28) 
(Table 3). The sensitivity analysis returned similar results when the model was restricted to 
participants with no history of CVD at baseline.
Modification by frailty
Our results did not change in our subgroup analyses for all-cause mortality (Table 2), when 
we stratified by low or high hand grip strength in participants prescribed antihypertensive 
therapy (p for interaction=0.28) or not prescribed antihypertensive therapy (p for interac-
tion=0.29). There was weak evidence for an association in those participants not prescribed 
antihypertensives who had low hand grip strength (HR 1.10, 95% CI 1.00 to 1.21, p=0.060).
The subgroup analyses for annual change in cognitive function (Table 3) showed that ac-
celerated change in MMSE with lower SBP was significant for those under antihypertensive 
therapy when they had low hand grip (annual change in MMSE -0.37, 95% CI -0.70 to -0.05 
per 10mmHg drop in SBP; p=0.023) but did not reach significance for those with high hand 
grip strength (annual change in MMSE -0.24, 95% CI -0.57 to 0.09 per 10mmHg drop in SBP; 
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Figure 2. Annual change in cognitive function (measured by the Mini-Mental State Examination, MMSE) 
grouped by under/without antihypertensive therapy and lowest/highest quintile of systolic blood pressure.
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p=0.15). There was no evidence of interaction of hand grip strength in those without therapy 
(p for interaction=0.10). The sensitivity analysis returned similar results when participants 
who could not perform the hand grip strength test were classified as missing data instead of 
categorized as having low hand grip strength.
DisCussion
In this population-based cohort of individuals aged 85 years with a 5-year follow-up, we found 
lower SBP was associated with higher all-cause mortality and faster annual cognitive decline 
in participants prescribed antihypertensive therapy. In participants without antihypertensive 
treatment, no relation was found between SBP and mortality or cognitive decline. Low grip 
strength did not modify the association of SBP and mortality but did for cognitive decline.
Our findings are in line with other cohort studies showing the same associations of low SBP 
and increased mortality although previous analyses did not stratify for antihypertensive treat-
ment [25, 26]. For cognition, age seems to modify the associations; in studies with patients 
aged >60 there was either no association between SBP and cognitive decline [27] or an as-
sociation of higher SBP with a lower risk of dementia [28]. At age 85 years and older, low 
SBP predicts the onset of dementia [15] and is associated with worse cognitive function [17]. 
table 3. Subgroup analysis for hand grip strength and changes in cognitive function measured by the Mini-
Mental State Examination (MMSE) according to systolic blood pressure (SBP) at age 85 (per 10 mmHg lower 
SBP).
Baseline difference Annual change Accelerated change
estimate (95% Ci) P-value estimate (95% Ci) P-value estimate (95% Ci) P-value
treatment
Overalla (n=220) -0.33 (-0.63, -0.03) 0.032 +1.20 (-0.50, +2.91) 0.17 -0.35 (-0.60, -0.11) 0.004
By hand grip
strengthb
Low (n=141) -0.38 (-0.78, +0.02) 0.061 +1.14 (-1.18, +3.45) 0.34 -0.37 (-0.70, -0.05) 0.023
High (n=79) -0.04 (-0.47, +0.39) 0.84 +0.87 (-1.30, +3.05) 0.43 -0.24 (-0.57, +0.09) 0.15
no treatment
Overalla (n=284) -0.72 (-1.00, -0.44) <0.001 -0.62 (-2.39, +1.16) 0.50 -0.14 (-0.39, +0.11) 0.28
By hand grip
strengthb
Low (n=172) -0.80 (-1.20, -0.40) <0.001 -0.90 (-3.60, +1.79) 0.51 -0.13 (-0.49, +0.24) 0.50
High (n=112) -0.18 (-0.49, +0.12) 0.23 -0.76 (-2.13, +0.61) 0.28 -0.04 (-0.24, +0.17) 0.74
‘Baseline difference’ means the association per 10 mmHg lower SBP and MMSE at baseline. ‘Annual change’ 
indicates the annual difference in MMSE over time until age 90. ‘Accelerated change’ is the additional change in 
MMSE over time associated per 10 mmHg lower SBP.
a  Participants with and without antihypertensive treatment, adjusted for sex and cardiovascular disease
b  Participants unable to perform the test (n=35) were classified to have less hand grip strength, adjusted for sex 
and cardiovascular disease
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Similarly, a cohort of male participants whose SBP trajectories were followed over 32 years 
showed that those who develop dementia had a greater increase in SBP followed by a decrease 
in SBP compared to those who did not develop dementia [29]. These findings could explain 
the accelerated cognitive decline we found in our patients with low SBP under antihyperten-
sive treatment. Our results are also in line with Mosello et al.’s findings [12] where 172 patients 
with a mean age of 79 years, taking antihypertensive therapy, and with a diagnosis of dementia 
or mild cognitive impairment of outpatient memory clinics were followed-up for a median of 
9 months. Our results confirm and extend these findings by showing similar associations in a 
population-based cohort over a longer observation period of 5 years.
This cohort study has several strengths. The population-based sample included a large number 
of participants, extensive measurements and high follow up rates with a low risk for selection 
bias. The inclusion of participants from nursing homes further enhances the generalisability 
of the findings.
This is an observational study, with all the limitations that implies. However, it is useful to 
look at the associations we identified by situating them within the GRADE framework and 
apply the Bradford Hill’s criteria for causation because ‘observational studies may provide 
more relevant information than RCTs’ [30]. The strength of association we found, consistency 
with prior studies, and the dose-response relationship in our study are three of these criteria. 
In addition, this study established a temporal relationship between SBP values measured at 
baseline and outcome assessments over 5 years. Our sensitivity analysis showed robust results 
when we excluded deaths within 1 year after baseline, which reduces, but does not exclude, the 
risk that our findings are due to reverse causality.
We acknowledge further limitations. First, there was no SBP measurement at baseline for about 
5% of participants. Excluding these participants is unlikely to introduce bias as the numbers 
are small. Second, the risk for confounding by indication limits the causal interpretation of 
our associations. Interpretation of the results is helped by the findings of a large international 
study including >2500 GPs [31], which may allow us to understand and adjust for factors (for 
example frailty) that influence GPs’ decision to start or not start antihypertensive therapy in 
the oldest-old. Third, if participants are prescribed with antihypertensive therapy but did not 
adhere to treatment, misclassification bias could be introduced. However, Dutch individuals 
seem to adhere best to therapy compared to seven other countries [32], and this high level of 
adherence reduces the risk of such bias in our sample.
Despite these limitations, the finding that low SBP is associated with increased mortality and 
cognitive decline in oldest-old under antihypertensive therapy is concerning. For clinicians, 
this study raises the question of what the optimal target blood pressure level is for 85-year-
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oldm frail patients. We support the suggestions from Benetos et al. [33] to follow an individu-
alized approach when treating hypertension in oldest-old >80 years with frailty, due to the 
lack of evidence [6, 34]. Observational studies remain at risk for bias (i.e. reverse causality, 
residual confounding), and the way to provide more evidence could be via deprescribing trials 
to test effectiveness and safety of lowering or removing antihypertensive therapy. The Dutch 
DANTE trial used this approach over a 16-week period in patients aged 75 and older with 
mild cognitive impairment [35]. In DANTE, deprescribing was not beneficial but was safe. 
Future studies should try to recruit patients that could benefit the most from deprescribing 
such as individuals with frailty and/or limited life expectancy.
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Appendix text – detailed plan of analysis
We assessed associations between exposure (level of SBP with/without antihypertensive 
therapy) and outcomes (all-cause mortality/annual change in cognitive function) over 5 years.
Missing data was handled two ways: 1) We excluded participants with missing information on 
baseline SBP (n=24, 4%) and potential confounders (n=3-20, 1%-3%, income was the variable 
with most [n=20] missing data). 2) We grouped participants who were unable to perform the 
hand grip strength test (n=35, 6%) in the group of lower than median hand grip strength.
Our descriptive analysis compared baseline characteristics in those with/without antihy-
pertensive treatment. Chi-square tests were performed for categorical variables, t-tests or 
Wilcoxon rank-sum test for continuous data where appropriate.
In a crude regression model, SBP was first grouped into quintiles. Only participants from the 
two most extreme quintiles of lowest and highest SBP (<140 and >170 mmHg) were retained. 
Finally, we re-parameterized both exposure variables (SBP and antihypertensive therapy) into 
a new categorical variable, with four sub-categories (2 levels of SBP by 2 levels of treatment) 
so we could visually explore associations of both exposure variables and each outcome at 
once. We then presented all-cause mortality in crude Kaplan-Meier time-to-event curves for 
each of the four groups. Groups (SBP/treatment) were compared with log-rank tests. Next, 
we grouped SBP in 10mmHg units for all participants. We found no evidence for a significant 
departure from linear trend (tested with Likelihood ratio test [LRT]).
For all-cause mortality, we used Cox proportional hazards models with SBP as the exposure, 
testing separately for antihypertensive treatment (yes/no). We tested proportional hazard 
assumptions and they were all valid. We, a priori, chose sex, and CVD as confounders, and 
took a causal modelling approach to identify potential confounders to the association of SBP/
treatment and the outcomes: living situation, income, education, smoking status, diabetes, 
and depression (i.e. GDS-score). We calculated crude and adjusted hazard ratios (HR) and 
95% confidence intervals (CI) and tested the later for multicollinearity. Interaction was only 
tested as pre-specified for frailty in a subgroup analysis.
Annual change in cognitive function was calculated as the median annual difference and 
inter-quartile range (IQR) in MMSE for each of the four groups. We then compared estimates 
and IQR for low and high SBP, using Wilcoxon rank-sum tests separately for participants 
with/without antihypertensive treatment. While this approach did not account for correlated 
data (i.e. multiple measurements per participant), we later used a mixed-effects linear regres-
sion models that account for the clustering within each participant as a random effect [25]. 
57
Lower blood pressure during antihypertensive therapy, mortality and cognition in oldest-old
The models provided estimates for ‘SBP’, ‘year’ (of follow-up) and ‘SBP * year’. The estimate 
for ‘SBP’ indicated the baseline difference in MMSE per 10mmHg lower SBP (presented in 
Table 3 as ‘baseline difference’). The estimate for ‘year’ indicated the annual change in MMSE 
(presented in Table 3 as ‘annual change’). The estimate for ‘SBP * year’ indicates the acceler-
ated change in MMSE per year per 10mmHg lower SBP (presented in Table 3 as ‘accelerated 
decline’).
Subgroup analyses were performed for the second aim, to see if frailty modified the associa-
tions of SBP/treatment with the outcomes. We stratified both models for low/high hand grip 
strength to explore effect sizes and directions of effects. We tested for interaction using LRT. 
However, due to small sample sizes, this subgroup analysis was only exploratory.
A two-sided P-value of 0.05 was statistically significant. We used STATA 15.0 (StataCorp, 
College Station, TX, USA) for all analyses.
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Appendix table 1. Subgroup of participants with baseline systolic blood pressure (SBP) at baseline of <140 
mmHg (lowest quintile) and >170 mmHg (highest quintile) stratified by antihypertensive treatment (n=214).
Domains
Antihypertensive
treatment
P-valuea
no antihypertensive
treatment
P-valuea<140
mmhg
(n=43)
>170
mmhg
(n=44)
<140
mmhg
(n=60)
>170
mmhg
(n=67)
sociodemographic characteristics
Women, n (%) 30 (69.8) 32 (72.7) 0.76 40 (66.7) 41 (61.2) 0.52
Low educationb, n (%) 26 (66.7) 31 (72.1) 0.59 39 (66.1) 45 (69.2) 0.71
Low incomec, n (%) 18 (47.4) 16 (37.2) 0.36 32 (54.2) 32 (50.0) 0.64
Institutionalized, (%) 13 (33.3) 2 (4.7) 0.001 23 (38.3) 6 (9.2) <0.001
Cardiovascular characteristics
Current Smoker, n (%) 2 (4.7) 8 (18.2) 0.089 9 (15.5) 12 (17.9) 0.81
Diabetes mellitus, n (%) 10 (25.6) 5 (11.6) 0.15 14 (23.3) 8 (12.3) 0.16
CVDd, n (%) 33 (76.7) 26 (59.1) 0.078 25 (41.7) 29 (43.3) 0.86
Functional characteristics
Cognition (MMSE e), median (IQR) 26 (19-27) 27 (23-28) 0.021 23.5 (13-27) 27 (23-28) 0.002
Depression (GDSf), median (IQR) 2 (1-4) 2 (1-3) 0.35 2 (1-4) 1 (1-3) 0.17
Low hand grip strengthg, n (%) 32 (74.4) 27 (61.4) 0.19 48 (80.0) 38 (56.7) 0.005
a  P-values were derived from Chi-square tests for categorical variables, exact Fisher tests (if too few observa-
tions per cell expected), and Wilcoxon rank-sum test for continuous not-normally distributed data.
b defined as primary school only
c defined as state pension only (about EUR 750 monthly)
d   CVD included angina pectoris, myocardial infarction, heart failure, intermittent claudication, peripheral 
arterial surgery, TIA, and stroke
e  MMSE, possible scores range from 0 to 30 points (worst to best). Missing data in n=3.
f  GDS-15, possible scores range from 0-15 (worst to best). Data not available for participants with Mini-Mental 
State Examination (MMSE) scores <18 (n=44).
g  Participants unable to perform the test (n=16) were classified to have low hand grip strength.
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Appendix table 2. Sensitivity analysis excluding participants that died within one year after baseline. Subgroup 
analysis for hand grip strength and associations of systolic blood pressure (SBP) and all-cause mortality per 10 
mmHg lower SBP (n=534)
hazard ratio (95% Ci)
per 10 mmhg lower sBP P-value
treatment
Overalla (n=235) 1.25 (1.10, 1.42) 0.001
By hand grip strengthb Low (n=150) 1.22 (1.05, 1.41) 0.009
High (n=85) 1.28 (0.97, 1.67) 0.078
no treatment
Overalla (n=299) 1.09 (0.99, 1.19) 0.074
By hand grip strengthb Low (n=184) 1.11 (0.99, 1.23) 0.069
High (n=120) 0.99 (0.85, 1.17) 1.00
a  Participants during and without antihypertensive treatment, adjusted for sex and cardiovascular disease
b  Participants who were unable to perform the test (n=32) were classified to be low in hand grip strength, ad-
justed for sex and cardiovascular disease
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ABstrACt
Background/objectives
Determine if systolic blood pressure (SBP) and antihypertensive treatment are associated with 
one-year changes in cognitive/daily functioning or quality of life (QoL) in older participants 
with/without complex health problems.
Design
Population-based prospective cohort with one-year follow-up.
setting
Participants in the Integrated Systematic Care for Older Persons (ISCOPE) trial.
Participants
Primary care patients, eligible when ≥75 years and SBP recorded in electronic medical records 
one-year before baseline.
Measurements
Grouped participants into SBP categories (<130mmHg/130-150mmHg/>150mmHg) and anti-
hypertensive treatment (yes/no). Used mixed-effects linear regression models to evaluate change 
from baseline to one-year follow-up in outcome measures (Mini Mental State Examination 
(MMSE), Groningen Activities Restriction Scale (GARS), and EQ-5D-3L). Adjusted models for 
age, sex, baseline values of MMSE/GARS/EQ-5D-3L and stratified for complex health problems.
results
Participant (n=1,266) age averaged 82.4 (5.1) years; 874 were women (69.2%). In participants 
under antihypertensive therapy (1,057, 83.5%) with SBP<130mmHg, cognitive decline was 
0.90 points in MMSE while in those with an SBP >150mmHg it was 0.14 (i.e. 0.76 less decline). 
In the multivariable model, cognitive decline was 1.01 (95%CI 0.47-1.55, P<0.001) when SBP 
was >150mmHg (P-for-trend<0.001). Complex health problems modified the association of 
SBP with cognitive function: the association was mainly seen in those with complex health 
problems (P-for-trend<0.001) and not in those without (P-for-trend=0.13). Daily functioning 
or QoL did not differ across strata of SBP and antihypertensive treatment.
Conclusions
Participants aged ≥75years under antihypertensive treatment with a SBP ≥130mmHg com-
pared to <130 showed a significantly and clinically relevant benefit in cognition after one year, 
without loss of daily functioning or QoL. This effect was strongest in participants with com-
plex health problems. For those, future trials should investigate if deprescribing is beneficial.
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introDuCtion
In Western countries, hypertension is present in up to 30% of the population [1] and is a 
leading disability risk [2]. Its prevalence sharply increases with age [3], but for many years 
many physicians believed hypertension in old age was a healthy adaptation to arteriosclerotic 
rigidity [4] and did not treat patients >60 for hypertension [5]. In the 1990s, trials began to 
show that antihypertensive treatment reduced stroke and myocardial infarction in patients 
>60 [6-8], and physicians changed their practice. However, as populations “grey”, definitions 
of “old” are shifting. Life expectancy has increased worldwide: people ≥75 years are now 
the fastest-growing age group; this population will triple within 35 years [9]. Some older 
individuals are very healthy, but others are frail and have two or more chronic conditions 
(multimorbidity) or other complex health problems [10].
Though updated guidelines recommend lowering blood pressure targets in older patients, 
cohort studies have raised concern that lowering SBP too much might harm them, by, for ex-
ample accelerating cognitive decline [11-21]. A recent network meta-analysis of 17 hyperten-
sion trials proved the effectiveness and safety of lowering SBP to <130 mmHg in patients with 
hypertension [22], spurring the American College of Cardiology/American Heart Association 
Task Force (ACC/AHA) to update their guidelines. ACC/AHA recommends a target SBP of 
<130mmHg for non-institutionalized older patients [23]. Hypertension trials often exclude 
older, frail patients and those with complex health problems [24], so some have questioned 
the generalizability and applicability of the results of these studies of the general population, 
especially to older patients [25, 26]. An observational study of 172 patients (mean age 79 
years) by Mosello et al. found low SBP and cognitive decline were associated in patients with 
dementia or mild cognitive impairment (MCI) under antihypertensive treatment, but not in 
untreated patients [27]. This study concluded that optimal SBP in those patients was between 
130 and 145 mmHg, since lowering target values might further impair cognitive function, and 
was the only study that analysed patients under antihypertensive treatment separately from 
patients without treatment.
We set out to determine if low SBP and cognitive decline were similarly associated in a larger 
cohort of Dutch community-dwelling older participants under antihypertensive treatment 
and without. We also tested for an association between SBP and daily functioning and quality 
of life (QoL). We hypothesized these associations would be strongest in older participants 
with complex health problems.
Chapter 4
64
MethoDs
Design
This is a prospective cohort study based on data from the Integrated Systematic Care for Older 
Persons (ISCOPE) study, a cluster-randomized trial.
isCoPe trial
The ISCOPE study included participants from 2009 to 2010 in Leiden, the Netherlands [28]. 
560 general practitioners (GPs) were invited, and, of these, 104 (19%) invited their patients to 
participate. In the Netherlands, every person is registered at a GP practice. Inclusion criteria 
were age ≥75 years; terminal illness or life expectancy of <3 months were the only exclusion 
criteria. Participants were randomized to either an integrated care plan with a functional ge-
riatric approach or usual care [28]. Of 11,476 patients in the target population, 7,285 (63.4%) 
answered a screening questionnaire. We selected a random sample of 1,921 to follow up for 
one year. Of these, 106 (5.5%) participants died; mortality risk was the same in intervention 
and control groups (P=0.48).
study population and eligibility criteria
We needed electronic medical records (EMR) data in order to extract SBP measurements and 
identify antihypertensive drugs from their Anatomical Therapeutic Chemical (ATC) codes. 
We thus selected participants based on four criteria: 1) they consented to allow us to analyse 
their EMR data; 2) we could link their EMR data to link the ISCOPE dataset; 3) they were 
selected for one year of follow-up in ISCOPE; and 4) their SBP measurements were recorded 
for the year before they were included in ISCOPE (Study flow chart in Figure 1).
ethical approval
Informed consent was obtained from each patient. The study protocol conforms to the ethical 
guidelines of the 1975 Declaration of Helsinki. The Ethics Committee of the Leiden University 
Medical Center, the Netherlands (P09.096) approved the ISCOPE study, registered in the 
Netherlands Trial Register (NTR1946).
exposures
We averaged SBP values from EMR of up to five of the most recent measurements taken the 
year before baseline. We grouped participants, based on mean SBP, into 3 categories (<130 
mmHg, 130-150 mmHg, and >150 mmHg). Those with SBP <130mmHg were the reference 
group. We used EMR data at baseline to determine if participants were under antihypertensive 
treatment or not.
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outcome measurements
In ISCOPE, research nurses made home visits at baseline and at one-year follow-up [28]. The 
MMSE measures cognitive function on a scale of 0-30 points (higher scores indicate better 
function) [29]. The GARS questionnaire measures basic and instrumental activities of daily 
living. The combined score ranges from 18-72 points (higher score indicates greater disability 
[30]). QoL was assessed with EQ-5D-3L index values: participants rated their health status in 
5 dimensions (mobility; self-care; usual activities; pain and discomfort; anxiety and depres-
sion), and at three levels (no, some, or extreme problems) [31], and we converted them to a 
weighted index, based on the EuroQoL Group (full health has a value of 1, death, a value of 
0) [32].
Confounders
We, a priori, chose age, sex, and either MMSE, GARS, or EQ-5D-3L at baseline, depending 
on the outcome as confounders. We took a causal modelling approach to identifying potential 
confounders of the association between SBP/treatment and our outcomes. We assessed the 
strength of confounding by examining change between our crude and adjusted models for 
each of the following covariates: living situation; income; education; diabetes; cardiovascu-
lar disease (CVD) (myocardial infarction, angina pectoris, intermittent claudication, other 
ischemic heart disease, stroke, TIA, or heart failure); and non-cardiovascular co-morbidities 
(cancer, diabetes, and depression). The final model included all variables a) considered to be 
confounders (change of +/-10% from crude model) or b) prespecified.
Supplementary Figure S1. Study flow chart
Participants in ISCOPE 
responding to baseline questionnaire
(n = 7,285)
Participants consenting with 
compatible 
electronic medical records
(n = 4,351)
EXCLUDED:
• No BP measurements one year before 
study inclusion (n = 228)
EXCLUDED:
• No electronic medical record available 
(not compatible to extract or no 
consent to use data) (n = 2,934)
Eligible participants
(n = 1,494)
EXCLUDED:
• Not randomly selected for follow-up in 
ISCOPE (n = 2,857)
Data available for analysis
(n = 1,266)
Figure 1. Study flow chart
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To identify participants with complex health problems, we used scores from a questionnaire 
that participants received at baseline. The questionnaire covered four domains (functional, 
somatic, mental, and social) [28], which each contained 4-9 questions. If participants reported 
problems in ≥2 questions in a domain, their score was 1 for that domain; if they reported no 
problems, it was 0. Participants that scored 1 in three or all domains, were classed as having 
complex problems.
statistical analysis
In descriptive analysis, we compared baseline characteristics of participants with/without SBP 
measurements in the EMR to determine selection bias, then we compared participants with 
and without antihypertensive treatment. We used the Chi2-test for categorical data, t-test for 
normally distributed data, and Wilcoxon ranksum test for not-normally distributed continu-
ous data.
In a primary analysis, we assessed associations between SBP category (<130mmHg, 130-
150mmHg, >150mmHg) stratified by antihypertensive therapy (yes or no) and change in 
function in old age (MMSE, GARS, EQ-5D-3L) from baseline to one-year follow-up. We 
estimated the change in function and 95% confidence intervals (CI) in a crude mixed-effects 
regression model that only accounted for the correlated nature of data of participants under 
antihypertensive treatment or not by the same GP. We calculated P for trend to test a linear 
trend across categories of SBP within both strata (antihypertensive therapy yes and no). We 
then adjusted the mixed-effects regression models for sex, age and baseline values of MMSE, 
GARS, or EQ-5D-3L, depending on the outcome, and estimated the change in function re-
lated to SBP <130mmHg (reference category). Linear assumptions were tested and valid for 
all outcomes.
We performed two sensitivity analyses for the primary analysis: 1) we restricted our analysis 
to participants with no history of CVD at baseline; and, 2) we included the ISCOPE trial arm 
as confounder, although the original ISCOPE trial did not show that the integrated care plan 
increased QoL or daily function or changed health care use.
In a secondary analysis, we took the same approach, but we stratified for participants with and 
without complex health problems.
A two-sided P-value of 0.05 was statistically significant. We used STATA 15.1 (StataCorp, 
College Station, TX, USA) for all analyses.
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resuLts
Of 7,285 participants who responded to the screening questionnaire in ISCOPE, we excluded 
2,934 (40.3%) because they did not consent to providing a link to their EMR data or their 
EMR data could not be linked with ISCOPE data. Of the 4,351 who remained, 1,494 (34.3%) 
were followed-up for one year in ISCOPE. Of those, we excluded 228 (15.3%) because they 
had no SBP measurements recorded in EMR (flow chart in Figure 1). Those we excluded 
for lack of SBP measurements were healthier overall than the study participants; they had 
less CVD (21% vs. 40%, P<0.001), less antihypertensive therapy (49% vs. 84%, P<0.001), less 
diabetes (15% vs. 22%, P=0.030), lower GARS score (27 vs. 31, P<0.001), higher EQ-5D 0.81 
vs 0.77, P<0.001), higher MMSE-score [28 (26-29) vs. 28 (27-29), P=0.019], and less complex 
health problems (39% vs. 53%, P>0.001) (Appendix table 1).
The final dataset comprised 1,266 participants. Most of them (83.5%) were under antihy-
pertensive treatment for hypertension (Table 1). At baseline, the sociodemographic char-
acteristics of participants under or not under antihypertensive treatment were similar, but 
participants under antihypertensive treatment more often had an SBP >150 mmHg (35 % vs. 
23%; P=0.004), more CVD (48% vs. 4%; P<0.001), more diabetes (23% vs. 15%; P=0.013), 
higher GARS score (31 vs. 28, P=0.003) and lower QoL (EQ-5D 0.77 vs. 0.78, P=0.045).
Crude one-year changes in cognitive function, daily function and quality of life
Figure 2 displays the crude estimates of changes from baseline to one-year follow-up in cogni-
tive function (Panel A), daily functioning (Panel B), and QoL (Panel C). In participants under 
antihypertensive treatment, we found a clear trend across categories of SBP: with lower SBP, 
cognitive decline worsened (measured by MMSE) after one-year follow-up (P for trend 0.013). 
In participants under antihypertensive treatment and SBP <130mmHg, cognitive decline in 
one year averaged 0.90 points (95%CI 0.43-1.36) in MMSE, while it was 0.14 (95%CI 0.21-
0.49) in those with SBP >150mmHg (0.76 points less decline in MMSE in participants with an 
SBP >150mmHg than in those with SBP <130mmHg). In participants without antihyperten-
sive treatment, we observed a similar trend but it was not statistically significant (1.75 points, 
95%CI 0.80-2.70 if SBP<130mmHg vs. 0.54 points, 95%CI 0.43-1.41 if SBP>150mmHg; P for 
trend 0.08).
We found no association between SBP and daily functioning or QoL in participants under or 
not under antihypertensive therapy.
Multivariable models for cognitive function, daily functioning and QoL
Table 2 displays the changes in function among the reference group (<130mmHg) stratified 
by antihypertensive treatment for each outcome, separately (MMSE, GARS, EQ-5D-3L). 
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Compared to the reference group, participants under antihypertensive therapy showed less 
cognitive decline after one year by 0.71 points in MMSE (95%CI 0.20-1.22, P=0.007) when 
SBP was 130-150mmHg and by 1.01 points in MMSE (95%CI 0.47-1.55, P<0.001) when SBP 
was >150mmHg (P for trend <0.001). In participants not under antihypertensive therapy, the 
trend was in the same direction but not significant (P for trend 0.07).
table 1. Baseline characteristics of participants overall and grouped by antihypertensive treatment (n=1,266)
overall
(n=1,266)
Antihypertensive treatment
P-valueayes
(n=1,057)
no
(n=209)
Sociodemographic data
Female, n (%) 874 (69) 728 (69) 146 (70) 0.72
Age, years (SD) 82.4 (5) 82.5 (5) 82.3 (5) 0.59
Primary school only, n (%) 656 (52) 541 (52) 115 (55) 0.33
Low incomeb, n (%) 197 (16) 166 (16) 31 (15) 0.72
Residential home, n (%) 101 (8) 83 (8) 18 (9) 0.72
Systolic blood pressure, n (%)
<130 mmHg 237 (19) 197 (19) 40 (19)
130-150 mmHg 613 (48) 493 (47) 120 (57) 0.004
>150 mmHg 416 (33) 367 (35) 49 (23)
Comorbidities, n (%)
Cardiovascular disease (CVD)c 511 (40) 503 (48) 8 (4) <0.001
Diabetes mellitus 274 (22) 242 (23) 32 (15) 0.013
Depression 182 (15) 148 (14) 34 (16) 0.42
Cancer 159 (13) 134 (13) 25 (12) 0.75
Baseline function, median (IQRd)
MMSEe score 28 (26-29) 28 (26-29) 28 (26-29) 0.99
GARSf score 31 (24-39) 31 (24-40) 28 (22-36) 0.003
EQ-5D-3Lg index values 0.77 (0.57-0.84) 0.77 (0.51-0.84) 0.78 (0.65-0.89) 0.045
Complex health problemsh 674 (53) 571 (54) 103 (50) 0.23
a  P-value from chi-square test for categorical data; t-test for normally-distributed continuous data, Wilcoxon 
ranksum test for not normally-distributed continuous data
b  defined as state pension only (about EUR 750 monthly)
c  CVD included myocardial infarction, angina pectoris, intermittent claudication, other ischemic heart disease, 
stroke, TIA, and heart failure
d IQR = inter quartile range
e  Mini-Mental State Examination (MMSE) on a scale of 0-30 points (higher scores indicate better cognitive 
function)
f  Groningen Activities Restriction Scale (GARS); the score ranges from 18 to 72 (higher scores indicate greater 
disability)
g  Quality of life (EQ-5D-3L index values; full health has a value of 1, dead a value of 0)
h  Defined as patients having problems in three or more of four domains (functional, somatic, mental, and social)
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Figure 1. Associations of systolic blood pressure, antihypertensive 
treatment, and change in function after a one-year follow-up. Estimates, 
95% CI and p-for trend from crude mixed-effects linear regression 
accounting for clustering within general practitioners. Panel A: cognitive 
function measured by MMSE (less points = cognitive decline); Panel B: 
daily functioning measured by GARS (more points = more disability); 
Panel C: Quality of life measured by EQ-5D-3L, less points = lower QoL). 
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Figure 2. Associations of systolic blood pressure, antihypertensive treatment, and change in function after a 
one-year follow-up. Estimates, 95% CI and p-for trend from crude mixed-effects linear regression accounting 
for clustering within general practitioners. Panel A: cognitive function measured by Mini Mental State Exami-
nation (MMSE), (less points = cognitive decline); Panel B: daily functioning measured by Groningen Activities 
Restriction Scale (GARS), (more points = more disability); Panel C: Quality of life measured by EQ-5D-3L, (less 
points = lower q ality of life).
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For the outcomes of daily functioning and QoL, there was no association between SBP cat-
egory and change in GARS or EQ-5D-3L in either strata (antihypertensive therapy yes/no).
sensitivity analyses
The findings remained robust when we restricted the sample to participants with no history of 
CVD at baseline (Appendix table 2). When we added the ISCOPE trial arm to which partici-
pants were allocated our estimates remained the same (data not shown).
secondary analysis for complex health problems
In participants with complex health problems (n=674, 53%, Table 3), we found the same 
association. Compared to the reference group (SBP<130mmHg), participants showed less 
cognitive decline after one year by 0.99 points in MMSE (95%CI 0.32-1.66, P=0.004) when 
SBP was 130-150mmHg and by 1.39 points in MMSE (95%CI 0.68-2.11, P<0.001) when SBP 
was >150mmHg (P for trend <0.001). This association was not found in participants without 
complex health problems (P for trend 0.35, Appendix table 3). Complex health problems did 
not modify the effect on daily functioning or QoL.
table 2. Associations of baseline systolic blood pressure (SBP) and antihypertensive treatment with change 
in cognitive/daily function and quality of life after one-year follow-up (n=1,266). Multivariable mixed-effects 
regression model adjusted for age, sex, baseline MMSE/GARS/EQ-5D-3L and accounting for clustering within 
general practitioners.
Antihypertensive treatment
yes (n=1,057) no (n=209)
n Change (95% Ci) P-value P-trend n Change (95% Ci) P-value P-trend
Cognitive function
<130 mmHg 194 Ref. - <0.001 40 Ref. - 0.07
130-150 mmHg 485 0.71 (0.20, 1.22) 0.007 - 118 1.04 (-0.04, 2.12) 0.06 -
>150 mmHg 362 1.01 (0.47, 1.55) <0.001 - 48 1.22 (-0.03, 2.47) 0.06 -
Daily function
<130 mmHg 191 Ref. - 0.47 40 Ref. - 0.70
130-150 mmHg 480 -0.08 (-1.11, 0.96) 0.88 - 114 -1.73 (-4.54, 1.10) 0.42 -
>150 mmHg 359 -0.37 (-1.47, 0.74) 0.51 - 48 -0.75 (-4.02, 2.52) 0.65 -
Quality of life
<130 mmHg 193 Ref. - 0.17 39 Ref. - 0.14
130-150 mmHg 484 0.00 (-0.04, 0.04) 0.98 - 118 -0.06 (-0.14, 0.02) 0.13 -
>150 mmHg 364 0.03 (-0.02, 0.07) 0.24 - 49 -0.07 (-0.16, 0.02) 0.12 -
Reading example: Patients under antihypertensive treatment and a baseline SBP of >150mmHg had 1.01 (95% 
CI 0.47 to 1.55) less cognitive decline compared to patients under antihypertensive therapy with a baseline SBP 
of <130mmHg.
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DisCussion
In this large Dutch primary care cohort of older persons with a follow-up of one year, those 
under antihypertensive treatment had less cognitive decline if their SBP in the year before 
baseline was ≥130 mmHg. The association between higher SBP and less cognitive decline in 
participants under antihypertensive treatment was strongest seen in those with complex health 
problems. Daily functioning and QoL were the same across strata of SBP and antihypertensive 
treatment. Sensitivity analyses that excluded participants with CVD or that included the trial 
arm of the ISCOPE trial in the model supported these findings.
interpretation and scientific context
Our study builds on Mosello et al. [27], but is much larger (1,266 vs. 172 participants), and 
was conducted in a different setting (general practice vs outpatient memory clinics). Mosello 
et al. included only patients with dementia or mild cognitive impairment. Our study included 
participants often excluded from trials because they are sicker and have complex health prob-
lems. We found the same associations, but also demonstrated that complex health problems 
table 3. Subgroup analysis restricted to patients with complex health problems (n=674). Associations of base-
line systolic blood pressure (SBP) and antihypertensive treatment with change in cognitive/daily function and 
quality of life after one-year follow-up (n=1,266). Multivariable mixed-effects regression model adjusted for sex, 
age, baseline MMSE/GARS/EQ-5D-3L and accounting for clustering within general practitioners.
Antihypertensive treatment
yes (n=571) no (n=103)
n Change (95% Ci) P-value P-trend n Change (95% Ci) P-value P-trend
Cognitive function
<130 mmHg 117 Ref. - <0.001 20 Ref. - 0.13
130-150 mmHg 258 0.99 (0.32, 1.66) 0.004 - 60 1.90 (0.05, 3.75) 0.044 -
>150 mmHg 189 1.39 (0.68, 2.11) <0.001 - 22 1.78 (-0.42, 3.98) 0.11 -
Daily function
<130 mmHg 115 Ref. - 0.59 20 Ref. - 0.65
130-150 mmHg 254 -0.18 (-1.57, 1.20) 0.79 - 57 -2.02 (-6.14, 2.10) 0.34 -
>150 mmHg 188 -0.40 (-1.88, 1.09) 0.60 - 22 -1.20 (-6.11, 3.72) 0.63 -
Quality of life
<130 mmHg 117 Ref. - 0.61 19 Ref. - 0.19
130-150 mmHg 257 -0.03 (-0.08, 0.03) 0.21 - 60 -0.11 (-0.23, 0.01) 0.08 -
>150 mmHg 190 0.01 (-0.05, 0.07) 0.99 - 22 -0.10 (-0.24, 0.04) 0.16 -
Reading example: Patients under antihypertensive treatment and a baseline SBP of >150mmHg had 1.39 (95% 
CI 0.68 to 2.11) less cognitive decline compared to patients under antihypertensive therapy with a baseline SBP 
of <130mmHg.
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changed the association. This finding lines up with other studies that found associations 
changed with frailty [33, 34]. Studies of older patients that did not stratify on antihypertensive 
treatment, found either no association [35] or an association between higher SBP, better 
cognition, and lower risk of dementia [36]. Our study helps explain this difference by showing 
that, in participants without complex health problems, low SBP is not as clearly associated 
with cognitive decline [37] as in those with complex health problems.
Less cognitive decline by 1.39 points in MMSE (95%CI 0.68-2.11) than the reference group 
(SBP<130 mmHg) is a clinically meaningful difference: this difference of 1.39 MMSE points is 
greater than the average annual decline in MMSE in those aged 85 [12].
At the same time, we found no evidence SBP was associated with changes in daily function 
under antihypertensive therapy, though prior studies identified both positive and negative 
associations [13, 38, 39]. A cohort study of 35 centenarians in Poland found higher SBP ben-
efitted daily activity after follow-up [13]. The Leiden-85-plus study found higher SBP levels 
were associated with lower ADL disability over 5 years [38]. In contrast, a US longitudinal 
cohort study of about 600 75-year-olds found high SBP was associated with declining physical 
function (measured by gait speed) over 10 years of follow-up [39]. This diametric association 
might be explained by age: there was evidence that high SBP was associated with physical 
function at age 75, but that high SBP increased physical function in those >85 and >100. 
Most studies that assessed the association between SBP and function in old age did not assess 
QoL. A Polish study of about 11,500 old patients found that those treated for hypertension 
(especially those on multiple antihypertensive medications) had optimal QoL with higher 
SBP [40], but our results suggest no association between SBP and one-year change in daily 
function or QoL.
strengths and limitations
Strengths of our study are the high number of older participants recruited by a large group 
of GPs, and the extensive measurements that take into account cognitive function, daily 
functioning, and QoL. Our study has the following limitations. It was observational, so we 
cannot exclude residual confounding, but the strength of the associations we identified, 
consistency with prior studies, dose-response relationship, and temporal relationship of SBP 
measurements and outcome assessments all point towards a causal interpretation. Although 
the participants we excluded because they had no SBP measurements recorded in the last year 
before the start of the study were healthier, they did otherwise not differ from responders. This 
last limitation can also be considered a strength, since we included sicker, older participants 
with a high proportion of CVD under antihypertensive treatment, and this ever-increasing 
group is often excluded from trials.
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implications
If higher blood pressure under treatment is better for cognitive function, then it might benefit 
patients to increase their blood pressure by deprescribing antihypertensive treatment. Early 
trials like the Dutch DANTE study asked if deprescribing antihypertensive medication im-
proved cognitive function in older patients with mild cognitive impairment but found no 
evidence of effect after 16 weeks of follow-up [41]. The long term effects of deprescribing 
antihypertensives are still uncertain, but a recent Cochrane review found withdrawing from 
antihypertensive therapy in old age did not increase mortality [42]. We encourage researchers 
to conduct new randomized trials to test the long-term effectiveness and safety of depre-
scribing antihypertensive therapy to raise SBP, especially in individuals with complex health 
problems.
Until the results of these new trials are available, clinicians must daily decide on appropriate 
treatment for hypertension in older patients with limited evidence, including this study [25, 
26]. Antihypertensive treatment is intended to reduce the risk of cardiovascular events and to 
preserve cognitive/daily function and QoL in older people. But our results show that SBP <130 
mmHg under antihypertensive treatment is associated with additional cognitive decline. Our 
results suggest SBP thresholds for treatment should be redefined, especially for older persons 
with complex health problems. A more individualized approach might be best right now [43]. 
Since older patients are more likely to have complex problems and suffer accelerated cognitive 
decline, clinicians are advised to be cautious about lowering SBP too much.
Conclusions
In our study in the primary care setting, older participants aged ≥75 years under antihyper-
tensive treatment with an SBP ≥130 mmHg showed significant and clinically relevant benefit 
in cognitive function after one year compared to participants whose SBP was <130mmHg, 
without loss to either daily functioning or QoL. A similar, but not significant trend was seen 
in participants not under antihypertensive treatment. This effect was strongest in participants 
with complex health problems under antihypertensive treatment. A more individualized ap-
proach to treat hypertension in older patients with complex health problems might be best 
right now until deprescribing trials could test if deprescribing antihypertensive treatment is 
beneficial or not.
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Appendix table 1. Baseline characteristics of participants with and without blood pressure measurements 1 
year prior to study inclusion (n=1,494).
Domains overall(n = 1,494)
Blood pressure measurements 1 year 
before study inclusion
P-valuea
yes
(n = 1,266)
no
(n = 228)
Sociodemographic data
Female, n (%) 1,018 (68) 874 (69) 144 (63) 0.074
Age, years (SD) 82.3 (5) 82.4 (5) 81.4 (5) 0.006
Primary school only, n (%) 768 (52) 656 (52) 112 (49) 0.43
Low incomeb, n (%) 225 (15) 197 (16) 28 (12) 0.20
Residential home, n (%) 124 (8) 101 (8) 23 (10) 0.29
Comorbidities, n (%)
Cardiovascular disease (CVD)c 554 (37) 506 (40) 48 (21) <0.001
Under antihypertensive therapy 1,168 (78) 1,057 (84) 111 (49) <0.001
Diabetes mellitus 309 (20) 274 (22) 35 (15) 0.030
Depression 209 (14) 182 (15) 27 (12) 0.30
Cancer 186 (13) 159 (13) 27 (12) 0.76
Baseline function, median (IQRd)
MMSEe score 28 (26-29) 28 (26-29) 28 (27-29) 0.019
GARSf score 30 (24-39) 31 (24-39) 27 (21-34) <0.001
EQ-5D-3Lg index values 0.78 (0.60-0.84) 0.77 (0.57-0.84) 0.81 (0.67-0.89) <0.001
Complex health problemsh 764 (51) 674 (53) 90 (39) <0.001
a  P-value from chi-square test for categorical data; t-test for normally-distributed continuous data, Wilcoxon 
ranksum test for not normally-distributed continuous data
b  defined as state pension only (about EUR 750 monthly)
c  CVD included myocardial infarction, angina pectoris, intermittent claudication, other ischemic heart disease, 
stroke, TIA, and heart failure
d  IQR = inter quartile range
e  Mini-Mental State Examination (MMSE) on a scale of 0-30 points (higher scores indicate better cognitive 
function)
f  Groningen Activities Restriction Scale (GARS); the score ranges from 18 to 72 (higher scores indicate greater 
disability)
g  Quality of life (EQ-5D-3L index values; full health has a value of 1, dead a value of 0)
h  Defined as patients having problems in three or more of four domains (functional, somatic, mental, and so-
cial)
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Appendix table 2. Subgroup analysis restricted to patients without history of cardiovascular disease (n=755). 
Associations of baseline systolic blood pressure (SBP) and antihypertensive treatment with change in cognitive/
daily function and quality of life after one-year follow-up. Multivariable mixed-effects regression model adjust-
ed for age, sex, baseline MMSE/GARS/EQ-5D-3L and accounting for clustering within general practitioners.
Antihypertensive treatment
yes (n=554)
P-trend
no (n=201)
P-trendn Change (95% Ci) P-value n Change (95% Ci) P-value
Cognitive function
<130 mmHg 83 Ref. - 0.031 39 Ref. - 0.07
130-150 mmHg 249 0.79 (0.15, 1.57) 0.046 - 113 1.07 (-0.03, 2.17) 0.06 -
>150 mmHg 214 0.98 (0.18, 1.77) 0.017 - 47 1.22 (-0.03, 2.52) 0.06 -
Daily function
<130 mmHg 81 Ref. - 0.76 39 Ref. - 0.72
130-150 mmHg 248 -0.27 (-1.79, 1.25) 0.73 - 108 -1.69 (-4.61, 1.22) 0.26 -
>150 mmHg 214 -0.29 (-1.86, 1.28) 0.72 - 47 -0.73 (-4.08, 2.62) 0.67 -
Quality of life
<130 mmHg 82 Ref. - 0.08 38 Ref. - 0.14
130-150 mmHg 250 0.02 (-0.04, 0.08) 0.49 - 112 -0.07 (-0.15, 0.01) 0.09 -
>150 mmHg 216 0.05 (-0.01, 0.11) 0.11 - 48 -0.08 (-0.17, 0.02) 0.11 -
Reading example: Patients under antihypertensive treatment and a baseline SBP of >150mmHg had 0.98 (95% 
CI 0.18 to 1.77) less cognitive decline compared to patients under antihypertensive therapy with a baseline SBP 
of <130mmHg.
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Appendix table 3. Subgroup analysis restricted to patients without complex health problems (n=591). Asso-
ciations of baseline systolic blood pressure (SBP) and antihypertensive treatment with change in cognitive/
daily function and quality of life after one-year follow-up (n=1,266). Multivariable mixed-effects regression 
model adjusted for sex, age, baseline MMSE/GARS/EQ-5D-3L and accounting for clustering within general 
practitioners.
Antihypertensive treatment
yes (n=486)
P-trend
no (n=105)
P-trendn Change (95% Ci) P-value n Change (95% Ci) P-value
Cognitive function
<130 mmHg 77 Ref. - 0.35 19 Ref. - 0.15
130-150 mmHg 227 0.20 (-0.59, 0.99) 0.63 - 58 0.23 (-0.80, 1.25) 0.67 -
>150 mmHg 173 0.38 (-0.44, 1.20) 0.37 - 26 0.80 (-0.35, 1.96) 0.17 -
Daily function
<130 mmHg 76 Ref. - 0.56 19 Ref. - 0.84
130-150 mmHg 226 -0.03 (-1.54, 1.60) 0.97 - 57 -2.07 (-5.92, 1.78) 0.29 -
>150 mmHg 171 -0.38 (-2.02, 1.25) 0.65 - 26 -0.77 (-5.06, 3.51) 0.72 -
Quality of life
<130 mmHg 76 Ref. - 0.35 19 Ref. - 0.44
130-150 mmHg 227 0.03 (-0.03, 0.08) 0.36 - 58 0.02 (-0.08, 0.12) 0.7868 -
>150 mmHg 174 0.03 (-0.03, 0.09) 0.29 - 27 -0.04 (-0.15, 0.08) 0.52 -
Reading example: Patients under antihypertensive treatment and a baseline SBP of >150mmHg had 0.38 (95% 
CI -0.44 to 1.20) less cognitive decline compared to patients under antihypertensive therapy with a baseline 
SBP of <130mmHg.
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ABstrACt
Background
In oldest-old patients (>80), few trials showed efficacy of treating hypertension and they 
included mostly the healthiest elderly. The resulting lack of knowledge has led to inconsistent 
guidelines, mainly based on systolic blood pressure (SBP), cardiovascular disease (CVD) but 
not on frailty despite the high prevalence in oldest-old. This may lead to variation how General 
Practitioners (GPs) treat hypertension. Our aim was to investigate treatment variation of GPs 
in oldest-olds across countries and to identify the role of frailty in that decision.
Methods
Using a survey, we compared treatment decisions in cases of oldest-old varying in SBP, CVD, 
and frailty. GPs were asked if they would start antihypertensive treatment in each case. In 
2016, we invited GPs in Europe, Brazil, Israel, and New Zealand. We compared the percentage 
of cases that would be treated per countries. A logistic mixed-effects model was used to derive 
odds ratio (OR) for frailty with 95% confidence intervals (CI), adjusted for SBP, CVD, and GP 
characteristics (sex, location and prevalence of oldest-old per GP office, and years of experi-
ence). The mixed-effects model was used to account for the multiple assessments per GP.
results
The 29 countries yielded 2,543 participating GPs: 52% were female, 51% located in a city, 71% 
reported a high prevalence of oldest-old in their offices, 38% and had >20 years of experience. 
Across countries, considerable variation was found in the decision to start antihypertensive 
treatment in the oldest-old ranging from 34-88%. In 24/29 (83%) countries, frailty was associ-
ated with GPs’ decision not to start treatment even after adjustment for SBP, CVD, and GP 
characteristics (OR 0.53, 95%CI 0.48-0.59; ORs per country 0.11-1.78).
Conclusions
Across countries, we found considerable variation in starting antihypertensive medication in 
oldest-old. The frail oldest-old had an odds ratio of 0.53 of receiving antihypertensive treat-
ment. Future hypertension trials should also include frail patients to acquire evidence on the 
efficacy of antihypertensive treatment in oldest-old patients with frailty, with the aim to get 
evidence-based data for clinical decision-making.
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introDuCtion
Hypertension is the most important preventable cause of poor cardiovascular outcome and 
is responsible for disability and deaths from stroke, myocardial infarction and other diseases 
[1]. Treating hypertension is beneficial and (since the 1990s) it is known that treatment also 
reduces stroke rates and myocardial infarction in patients aged >60 years [2-4]. As life ex-
pectancy has increased worldwide, a new term was needed to describe those in the fastest-
growing age group expected to triple within the next 35 years [5], i.e. the group ‘oldest-old’ is 
now defined as those aged >80 years.
The population of the oldest-old is heterogeneous. Some oldest-old are very healthy 
whereas others are multimorbid with complex problems. Although the group of multimorbid 
oldest-old is rapidly increasing, most trials still exclude them. Messerli et al. highlighted this 
commonly-applied exclusion by applying exclusion criteria taken from 13 hypertension trials 
with oldest-old participants, to a primary care cohort of hypertensive patients aged >60 years 
[6]: in this case, ≥70% of the oldest-old would have been excluded and they were both older 
and sicker.
The exclusion of such a large percentage of oldest-old has caused a serious gap in our knowl-
edge and in guidelines to treat hypertension in patients with multimorbidity. Even more scarce 
are recommendations for frail patients: for example, of six current hypertension guidelines, 
only those of the European Society of Hypertension and of the European Society of Cardiol-
ogy have a specific recommendation to leave decisions on antihypertensive therapy in the frail 
and oldest-old patients to the treating physician (class I C recommendation) [7].
Due to the current lack of clear evidence, the best management of hypertension in the oldest-
old remains unknown; this may, in turn, lead to clinical variation. Although it is difficult 
to quantify, variation exists in the way that the best available evidence is applied in clinical 
practice [8]. Among the diverse reasons for this variation, the appropriateness of guidelines 
for physicians in treating specific groups of patients is of particular importance. However, to 
reduce clinical variation and improve quality of care/patient safety, there is a need to assess 
clinical variation among the oldest-old patients, who are consistently excluded from trials but 
suffer from both multimorbidity and frailty.
Therefore, the present study investigates clinical variation across countries of general practi-
tioners’ (GPs) decisions to start antihypertensive treatment in patients aged >80 years. Our hy-
pothesis was that frailty would be an important factor in deciding not to start antihypertensive 
treatment in clinical practice, although this is not specifically addressed in most guidelines.
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MethoDs
Design
GPs from different countries were invited to participate in a survey based on case vignettes.
setting
The aim was to recruit national representatives (defined as a GP in contact with a national 
GP network) of 40 countries on the European continent, and in Brazil and New Zealand. 
We also re-contacted six national representatives of GP networks participating in a previous 
survey [9]. Also invited to participate were: 1) national representatives of WONCA Europe 
(European Branch of the World Organization of National Colleges, Academies and Academic 
Associations of General Practitioners/Family Physicians) [10]; 2) the European General Prac-
tice Research Network (EGPRN) [11]; and 3) the Network of Junior GPs in Europe (the Vasco 
da Gama Movement, VdGM) [12].
The study was conducted in accordance with the Declaration of Helsinki [13]. Because the 
responses of GPs were collected anonymously, most countries required no approval from an 
ethics committee. In countries where approval was mandatory (Switzerland, Brazil), a waiver 
from the ethics committee was obtained. In New Zealand, approval for the study was granted 
by the University of Auckland Ethics Committee.
Participants
All national representatives were asked to include as many GPs as possible from their GP net-
work. Because primary care surveys usually score low on response rates, we regularly reported 
the numbers of participating GPs to the national coordinators, so they could send reminders 
if needed. The only inclusion criterion for the survey was to be actively working as a GP; this 
was asked at the beginning of the survey. Participants who did not meet this criterion (e.g. due 
to retirement) were excluded from completing the survey.
Procedures
Beforehand, we developed/tested the survey for optimal technicality between SurveyMonkey 
(www.surveymonkey.com, Palo Alto, CA, USA) and Stata, among five GPs. Then, to test for 
clarity/feasibility, the survey was piloted among a sample of 16 physicians working in Swit-
zerland.
National representatives translated the survey from English to their own language. Finally, the 
survey was available in 21 languages. National representatives of Greece, Israel and Finland 
decided to distribute the survey in English. The correctness of all translations was evaluated 
by the team of collaborators.
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First, we asked the GP’s gender, office location (city, suburban, rural), and years of experience 
working as a GP (in 5-year bands). Second, GPs were asked to estimate the proportions of 
patients aged >80 years attending their GP office. Third, eight case vignettes were presented of 
oldest-old patients of both gender, presenting for a routine visit in a GP office without blood 
pressure-related symptoms and not receiving any antihypertensive treatment. For each case 
vignette, GPs were asked to decide if they would start antihypertensive treatment. All case vi-
gnettes differed in three primary characteristics: systolic blood pressure (SBP), cardiovascular 
disease (CVD), and frailty (Appendix table 1). SBP was either 140 mmHg or 160 mmHg. CVD 
was either present (e.g. case vignettes with a history of myocardial infarction or stroke) or 
absent. Because the condition of frailty lacks a common definition [14], we stated that frailty 
is defined as patients with at least two of the following criteria: unintentional weight loss, 
exhaustion, low level of activity, muscle weakness, and slow gait speed. Thus, a patient with 
a low level of activity and unintentional weight loss was considered to be frail. To facilitate 
filling in the survey, for each case vignette we indicated one of the following statements: “You 
consider this patient to be frail” or “You don’t consider this patient to be frail”.
The survey was distributed by email between March 9 and July 31 2016. As the only exception, 
Ukraine distributed the survey on paper during a regional GP meeting because there is insuf-
ficient internet access for GPs in Ukraine.
statistical analysis
To describe baseline characteristics, proportions were calculated for dichotomized or catego-
rized data, and means were calculated for continuous data.
To assess international variation in decisions for treatment, per country the crude proportions 
and confidence intervals (CI) were calculated for GPs who would start treatment.
To assess the role of frailty in the decision to start treatment per country, odds ratios (ORs) and 
CI were calculated per country using a mixed-effects model adjusted for GP’s gender, years of 
experience, office location, prevalence of oldest-old in the GP practice, guideline compliance, 
SBP, and CVD. The mixed-effects model was used to account for the multiple assessments per 
GP. The estimate of each country was presented on a forest plot.
For each case vignette, we calculated the crude proportions of GPs starting treatment and also 
compared two corresponding case vignettes (e.g. in Case 1 the patient is not frail, whereas in 
Case 2 the patient is frail).
To assess the overall influence of SBP, CVD and frailty, the same mixed-effects model was used 
but, in addition, clustering within countries was taken into account.
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A two-sided p-value of 0.05 was considered statistically significant. Analyses were performed 
with STATA 14.2 (StataCorp, College Station, TX, USA).
resuLts
From March through July 2016, we contacted 40 national representatives from Europe, Brazil, 
Israel, Russia, and New Zealand and received replies from 29 countries. Overall, 13,671 GPs 
were invited, of whom 2,585 responded. Subsequently, 42 respondents were excluded because 
they were no longer working as a GP, resulting in 2,543 participants. The median response rate 
was 26% (IQR 10-62%) (Appendix table 2).
Table 1 presents the baseline characteristics of the participating GPs; 52.3% were female, 
50.8% lived in a city, and 37.6% had >20 years of experience. The majority of GPs (61.3%) 
estimated the prevalence of the oldest-old patients in their practice to be >10%.
Overall, the crude proportions of treatment varied considerably between countries (Figure 1). 
For example, the lowest proportion of treatment was found in the Netherlands (34.2%; 95% CI 
32.0-36.5%) whereas Ukraine had the highest proportion (88.3%; 95% CI 85.3-90.9%).
table 1. Baseline characteristics of participating GPs from 29 countries.
Baseline characteristics (n=2,543) n (%)
Female GP 1,341 (52.3)
Practice location
City 1,292 (50.8)
Suburban 599 (23.6)
Rural 651 (25.6)
experience as GP
<5 years 471 (18.5)
5-10 years 445 (17.5)
11-15 years 341 (13.4)
16-20 years 328 (12.9)
>20 years 956 (37.6)
self-estimated prevalence of patients >80 years at own practice
<10% 851 (38.7)
10-20% 865 (39.4)
21-30% 323 (14.7)
>30% 159 (7.2)
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Figure 2 shows the GPs’ treatment probability in frail oldest-old compared to non-frail oldest-
old for each of the 29 countries. Overall, the treatment probability for all countries was OR 
0.59 (95% CI 0.47-0.75) and the probability per country ranged from OR 0.11 in New Zealand 
to 1.78 in the Czech Republic. In 8/29 (28%) countries (i.e. New Zealand, Finland, Denmark, 
the Netherlands, Ireland, Switzerland, France and Israel) we are 95% confident that GPs would 
be less likely to start antihypertensive treatment in the frail oldest-old patients compared to 
the non-frail oldest-old patients. In 16/29 (55%) countries, an OR <1 was found but a 95% CI 
including 1; this larger 95% CI was due to the lower number of respondents per country (<30 
per country in 45% of all countries). In 5/29 (17%) countries, the OR was >1 but (to a large 
extent) the 95% CI included 1.
GPs’ decision to treat hypertension in the oldest-old varied considerably, ranging from 17.3% 
to 96.8% according to the specific case vignette (Table 2). The lowest level of treatment de-
cision was scored in those case vignettes that included no frailty, no CVD, and a SBP 140 
mmHg (17.3%; 95% CI 15.7-19.0%). The case vignettes that included CVD, SBP 160 mmHg 
and no frailty scored the highest (96.8%; 95% CI 95.9-97.5%). Besides frailty (adjusted OR 
0.53; 95% CI 0.48-0.59), a SBP of 140 mmHg (adjusted OR 0.01; 95% CI 0.01-0.01) and no 
CVD (adjusted OR 0.29; 95% CI 0.26-0.32) were also independent factors that caused GPs not 
to start treatment.
Figure 1. National percentages in which general practitioners decide to start 
antihypertensive treatment in all eight cases of oldest-old patients (unadjusted).
Brazil
New Zealand
Israel
<40%
40-49%
50-59%
60-69%
>70%
Percent
Figure 1. National percentages in which general practitioners decide to start antihypertensive treatment in all 
eight cases of oldest-old patients (unadjusted).
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Overall  (I-squared = 71.2%, p = 0.000)
Germany
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Figure 2. Influence of frailty on 2,053 general practitioners (GPs) when 
deciding to start antihypertensive treatment per country (
aAdjusted for GP characteristics (gender, experience, location, prevalence of oldest-old, guideline 
compliance) and patient characteristics (cardiovascular disease, systolic blood pressure). A mixed-
effects model was used to account for multiple assessments per GP.
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Figure 2. Influence of frailty on 2,053 general practitioners (GPs) when deciding to star  antihypertensive treat-
ment per country (adjusted).
table 2. Percentages of general practitioners (GPs) starting antihypertensive treatment for the eight individual 
cases (n=2,053 GPs)
Cases
Proportion of GPs 
starting treatment Case characteristics
% (95% Ci) Frailty CVD sBP 160 mmhg
overall 54.9 (54.1-55.7)
Case 1 17.3 (15.7-19.0) – – –
Case 2 18.2 (16.6-20.0) + – –
Case 3 85.4 (83.7-86.9) – – +
Case 4 75.6 (73.6-77.5) + – +
Case 5 96.8 (95.9-97.5) – + +
Case 6 84.9 (83.2-86.4) + + +
Case 7 32.5 (30.4-34.6) – + –
Case 8 29.5 (27.5-31.6) + + –
CVD=cardiovascular disease; SBP=systolic blood pressure
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DisCussion
After sampling >2,500 GPs in 29 countries, this study revealed large clinical variation in start-
ing antihypertensive treatment (ranging from 34-88%) based on case vignettes of oldest-old 
patients. As hypothesized, frailty proved to be an important patient characteristic for GPs in 
deciding whether or not to start antihypertensive treatment in 24/29 (83%) countries. The 
probability of a GP treating a frail patient was almost half that compared with a GP managing 
a non-frail patient. Current guidelines are clearer about the level of SBP related to initiating 
treatment; this was confirmed in the present study in which GPs were less inclined to start 
treatment in the case of SBP 140 mmHg compared to SBP 160 mmHg. Nevertheless, how to 
manage frailty will become increasingly important for an increasingly older and multimorbid 
population. When specific data from future trials that include frail patients become available, 
hypertension and other guidelines can be updated accordingly.
scientific and Clinical Context of the results
Treatment goals for hypertension are constantly changing [15]. Recent trials including oldest-
old patients indicate aiming at the lower levels of SBP [3, 16]. However, these latter patients 
may differ from the general population that GPs are managing, due to the extensively applied 
exclusion criteria for the older and sicker patients [6]. Therefore, it remains unclear whether 
lowering SBP in multimorbid and frail patients does in fact lead to better outcomes. For 
example, in the SPRINT trial, frail patients showed smaller intertreatment group differences 
in SBP compared to non-frail patients, thus a lower SBP might be harder to achieve in frail 
patients [16]. On the other hand, there is evidence that frail oldest-old need a higher SBP. In a 
recent meta-analysis comparing pro- and retrospective cohort studies, Zhang et al. found that 
a higher SBP in frail oldest-old patients had a protective effect in lowering the risk of overall 
mortality [17]. Thus, current knowledge seems to be well summarized by Materson et al. who 
suggested to evaluate and treat frail oldest-old patients individually, while the healthier oldest-
old should be treated regardless of their chronological age [18].
In the present study, this wide spectrum of recommendations and lack of clear evidence may 
partly explain the variation found between the participating countries. Differences in national 
guidelines/campaigns may have also led to differences between the countries. Nevertheless, 
this study confirmed our hypothesis that frailty is a factor that GPs take into consideration 
when starting antihypertensive treatment; moreover, we found that GPs were less likely to 
treat frail patients, even after adjusting for SBP and CVD. This is in line with findings from a 
Dutch qualitative study, where vulnerability was an important patient-related barrier for GPs 
when implementing guidelines for secondary cardiovascular prevention in oldest-old [19].
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Interestingly, our findings share some findings and yet show difference with the only other 
published study on this topic. Mermans et al. conducted a similar survey among 305 GPs in 
Belgium. These authors also found large differences in treatment intentions for hypertension 
in the oldest-old patients between GPs and showed that there was a significant difference 
in the treatment intention of GPs between robust patients and strongly dependent patients. 
However, the stated that ‘differences in the patients’ level of dependency were not responsible 
for the variation in the overall treatment intention’ [20]. However, on an international level, 
when including many countries, frailty was established as an important factor influencing 
GPs’ treatment decisions.
strengths and limitations
A strength of this study is the high number of countries and relatively large number of re-
spondents (thanks to collaboration with WONCA Europe, EGPRN, and VdGM). Further, 
the sampled GPs were experienced with treating oldest-old patients. The inclusion of many 
countries enabled to produce a detailed map of treatment decision-making in Europe and 
elsewhere. In addition, we could establish that, in most countries, frailty is associated with a 
lower intention to treat, even when taking SBP and cardiovascular comorbidity into account.
This study has several limitations. First, although we report what the GPs stated they would 
do, this is not necessarily the same as what they would actually do. However, given the realistic 
case descriptions and the anonymous nature of the survey, we are relatively confident that this 
limitation has not introduced a systematic bias. Second, the response rate varied considerably 
between countries and the median rate was only 26%; this is a commonly occurring problem 
in primary care surveys [21]. However, our response rate was well within the range of other 
published survey among GPs in major journals [22]. Several reviews further noted that a low 
response rates in GP survey do not necessarily introduce selections bias [23, 24]. Third, in 
the case vignettes, only three patient characteristics were taken into consideration. However, 
because we focused on variation in treatment decision and the role of frailty in that decision, 
it was beyond the scope of this study to address all possible reasons related to GPs’ treatment 
decision-making. Fourth, we mainly recruited one GP network per country, which is a selec-
tion of GPs dependent on their region of origin or area of interest; however, by adjusting our 
analysis for GP characteristics we aimed to take this possible confounder into account.
implications
This study has several implications for research and clinical practice. First, the large variation 
in starting treatment in hypertensive oldest-old calls for high-quality cohort studies or (ideally) 
new hypertension trials specifically including frail patients to acquire evidence as to whether 
frailty is indeed an important factor when treating hypertension in oldest-old patients. Sec-
ond, future studies should investigate whether treatment variation might be explained by e.g. 
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the recommendations in guidelines that individual GPs follow. Third, qualitative studies could 
help us to understand more of the variation we have found. If reasons for the international 
variation in treatment are established, educational campaigns can be launched to unify the 
quality of care in Europe (and elsewhere) based on the current body of evidence. Finally, 
future hypertension guidelines should stratify their recommendations not only for age, blood 
pressure level and cardiovascular comorbidity, but also for frailty.
Conclusions
In Europe, Brazil, Israel and New Zealand, GPs’ decisions concerning starting antihyper-
tensive treatment in the oldest-old varied considerably. Independently, the frail oldest-old 
patients had an almost 50% lower probability for their GP to consider them eligible to receive 
antihypertensive treatment. Future hypertension trials should also include frail patients to 
acquire evidence on the efficacy of antihypertensive treatment in oldest-old patients with 
frailty, with the aim to support and unify clinical decision-making.
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Appendix table 1. Characteristics of the eight case vignettes used in this survey.
Cases Frailty Cardiovasculardisease
systolic blood
pressure (mmhg)
Case 1 No No 140
Case 2 Yes No 140
Case 3 No No 160
Case 4 Yes No 160
Case 5 No Yes 160
Case 6 Yes Yes 160
Case 7 No Yes 140
Case 8 Yes Yes 140
All patients were aged >80 years and presented at the GP’s office for routine control. None of the patients had 
blood pressure-related complaints and none was receiving any antihypertensive treatment.
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Appendix table 2. Participating countries: number of invited GPs and response rates per country.
Country invited (n=13,671) Participated (n=2,543) response rate (%)
Austria 549 28 5
Bosnia Herzegovina 260 26 10
Brazil 67 63 94
Czech Republic 356 27 8
Denmark 203 22 11
Finland 118 24 20
France 150 63 42
Germany 300 29 10
Greece 89 23 26
Hungary 515 332 64
Ireland 2576 401 16
Israel 395 140 35
Italy 120 38 32
Latvia 990 88 9
Luxembourg 40 7 18
Macedonia 28 21 75
Netherlands 1720 239 14
New Zealand 1524 39 3
Norway 99 31 31
Poland 79 69 87
Portugal 82 51 62
Romania 53 45 85
Slovenia 312 24 8
Spain 411 57 14
Sweden 130 34 26
Switzerland 1756 510 29
Turkey 648 17 3
Ukraine 73 69 95
United Kingdom 28 26 93
Median (iQr) 26 (10-62)
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ABstrACt
objectives
We previously found large variations in general practitioner (GP) hypertension treatment 
probability in oldest-old (>80 years) between countries. We wanted to explore whether dif-
ferences in country-specific cardiovascular disease (CVD) burden and life expectancy could 
explain the differences.
Design
Survey study using case-vignettes of oldest-old patients with different comorbidities and 
blood pressure levels. An ecological multilevel model analysis was performed.
setting
GP respondents from European General Practice Research Network (EGPRN) countries, 
Brazil and New Zeeland.
subjects
2,543 GPs from 29 countries
Main outcome measures
GP treatment probability to start or not start antihypertensive treatment based on responses 
to case-vignettes. Either low (<50% started treatment) or high (≥50% started treatment). 
CVD burden defined as ratio of disability-adjusted life years (DALYs) lost due to ischemic 
heart disease and/or stroke and total DALYs lost per country. Life expectancy at age 60 and 
prevalence of oldest-old per country.
results
Of 1,947 GPs (76%) responding to all vignettes, 787 (40%) scored high treatment probability 
and 1160 (60%) scored low. GPs in high CVD burden countries had higher odds of treatment 
probability (OR 3.70; 95%CI 3.00-4.57); in countries with low life expectancy at 60, CVD was 
associated with high treatment probability (OR 2.18, 95%CI 1.12-4.25); but not in countries 
with high life expectancy (OR 1.06, 95%CI 0.56-1.98).
Conclusion
GPs’ choice to treat/not treat hypertension in oldest-old was explained by differences in 
country-specific health characteristics. GPs in countries with high CVD burden and low life 
expectancy at age 60 were most likely to treat hypertension in oldest-old.
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introDuCtion
In the Global Burden of Disease (GBD) study (2015), elevated blood pressure was among the 
leading risk factors for disability-adjusted life years (DALYs) [1]. Globally, about 10% of all 
DALYs are lost due to hypertension. To improve management of hypertension, the Lancet 
Commission issued a 10-point action plan in which one of these points was to individualize 
antihypertensive treatment according to cardiovascular risk, cultural differences, age, etc. [2].
The group of the oldest-old (patients aged >80 years) is both the fastest growing and also 
the most heterogeneous age group [3]. Some are healthy with very few chronic conditions, 
whereas others are frail, have multimorbidity (≥ 2 chronic conditions), or other complex 
problems [4]. This heterogeneity makes it particularly challenging for general practitioners 
(GPs) to find the best strategy (with optimal benefit to risk ratio) when deciding whether or 
not elevated blood pressure should be treated in this group [5]. This clinical dilemma can lead 
to variation in treating hypertension in oldest-old [6-9].
In the ATTENTIVE study [10], a large variation was found in GPs’ decision to start antihyper-
tensive treatment in oldest-old. In that study, eight case vignettes of oldest-old were presented 
to >2,500 GPs from 29 (mainly) European countries and, for each case, they were asked 
whether or not they would start treatment. In the Netherlands, 34% of all cases would have 
been treated compared with 88% in Ukraine. Part of this variation was explained by the differ-
ences in patient characteristics, i.e. level of blood pressure, cardiovascular disease (CVD), and 
frailty. However, given the variation across countries, it seems feasible that country-specific 
health characteristics could explain part of the variation.
Therefore, the present study investigates whether country-specific health differences in CVD 
burden in older patients, and life expectancy at age 60 years, are related to GP treatment prob-
ability to start antihypertensive treatment. We hypothesized that there would be a positive 
association between CVD burden and GP treatment probability, but that life expectancy at age 
60 years would modify that association.
MethoDs
Design and setting
This was an ecological study using a multilevel model. Aggregated country-specific data were 
used from publicly available sources (see section ‘Variables’) and individual-level data (level 
of GPs) were used from the Antihypertensive TreaTmENT In Very Elderly (ATTENTIVE) 
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study. In the ATTENTIVE study, GPs from 29 countries (including Brazil, Israel and New 
Zealand) were enrolled (March-July 2016) [10].
ethical considerations
The ATTENTIVE study was conducted in compliance with the Declaration of Helsinki [11]. 
GPs provided informed consent by responding to the questionnaire. Since the participating 
GPs responded anonymously, no formal medical ethics approval was required from most 
of the countries. However, in Brazil and Switzerland the research ethics committees issued 
a waiver, and in New Zealand the research ethics committee of the University of Auckland 
approved this study.
Participants
The only inclusion criteria for ATTENTIVE was that each participant had to be a practic-
ing GP; this was established from the first question in the survey. Non-practicing GPs were 
excluded. GPs were invited by email without offering an incentive. For this study, only GPs 
that provided an answer for all eight case vignettes were included; this stipulation enabled us 
to calculate GP treatment probability over all the cases.
survey
In short, the survey contained eight case vignettes of oldest-old patients (aged >80 years; males 
and females) that consulted their GPs for a routine visit without showing blood pressure-
related symptoms or receiving antihypertensive treatment. All case vignettes differed in three 
primary characteristics: systolic blood pressure (SBP) of 140 or 160 mm Hg, CVD present 
or absent, and frailty (yes or no). For each case vignette, GPs were asked to decide if they 
would start antihypertensive treatment. We piloted and then translated the questionnaire into 
21 languages (Additional file 1 in [10]). SurveyMonkey (www.surveymonkey.com, Palo Alto, 
CA, USA) was used to build the online questionnaire. As an exception, in Ukraine (where web 
access was limited) a paper questionnaire was used.
Variables
The outcome of this study was the proportion of case vignettes for which GPs decided to start 
antihypertensive treatment, i.e. GP treatment probability. GPs were dichotomised into two 
groups according to the median of GP treatment probability, i.e. ≤50% ‘low’, >50% ‘high’.
The exposure was CVD burden per country. CVD burden per country was defined as: the 
ratio of DALYs in persons aged >70 years lost due to ischemic heart disease and/or stroke and 
the total DALYs lost in persons aged >70 years. These data were retrieved from the GBD data-
base (hosted by the Institute for Health Metrics and Evaluation). Data specific for individuals 
>80 years were not available why we chose the next best estimate (>70). The GBD is a public 
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database capturing national estimates on total and disease-specific DALYs [12]. The country-
specific CVD burden ranged from 16% in France to 59% in Ukraine (Appendix figure 1). The 
countries were divided into two groups according to the median of CVD burden, i.e. <22.5% 
(‘low’) and ≥22.5% (‘high’).
Country-specific life expectancy at age 60 years was considered a possible effect modifier, and 
the prevalence of persons aged ≥80 years per country was considered a possible confounder 
for the association between CVD burden and GP treatment probability. Life expectancy at age 
60 years was obtained from the 2015 Global Health Observatory data repository of the World 
Health Organisation [13]. Prevalence of oldest-old was available from the 2015 report of the 
United Nations [14]. Data specific for individuals >80 years were not available why we chose 
the next best estimate (>60). Both covariates were dichotomized in two quantiles according 
to their medians: life expectancy at age 60 years low (<24 years) and high (≥24 years) and 
prevalence of oldest-old low (<4.6%) and high (≥4.6%).
Per GP, we included gender and years of experience on an individual level from the ATTEN-
TIVE data. Years of experience was categorized into two groups of about equal sizes: <15 years 
(‘low’) and ≥15 years (‘high’).
The previous ATTENTIVE study [10] showed that patient characteristics (SBP, CVD and 
frailty) were independently associated with the GPs’ decisions to start antihypertensive treat-
ment. However, for the present study, we were only interested in the overall effect of CVD 
burden on GP treatment probability; therefore, as an outcome, we chose the proportion of all 
case vignettes for which GPs decided to start treatment, and neglected the case characteristics 
(SBP, CVD and frailty).
statistical analysis
The ATTENTIVE dataset was visually explored and checked for missing data, outliers and 
inconsistencies. New dichotomized variables were generated (after visual checks) by group-
ing of the distributions using histograms. The exposure and all covariates were checked for 
multicollinearity by calculating pairwise correlation coefficients.
Chi-squared tests and unadjusted odds ratios (OR), as well as 95% confidence intervals (CI), 
were used to investigate whether the exposure (CVD burden) and the other independent vari-
ables (GP gender/years of experience, life expectancy at age 60, and prevalence of oldest-old) 
were associated with the outcome (GP treatment probability).
On a country level, continuous data of CVD burden and averaged GP treatment probability 
per country were visualized using scatter plots. A linear regression line with 95% CI was 
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derived using a univariate linear regression model. In a sensitivity analysis, this analysis was 
restricted to those countries where >60% of the GPs responded to the survey.
Chi-squared tests were then used to investigate whether CVD burden was associated with 
any of the independent variables and, if not on a causal pathway, these were considered to be 
potential confounders.
All potential confounders were tested for the degree of confounding and/or effect modifica-
tion using the Mantel-Haenszel test of homogeneity of ORs (detailed in Appendix table 1). 
As pre-specified, the causal model presented stratum-specific ORs and 95% CI for low and 
high life expectancy at age 60 years. Variables that confounded the association between the 
exposure and the outcome were included in the final model.
A two-sided p-value of 0.05 was considered statistically significant. All analyses were per-
formed in STATA release 14.2 (Stata Corp, College Station, TX, USA).
resuLts
In the ATTENTIVE study, 2,543 GPs from 29 countries participated. The median response 
rate for all countries was 26% (21 countries with <60%, 8 countries with ≥60%). Of those 
participating, 1,947 GPs (76.6%), provided an answer for all eight case vignettes.
Table 1 presents the baseline characteristics of the participating GPs and the countries, strati-
fied by GP treatment probability. There were 1,160 (59.6%) GPs with a low and 787 (40.4%) 
GPs with a high GP treatment probability. Countries with a high CVD burden showed a posi-
tive association with GP treatment probability (OR 3.70, 95% CI 3.03, 4.52; p<0.001).
Figure 1 shows the association between CVD burden and GP treatment probability on a coun-
try level using continuous data. Strong evidence was found for an association between CVD 
burden and GP treatment probability (p<0.001). Of all countries, the Netherlands had the 
lowest GP treatment probability (34%) and one of the lowest CVD burdens (16%), whereas 
Ukraine was among the countries with both the highest GP treatment probability (88%) and 
CVD burden (59%). When restricting the analysis to countries with a response rate of >60%, 
the sensitivity analysis confirmed this association (p=0.001) (Appendix figure 2).
In countries with a high CVD burden, the ORs for treatment was higher compared to countries 
with a low CVD burden (3.70, 95% CI 3.00, 4.57). Country-specific prevalence of oldest-old 
was a significant confounder (adjusted OR 2.71, 95% CI 2.17, 3.38) while GP gender and 
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Figure 1 Association between country-specific cardiovascular disease (CVD) burden and mean general practitioner (GP) 
treatment probability per country in oldest-old. Univariate linear regression was used (red line), 95% confidence intervals 
(grey lines) and p-value. FR=France; NZ=New Zealand; SE=Sweden, UK=United Kingdom 
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Figure 1. Association between country-specifi c cardiovascular disease burden and mean general practitioner 
(GP) t atment probability per ountry in oldest-old. Univariate linear regression was used (bold line), 95% 
confi dence intervals (fi ne lines) and p-value. FR=France; NZ=New Zealand; SE=Sweden, UK=United Kingdom
table 1. Baseline characteristics of general practitioners (GPs) and countries, and their association with high 
GP treatment probability to start antihypertensive treatment in oldest-old (n=1,947).
Characteristics
GP treatment probability
P-valueLow (≤50%)
(n=1,160)
high (>50%)
(n=787)
Crude odds ratio of high GP 
treatment probability (95% Ci)
GP Gender
Female 535 (54.6) 445 (45.4) 1.00 (reference)
Male 625 (64.6) 342 (35.4) 0.66 (0.55, 0.79) <0.001
experience as GP
<15 years 558 (56.7) 427 (43.4) 1.00 (reference)
>15 years 602 (62.7) 358 (37.3) 0.78 (0.65, 0.93) 0.007
Prevalence of oldest-old
Low 404 (45.0) 493 (55.0) 1.00 (reference)
High 756 (72.0) 294 (28.0) 0.32 (0.26, 0.38) <0.001
Life expectancy at age 60 years
Low 216 (36.4) 378 (63.6) 1.00 (reference)
High 944 (69.8) 409 (30.2) 0.25 (0.20, 0.30) <0.001
Cardiovascular disease burden
Low 930 (69.4) 411 (30.7) 1.00 (reference)
High 230 (38.0) 376 (62.1) 3.70 (3.03, 4.52) <0.001
P-values are from univariate logistic regression
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GP years of experience were not confounders. Life-expectancy at age 60 years was an effect 
modifier (Mantel-Haenszel test of homogeneity p=0.005) of the association between CVD 
burden and GP treatment probability. Therefore, we included country-specific prevalence of 
oldest-old in the multivariate model and present stratum specific estimates for low and high 
life expectancy at age 60 years.
In the final model (Table 2), GPs working in countries with a high CVD burden and a low 
life expectancy at age 60 years were more likely to start antihypertensive treatment in the 
oldest-old (adjusted OR 2.18, 95% CI 1.12, 4.25) compared to their counterparts in countries 
with a low CVD burden. In countries with a high life expectancy at age 60 years, there was no 
evidence for such an association (adjusted OR 1.06, 95% CI 0.56, 1.98).
DisCussion
The clinical dilemma when deciding whether (or not) to start antihypertensive treatment in 
the oldest-old may not only be explained by differences in patient characteristics but also in 
country-specific characteristics. In the present study including 1,947 GPs from 29 countries, 
a high country-specific CVD burden was associated with a higher probability of GPs deciding 
to start antihypertensive treatment in patients aged >80 years. However, the association was 
modified by country-specific life expectancy at age 60 years. While there was a positive asso-
ciation for GPs in countries with a low life expectancy at age 60 years, there was no association 
for GPs in countries with a high life expectancy at age 60 years. These findings (partly) explain 
some of the large variation seen in the decision as to whether or not to treat hypertension in 
the oldest-old [10].
strengths and limitations
The inclusion of a large number of GPs from a large number of countries (in Europe and be-
yond) is a strength of this study; this allowed us to study the relation between country-specific 
health characteristics and GP decisions in an ecological analysis. Also, we could describe GP 
treatment probabilities in countries that are not usually included in international studies.
table 2. Final model including 1,947 GPs for the association of cardiovascular disease (CVD) burden on GP 
treatment probability in oldest-old.
Fully-adjusted odds ratio of GP treatment 
probability (95% Ci)
CVD burden (stratum-specific)
Low life expectancy at age 60 2.18 (1.12, 4.25)
High life expectancy at age 60 1.06 (0.56, 1.98)
Prevalence of oldest-old 0.48 (0.39, 0.59)
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This study also has limitations. First, GP treatment probability was self-reported and based 
on fictive cases stories and not on, for example, chart reviews. Second, the overall response 
rate was only 26% across all countries, which is not uncommon in surveys involving GPs 
[15]. However, our response rate was not lower than in other GP survey studies [16, 17] and 
low response rates of GPs do not necessarily result in selection bias [18, 19]. In addition, 
when restricting our analysis to countries where the GPs responded for ≥60%, the results 
remained unchanged. Third, we can only report associations and not causation as this was an 
observational study with limitations such as residual confounding. However, we explored and 
reported patient-related factors associated with GP treatment probability in an earlier study 
[10].
Findings in relation to other studies
The results from this study suggest that GPs in countries where their 60-year-old patients 
will die (on average) before the age of 84 years, base their decision to start antihypertensive 
treatment in the oldest-old not only on the individual risk or prevalence of oldest-old, but 
also on the CVD burden of their country. In our opinion, the daily experience and case load 
provides GPs with sufficient knowledge to assess CVD burden and country-specific DALY of 
the patients that they see and treat, even without knowing the exact burden. DALYs due to 
CVD burden are not only a problem in high-income countries but mostly in low- and middle-
income countries (LMIC) [20]. The inequity in cardiovascular health in LMIC compared 
to high-income countries, calls for empowering GPs with the knowledge/skills to meet the 
requirements in these countries [21]. While our study shows that, in countries with a lower 
life-expectancy, GPs are more inclined to treat hypertension when CVD burden is high, the 
effects of such treatment on e.g. mortality or patient-relevant outcomes such as quality of life, 
remain unclear. Treatment goals for hypertension (especially in older patients) are constantly 
changing [22]. Although trials including oldest-old show a clear benefit of lowering blood 
pressure [23, 24], the generalizability of these studies is still debated [22, 25-27]. In this clinical 
dilemma, prognosis and life expectancy are issues that GPs relate to in the decision-making 
process in older patients [6].
Meaning of the study
Future high-quality observational studies, or new trials including the otherwise excluded frail 
patients with multimorbidity, should be conducted to provide more evidence for decision-
making with respect to hypertension treatment in the oldest-old. With evidence that can be 
generalized for GP patients that are frail and multimorbid, the implementation into daily 
practice should be thoughtfully planned. Our study found also a crude association of female 
GPs and GPs with a shorter than 15-year experience to treat more often hypertension in 
oldest-old. Future studies could further investigate if this association is real. These steps are 
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needed to overcome inequities in treatment decisions across countries with different CVD 
burdens and life expectancies.
Conclusions
The clinical dilemma when deciding whether (or not) to start antihypertensive treatment in 
the oldest-old appears not only to be explained by differences in patient characteristics but 
also in country-specific health characteristics. In this ecological comparative study, GPs living 
in countries with a high CVD burden and low life expectancy at age 60 years were more likely 
to start antihypertensive treatment in the oldest-old than GPs in countries with a low CVD 
burden and a high life expectancy at age 60 years.
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Appendix figure 1. Characteristics of all 29 included countries (number of GPs per country)
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Appendix 2 Sensitivity analysis including only countries with a response rate of >60% (n=8). Association between country-
specific cardiovascular disease (CVD) burden on mean general practitioner (GP) treatment probability per country in oldest-
old. Univariate linear regression was used (red line), 95% confidence intervals (grey lines) and p-value. UK=United Kingdom
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Appendix table 1. Assessing confounding and testing for effect modification on the association of cardiovascu-
lar disease (CVD) burden on GP treatment probability in oldest-old.
odds ratio of GP treatment 
probability (95% Ci) P-value
unadjusted effect of CVD burden 3.70 (3.00, 4.57)
effect of CVD burden adjusted for …
Gender 3.55 (2.87, 4.41) 0.19
Female 4.01 (3.01, 5.34)
Male 3.01 (2.18, 4.16)
High experience (15 years) 3.73 (3.02, 4.60) 0.87
Low 3.79 (2.81, 5.12)
High 3.66 (2.71, 4.93)
Life expectancy at age 60 1.48 (0.97, 2.29) 0.005
Low 2.96 (1.53, 5.72)
High 0.82 (0.44, 1.53)
Prevalence of oldest old 2.71 (2.17, 3.38) 0.57
Low 2.59 (1.96, 3.41)
High 2.96 (2.06, 4.24)
P-values are from Mantel-Haenszel test of homogeneity of odds ratios. Variables highlighted in grey were cho-
sen for the final model.
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General Discussion
Physicians face a clinical dilemma when they treat hypertension in >75-year-olds, since this 
population varies widely in cognitive and physical function. Some are very healthy, while others 
have several chronic diseases (multimorbidity), take many different drugs (polypharmacy), or 
are frail. This thesis began with the case of a frail 90-year-old patient with polypharmacy (Mrs 
S) and her question about her ideal blood pressure target under antihypertensive treatment, 
given her age, medical conditions, and living situation. GPs aim to reduce the risk that Mrs S 
will suffer from a severe stroke or myocardial infarction, and also to preserve her function. As 
Mrs S put it, “I don’t want to live longer, but I want to be independent for as long as possible”.
In the context of Mrs S, this thesis set out to 1) measure the prevalence of polypharmacy in 
older patients; 2) test for an association between low SBP and mortality, cognitive function, 
daily functioning, and QoL in older patients under antihypertensive treatment; and, 3) to 
understand the role that frailty plays in GP decisions about treating hypertension in old age 
across countries, and see if those differences can be explained by country-specific cardio-
vascular disease burden and life expectancy. Below, the main findings and limitations are 
discussed, and suggestions are made about clinical practice, and directions for future research.
MAin FinDinGs oF the three AiMs
hypertension has the strongest association with polypharmacy
Most chronic conditions are addressed by guidelines that focus on a single disease. GPs must 
rely on these guidelines to treat patients with multiple chronic conditions, but when patients 
have multimorbidity, single-disease guidelines can increase the prevalence of polypharmacy 
and potentially inappropriate polypharmacy (PIP). Still, little is known about prevalence and 
drivers of polypharmacy.
Chapter 2 established the high prevalence of polypharmacy in patients from four university 
primary care settings in Switzerland. In the whole age group (50-80 years), about 40% had 
polypharmacy, but among 75-80-year-olds, more than 50%, and some took even 10 or more 
long-term medication. Patients with hypertension in the oldest age group had about a 9-fold 
greater risk of polypharmacy.
Mrs S’ hypertension is a factor in her polypharmacy, since, like many her age, she might need 
to take more than one drug to reach the blood pressure target set by current guidelines. In 
a sample of >60-year-old diabetic patients from the UK, about every third patient needed 
at least three different drugs to reach their blood pressure target of <150/85mmHg [1]. Hy-
pertension, diabetes mellitus, and chronic kidney disease are all strongly related to CVD, so 
patients with these comorbidities are often prescribed more drugs than recommended for 
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both primary and secondary prevention (e.g. aspirin, statins) [2-5]. The association we found 
between CVD and polypharmacy aligns with the results of other studies [6, 7], as does the 
association between polypharmacy and potentially inappropriate prescriptions [8].
Our study underlined the importance of reconsidering each prescription. Age and number 
of chronic conditions are key factors, as is type of disease (e.g. hypertension). The STOPP/
START criteria may be useful here [9, 10]. Because applying the whole set of explicit criteria 
is time-consuming and hard to implement in everyday clinical practice, physicians would 
appreciate another solution. Software programs that address polypharmacy are being devel-
oped and tested for effectiveness [11]. GPs could make a sound clinical judgment and then 
take shared decision-making approach to determine which prescriptions they should start, 
continue or deprescribe. This approach is even more sensible to take with older patients with 
frailty.
Low sBP associated with increased mortality and cognitive decline in patients with 
frailty
Deciding on the optimal SBP in older patients with frailty is not a simple task. GPs face a 
dilemma for GPs because results cannot be generalised from hypertension trials that excluded 
older and frail patients.
In Chapters 3 and 4, we thus tested for an association between low SBP and mortality, cogni-
tive function, daily functioning, and QoL in >75-year-olds under antihypertensive treatment. 
We stratified our analyses on frailty (defined as low hand grip strength or complex health 
problems) to test our hypothesis in patients who are usually excluded from previous trials.
In Chapter 3, we analysed the Leiden 85-plus Study, a Dutch population-based cohort (n=599) 
of all 85-year-olds, followed up for five years. We found low SBP under antihypertensive 
treatment was associated with increased all-cause mortality and accelerated annual cognitive 
decline. But frailty indicated by low hand grip strength modified the association with cogni-
tive function: frail patients suffered accelerated cognitive decline. In non-frail participants and 
in those not treated for hypertension, SBP and mortality/cognitive function were not related.
In ISCOPE, a more recent cohort (n=1,266) with younger participants (all ≥75 years-old) 
and a one-year follow-up (described in Chapter 4), we confirmed low SBP was similarly 
associated with cognitive decline with no negative effect on daily functioning and QoL in 
participants under antihypertensive treatment. Again, the association was modified by the 
presence of frailty (defined as having complex health problems): in participants with complex 
health problems, low SBP and cognitive decline were associated. In line with findings from the 
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Leiden 85-plus Study, we found no negative association of low SBP and cognitive decline in 
those not under antihypertensive treatment.
In the context of Mrs S, the Leiden 85-plus Study offers new insights because it was population-
based, and thus generalizable to the general population. The study also had a sufficiently long 
follow-up of 5 years. The ISCOPE study confirmed our results in a slightly younger population 
of older patients that were followed-up about 10 years after the Leiden-85 plus Study ended, 
so we conclude that these findings are very likely to be true regardless of the sample or time 
period being investigated.
Our findings on accelerated cognitive decline are in line with other cohort studies [12, 13]. 
However, the only other study that analyzed patients under antihypertensive treatment sepa-
rately from those without treatment was the landmark study by Mosello et al. [14]. Mosello’s 
cohort differs in setting (outpatient memory clinics), follow-up time (<1 year) and population 
and included only patients with dementia or mild cognitive impairment, while we included 
participants with the full range of cognitive function at baseline. Our study had a larger 
sample and was the first to show these associations between low SBP and cognitive decline in 
the general population, over an observation period of one or more years.
Other studies of patients aged >60 found no association when adjusting for antihypertensive 
treatment [15], or found an association between higher SBP and better cognitive function 
and lower risk of dementia [16]. Our studies added to the evidence that age modifies the 
association [17]. In studies that included >60-year-olds there was no association between SBP 
and cognitive decline [15], and no association between higher SBP and lower risk of dementia 
[16]. But in >75-year-olds, low SBP predicted the onset of dementia [18] and was associated 
with worse cognitive function [19]. The association reverses at about age 75, when hyperten-
sion no longer predicts dementia [18] and is not associated with worse cognitive function 
[19]. There is evidence that existing vascular injury cannot be reversed in late life, and low 
SBP in late life could disturb the hemodynamic regulation of the heart and brain and reduce 
cognitive function [20, 21].
We found no evidence SBP was associated with daily functioning, though prior studies identi-
fied both positive and negative associations [19, 22, 23]. A cohort study of 35 centenarians 
in Poland found higher SBP had a beneficial effect on daily activity [19]. The Leiden 85-plus 
Study found higher SBP levels were associated with lower ADL disability over 5 years [22]. But 
a US longitudinal cohort study of about 600 75-year-olds found high SBP was associated with 
declining physical function (measured by gait speed) over 10 years of follow-up [23].
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Most studies that assessed the association of SBP with function in old age did not assess QoL. 
We know of only a Polish cohort of 11,500 patients, which found that those under antihyper-
tensive treatment had optimal QoL with higher SBP [24].
Despite limited evidence, physicians must decide every day on appropriate treatment for 
hypertension in older patients with frailty like Mrs S [25, 26]. Physicians want to reduce 
stroke and myocardial infarction risk and preserve cognitive function, daily functioning 
and QoL. Benetos et al. [27] suggest GPs to take an individualized approach when treating 
hypertension in older patients with frailty. Since we showed that higher blood pressure under 
treatment is better for cognitive function, there is an argument for increasing blood pres-
sure by deprescribing antihypertensive treatment. Early trials, like the Dutch DANTE study, 
asked if deprescribing antihypertensive medication improved cognitive function in older 
patients with mild cognitive impairment, but found no evidence of this effect after 16 weeks of 
follow-up [28]. Long term effects of deprescribing antihypertensives are still uncertain, but a 
recent Cochrane review found withdrawing from antihypertensive therapy in old age did not 
increase mortality [29]. We encourage researchers to conduct new randomized trials to test 
the long-term effectiveness and safety of deprescribing antihypertensive therapy to raise SBP, 
especially in >75-year-olds with frailty.
Variation in antihypertensive treatment in old age, according to GPs
We speculated that GPs practicing in countries with a high CVD burden from stroke and 
myocardial infarction might decide to treat Mrs S differently than GPs in countries with low 
burden of CVD. We thus set out to collaborate with GPs from 29 countries in Europe, Brazil, 
Israel, and New Zealand. Using case-vignettes, similar to the story of Mrs S, revealed that the 
2,543 GP participants made very different decisions about when and if to start antihyperten-
sive treatment. To try to explain part of the variation, we also categorized countries in groups 
of CVD burden based on disability adjusted life years (DALY) [30] and life expectancy at age 
60 [31].
In Chapter 5, we found wide variation in how GPs decided to start antihypertensive treatment 
in old age. Dutch GPs advised starting antihypertensive treatment in 34% of all case-vignettes, 
while GPs from Ukraine did so in 88%. As hypothesized, frailty was important for GPs when 
they decided about antihypertensive treatment. In Chapter 6, we confirmed that in countries 
with a high CVD burden, GPs were more likely to advise starting antihypertensive treatment. 
This association was modified by country-specific life expectancy at age 60. While there was a 
positive association for GPs in countries with low life expectancy at age 60 years, this associa-
tion was absent for GPs in countries with high life expectancy.
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The wide spectrum of recommendations and lack of clear evidence may explain some of the 
variation between GPs in different countries. Differences may also be caused by national 
guidelines/campaigns. This study did confirm our hypothesis that GPs factor in frailty when 
they treat hypertension in patients like Mrs S. GPs were also less likely to treat frail patients, 
even after we adjusted for SBP and history of CVD. Our results are in line with findings from 
a Dutch qualitative study where vulnerability was a significant patient-related barrier for GPs, 
who hesitated to implement guidelines for secondary cardiovascular prevention in old age 
[32]. The only other published study on this topic, Mermans et al., surveyed GPs in Belgium 
and also found wide variations in GPs’ intentions to treat hypertension in old age, but frailty 
was not associated with variation found in Belgium [33]. On an international level, when we 
included many countries and more GPs, we found frailty was an important factor influencing 
GPs’ treatment decisions.
Part of the international variation could be explained by national differences of CVD burden 
and life expectancy at age 60. We believe GPs base their assessment of CVD burden and 
country-specific DALY on their own experience and case load, even if they do not know 
the exact numbers. This might explain why Mrs S, who lives in Switzerland where the CVD 
burden is low, and life-expectancy is high, is likely to have a GP who is more concerned about 
prescribing antihypertensive treatment. DALYs caused by CVD burden pose a problem in 
high-income countries, but the problem is greater in low- and middle-income countries [34]. 
To address this inequity in cardiovascular health between low-, middle- and high-income 
countries remains challenging [35].
These studies confirmed the hypothesis that GPs do not treat hypertension in old age uni-
formly, and that patient characteristics, national burden of CVD, and life expectancy play a 
role in their decisions, as in the case of Mrs S. There is a need for more high-quality cohort 
studies and, ideally, new hypertension trials that deliberately include >75-year-olds with 
frailty. Future studies should seek to determine if treatment variation can be explained by, e.g., 
the fact that individual GPs follow different guideline recommendations. Qualitative studies 
could help us better understand the variation we identified.
MethoDoLoGiCAL ConsiDerAtions
Study design and data from the studies presented in this thesis have some methodological 
limitations, including selection bias, the question of causality in associations, the possibility of 
reverse causality, confounding, missing data, and risk of misclassification.
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selection Bias
Selection bias can occur when individuals included in a study differ from individuals not 
included or those that did not participate: an association between exposure and outcome 
could differ between those included and those not. Low response rates usually raise concerns 
about selection bias.
For example, in Chapter 2, we restricted our analyses to patients aged 50 to 80, so we cannot 
draw conclusions about younger or older patients. Ideally, our sample would have included 
patients over 80, but the CORIF dataset was extracted from medical charts and we could 
not revisit these charts to collect data from those >80-year-olds. Prevalence of polypharmacy 
increased linearly with age, but it might have increased even more steeply in >80-year-olds.
In Chapter 4, about 63% of invited individuals responded to the baseline questionnaire in 
ISCOPE. Non-responders were more frail but otherwise similar to responders, though selec-
tion bias cannot be ruled out.
In Chapters 5 and 6, our overall response rate was only 26% across all countries, which is not 
uncommon in surveys of GPs [36]; this response rate was not lower than in other surveys [37, 
38]. Low response rates of GPs do not necessarily create selection bias [39], since also studies 
‘with low response rates may provide a representative sample’ [40]. For example, when we 
restricted our analysis in Chapter 6 to countries where ≥60% of GPs responded, our results 
were robust.
Association versus causation
When chance, bias, or confounding are unlikely to explain a given association, we can assume 
the association is true. The next step to judging causality can only be taken based on current 
available evidence. The GRADE framework [40] situates such associations in this context. 
Bradford Hill’s criteria for causation can be applied [41] to determine if associations can be 
considered to be causal. For example, several factors suggest a causal association in Chapters 
3 and 4, but do not prove causality in the relationship between low SBP, and mortality and 
cognitive function in >75-year-olds. Using Bradford Hill’s criteria, we determined the fol-
lowing: 1) SBP, antihypertensive treatment and cognitive function were strongly associated 
in this study, consistent with other studies. 2) This study established a temporal relationship 
between SBP values measured a year prior to study inclusion and assessments of outcome one 
year after (Chapter 4), and up to five years after (Chapter 3). 3) We also identified a pattern of 
dose-response relationship because SBP had an incremental effect on mortality and cognitive 
function in old age. 4) There is more evidence for the biological plausibility of an association 
between SBP, antihypertensive treatment and cognitive function. Existing vascular injury 
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cannot be reversed in late life; where it is present, antihypertensive treatment may disturb the 
hemodynamic regulation of the heart and brain and reduce cognitive function [20, 21].
Confounding
When an exposure is associated with an outcome, there could be other factors (confounders) 
that are all or in part responsible for the association. For example, age, sex, or many others. 
Confounding can be controlled for in the study design by randomization, restriction, match-
ing, stratification, or adjusting in a multivariable model. For example, in Chapters 3 and 4, 
where we adjusted for a set of predefined known confounders such as age, sex, and history of 
CVD. However, other potentially important confounders were unavailable. For example, there 
could be other reasons that we do not know for why GPs prescribe or do not prescribe antihy-
pertensive treatment in old age, which is a problem of confounding by indication. This might 
have led to residual confounding. But in the Netherlands, GPs issue national guidelines (NHG 
Standaard) that also make evidence-based recommendations on antihypertensive therapy in 
old age [42]. We know from international comparisons that almost all Dutch GPs use the 
NHG Standaard when they treat hypertension in old age (unpublished subgroup analysis 
of the ATTENTIVE Study in Chapter 5 and 6). ATTENTIVE helped us to identify a set of 
confounders most often mentioned by GPs when they decide on antihypertensive treatment 
and define SBP goals in old age.
reverse causality
Reverse causality means that factor X and Y are associated differently than one would expect. 
While common sense often allows us to exclude reverse causality (e.g., lung cancer does not 
cause smoking), in other examples exclusion can be less trivial. For example, in Chapters 3 
and 4, our observations of the relationship between SBP and cognitive function can also be 
explained by reverse causality, if cognitive decline leads to lower SBP. To minimize the risk of 
bias, in Chapter 3, patients who died within 12 months of follow-up were excluded from the 
analysis to reduce the risk of reverse causality. In Chapter 4, we used the SBP measure taken a 
year before baseline, and the cognitive function measure taken after one year.
Missing data and risk of misclassifications
Missing data is a common problem in clinical research when some of the participants are not 
measured or participants did not answer all questions in a questionnaire. Missing data leads 
to a biased dataset restricted only to participants with complete data. There are two types of 
missing data. If some data is missing completely at random (e.g. postal questionnaires not 
returned to the study centre because they are lost), the associations found in the remaining 
data are likely not affected by missing data. But when data is not missing at random (e.g. 
frail patients cannot perform a test) the identified associations are biased. For example, in 
Chapter 4, about 15% of participants had no SBP measurement in the year before they were 
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included in the study. GPs may have been less likely to measure or record SBP in participants 
at lower cardiovascular risk, or to measure at intervals greater than one year. In Chapter 3, a 
research nurses had not taken SBP measurements at baseline for about 5% of participants in 
this cohort study. Since the association between SBP and cognitive function was the same in 
a sensitivity analysis that included only participants with low cardiovascular risk (no history 
of CVD), we do not think that excluding participants with missing SBP data changed the 
associations. In Chapter 3 and 4, we classed antihypertensive therapy (yes or no) based on 
prescriptions recorded in EMRs. If participants were prescribed antihypertensive drugs, but 
did not adhere to the treatment regimen, they would have been misclassified as exposed to 
therapy. However, patients treated for hypertension in the Netherlands adhered better than 
patients in seven other European countries [43], so the risk of misclassification was lowest in 
this country where both studies were conducted.
ConCLuDinG reMArks
Earlier, we met Mrs S, a 90-year old woman under treatment for hypertension, consulting 
her GP for a routine check of her blood pressure, which was 154 mmHg in the office and 
between 145-150 mmHg at home. She, and patients like her, are unlikely to be included in 
randomized trials that contribute evidence for the development of clinical guidelines on how 
to treat hypertension in old age.
From a clinical perspective, the evidence presented in this thesis and other current evidence 
suggest we consider moving cautiously to re-define SBP treatment goals, especially in older 
patients with frailty [27]. Mrs S’ GP could decide that her current SBP of 154 mmHg is ac-
ceptable and it might be harmful to reduce it to <130 mmHg. Her GP might want to explain 
his dilemma to her: The results of existing trials are valid but cannot be generalized to her 
situation. Even though observational studies show the same associations in participants like 
Mrs S, we cannot prove causality. But we do not believe that trials and observational studies 
conflict. Together, both support the goal of individualizing antihypertensive treatment in 
older patients with frailty. This approach might also help us to reduce the wide treatment 
variation we identified across 29 mainly European countries, although these variations are 
explained not only by patient characteristics but also by disease burden and life expectancy 
in each country.
We should conduct new trials to test the effectiveness and safety of deprescribing antihy-
pertensive medications and raising SBP. The most recent Cochrane review of the effects of 
deprescribing was uncertain about its effect [29], but mortality did not significantly increase 
in participants allocated to deprescribing from antihypertensive treatment. The next round 
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of trials should test the long-term effectiveness and safety of deprescribing antihypertensive 
therapy to raise SBP in >75-year-olds with frailty.
Patients such as Mrs S often have polypharmacy, and conditions like hypertension combined 
with age to increase risk of polypharmacy. Mrs S is >75-years-old with frailty. In patients 
like her, we found an association between low systolic blood pressure and risk of mortal-
ity and cognitive decline, with no negative effect on daily functioning or quality of life. We 
did not find these associations in participants without antihypertensive treatment or frailty. 
Finally, we found wide variation in the advice given by GPs across Europe, Brazil, Israel and 
New Zealand on starting antihypertensive treatment in Mrs S’ case. Frailty and burden from 
cardiovascular diseases explained part of the variation. This study lays the groundwork for 
individualized treatment goals in >75-year-olds with hypertension, and for new deprescribing 
trials to test the effectiveness of stopping/reducing antihypertensive treatment in >75-year-
olds with frailty. Patients like Mrs S will benefit from the findings of such studies, and GPs 
might face less of a clinical dilemma when they treat hypertension in old age.
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Summary
Physicians face a clinical dilemma when deciding on the optimal systolic blood pressure (SBP) 
target in old age especially in >75-year-olds, a population characterized by wide variation 
of cognitive and physical function. Some are very healthy, others have co-existing chronic 
conditions (i.e. multimorbidity) are therefore under treatment with multiple drugs (i.e. poly-
pharmacy) or are frail.
With increasing age, blood pressure rises as a consequence of arterial stiffness and it has 
been debated whether or not to it is beneficial to treat hypertension in old age especially in 
>75-year-olds when they have multimorbidity, polypharmacy or frailty. Large hypertension 
trials showed that lowering SBP in >60-year-olds is beneficial and lowers the risk for myo-
cardial infarction, stroke and all-cause mortality, even in >80-year-olds. However, these trials 
lack generalizability and typically excluded multimorbid patients that are frail. At the same 
time, observational studies rose concerns about lowering SBP too much since there are several 
cohort studies showing a reverse association of low SBP and increased mortality and acceler-
ated cognitive decline especially in >75-year-olds. However, current hypertension guidelines 
advise physicians to lower SBP to values of even <130mmHg in all patients from the age of 60 
years, which fuelled the discussions about the benefits and harms of lowering SBP too much 
in >75-year-olds under antihypertensive treatment especially when they are frail defined as 
having low hand grip strength or complex health problems in multiple domains of daily living.
This dilemma is summarized in Chapter 1 in a case report of Mrs S, a frail 90-year-old with 
multimorbidity and polypharmacy, that came to her general practitioner (GP) for a routine 
check of her blood pressure: her SBP was 154 mmHg under antihypertensive treatment. A GP 
would want to protect Mrs S by treatment from stroke or myocardial infarction, and preserv-
ing her cognitive function, daily functioning and quality of life (QoL) at the same time. Mrs S 
represents these individuals that are often excluded from hypertension trials, thus we cannot 
be sure that results from such trials apply to Mrs S.
The general aim of this thesis is to increase the scientific knowledge about the effects of treat-
ing hypertension in >75-year-olds with frailty. This thesis has three aims: 1) to measure the 
prevalence of polypharmacy in older patients; 2) to test for an association between low SBP 
and mortality, cognitive function, daily functioning, and QoL in older patients under antihy-
pertensive treatment; and 3) to understand the role that frailty plays in GP decisions about 
treating hypertension in old age across countries and see if those differences can be explained 
by country-specific cardiovascular disease burden and life expectancy.
Polypharmacy – Part of preventive cardiovascular medication
Most chronic conditions are addressed by guidelines that focus on a single disease. GPs must 
rely on these guidelines to treat patients with multiple chronic conditions, but when patients 
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have multimorbidity, single-disease guidelines can increase the prevalence of polypharmacy 
and potentially inappropriate polypharmacy (PIP). Still little is known on prevalence and 
drivers of polypharmacy.
In Chapter 2, we set out to measure the prevalence of polypharmacy in a random sample of 
1,002 patients in Switzerland, 50 to 80 years old, in university primary care settings. We fur-
ther wanted to assess the association of polypharmacy with specific comorbidities, including 
cardiovascular prevention, to identify subgroups of patients at higher risk of polypharmacy.
We found a high prevalence of polypharmacy: In the total age group (50-80 years), about 40% 
had polypharmacy, in the oldest age group (75-80), even more than half, some of them even 
taking 10 or more long-term medication. Patients in the oldest age-group with hypertension 
had an about 9-fold risk of having polypharmacy.
This study underlines the importance of reconsidering each prescription. Age and number of 
chronic conditions are key factors, and so is the type of disease (e.g. hypertension). GPs must 
both make a sound clinical judgment, and then work with their patient to determine which 
prescriptions should be started, continued or deprescribed, in a shared decision-making 
process.
Low sBP associated with mortality and cognitive decline in frail older patients with 
complex health problems
Observational studies that follow the population of older and frail patients with multimorbid-
ity and polypharmacy have found that low SBP is associated with cognitive decline. Some 
speculate that low blood pressure due to intense antihypertensive treatment disturbs the 
hemodynamic regulation of the heart and brain and reduces cognitive function. A landmark 
study found that, in a select sample of 80-year-olds with dementia or mild cognitive impair-
ment, low SBP was associated with worse cognitive function in patients under antihypertensive 
treatment but not in those without antihypertensive treatment. These findings were limited by 
the study’s small sample size and short follow-up period of less than one year.
In Chapters 3 and 4, we therefore tested for an association between SBP and mortality, cogni-
tive function, daily functioning, and QoL in older patients under antihypertensive treatment 
and stratified our analyses on frailty.
In Chapter 3, we analysed data from the Leiden 85-plus Study, a population-based prospec-
tive cohort study of 85-year-olds inhabitants of Leiden were invited (n=599). We found low 
SBP under antihypertensive treatment was associated with increased all-cause mortality and 
accelerated annual cognitive decline. But frailty, measured by hand grip strength, modified the 
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association with cognitive function in ways that in those with a weak hand grip strength, there 
was cognitive decline. In non-frail participants and in those not treated for hypertension, we 
found no relationship between SBP and mortality/cognitive function.
In ISCOPE, a more recent observational cohort study (n=1,266) of >75-year-olds with a 
one-year follow-up described in Chapter 4, we could confirm the same associations of low 
SBP with cognitive decline without any negative effect on daily functioning and QoL in 
participants under antihypertensive treatment. Again, the association was modified by frailty 
defined as having complex health problems in ways that participants with complex health 
problems showed an association of low SBP and cognitive decline, but not in those without. In 
line with the findings in the Leiden 85-plus Study, those not under antihypertensive treatment 
showed no evidence for the same negative association of low SBP and cognitive decline.
Since we showed that higher blood pressure under treatment is better for cognitive function 
and mortality, this encourages physicians to take an individualized approach when treating 
hypertension in >75-year-olds with frailty. We urge researchers to conduct new randomized 
trials to test the long-term effectiveness and safety of deprescribing antihypertensive therapy 
to raise SBP especially in >75-year-olds with frailty.
Variation in antihypertensive treatment in old age, according to GPs
Since evidence on optimal antihypertensive treatment in >75-year-olds with frailty is scarce 
and present data are conflicting, we hypothesised there could be treatment differences be-
tween physicians. In Chapters 5 and 6, we sought to understand the role that frailty plays in 
GP decisions about treating hypertension in >75-year-olds across countries and see if those 
differences could be explained by country-specific cardiovascular disease burden and life 
expectancy.
The study surveyed 2,543 GPs from 29 countries in Europe, Brazil, Israel, and New Zealand. 
We constructed case-vignettes, all aged >80 years like Mrs S, and found in Chapter 5 that 
GPs from different countries made very different decisions about advising treatment of hy-
pertension in these patients. Treatment advise rate ranged from 34% to 88% per country. As 
we hypothesized, frailty played an important role in a GPs decision to start antihypertensive 
treatment. In Chapter 6, we studied the differences between countries by specific health data 
about countries including CVD burden and life-expectancy at age 60. In countries with a high 
CVD burden, GPs were more likely to advise starting treatment of hypertension in old age. 
The association was modified by country-specific life expectancy at age 60. Though there was 
a positive association for GPs in countries with low life expectancy at age 60 years, we found 
no association for GPs in countries with high life expectancy at 60 years.
Chapter 8
132
Both findings confirmed the hypothesis that GPs do not uniformly treat hypertension in old 
age, and that patient characteristics as well as national burden of CVD and life expectancy play 
a role in their decision, in ways like in the case of Mrs S. Both studies have several implications 
for research and clinical practice. High-quality cohort studies or (ideally) new hypertension 
trials that deliberately include frail patients are needed to gather evidence about frailty as fac-
tor in treating hypertension in >75-year-olds. Future studies should see if treatment variation 
can be explained by, e.g., guideline recommendations followed by individual GPs. Qualitative 
studies could help us better understand the variation we have identified.
Chapter 7 summarizes the main findings that 1) polypharmacy is highly prevalent in older 
people and hypertension is a driver for polypharmacy. 2) We found low SBP under antihy-
pertensive treatment to be associated with increased all-cause mortality and cognitive decline 
in participants that were frail. 3) As hypothesised, we saw a large variation in how GPs across 
29 mainly European countries decide to start antihypertensive treatment in older patients. 
GPs less often treated frail patients but their decision was also influenced by how large CVD 
burden was in their countries especially in countries with a low life expectancy.
These findings are discussed in the context of current literature and the case of Mrs S. Method-
ological limitations are addressed, including the main limitations of association versus causa-
tion, reverse causality and confounding. This thesis has strong implications. As directions for 
future research, we encourage researchers to conduct new trials to test the effectiveness and 
safety of stopping or reducing antihypertensive treatment (i.e. deprescribing) to increase SBP 
in >75-year-olds with frailty. From a clinical perspective, the findings and results of this thesis 
suggest we move cautiously to re-define individualized SBP thresholds in those older people 
under antihypertensive treatment that are frail.
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neDerLAnDse sAMenVAttinG
Artsen staan voor een klinisch dilemma wanneer zij de streefwaarde moeten vaststellen van 
een optimale systolische bloeddruk (SBD) voor ouderen, en in het bijzonder bij ouderen vanaf 
75 jaar. Deze populatie van 75-plussers kenmerkt zich door een sterke variatie in cognitief 
en fysiek functioneren. Sommigen zijn zeer gezond, anderen hebben meerdere naast elkaar 
bestaande chronische aandoeningen (multimorbiditeit) en worden daarom behandeld met 
meerdere medicijnen (polyfarmacie) of zijn kwetsbaar.
Met het oplopen van de leeftijd stijgt de bloeddruk als gevolg van arteriële stijfheid. Er bestaat 
discussie of het gunstig is om hypertensie op oudere leeftijd te behandelen, vooral bij 75-plus-
sers met multimorbiditeit, polyfarmacie of kwetsbaarheid. In grote trials naar de effecten van 
behandeling van hypertensie is aangetoond dat het verlagen van de SBD bij 60-plussers gun-
stig is en dat dit het risico op myocardinfarcten, beroerten en sterfte verlaagt. Dit geldt zelfs 
voor de subgroep van 80-plussers in deze grote trials. Echter, het ontbreekt in deze trials aan 
generaliseerbaarheid; oudere patiënten met multimorbiditeit en kwetsbaarheid zijn meestal 
uitgesloten.
Tegelijkertijd zijn er vanuit observationele studies zorgen ontstaan over het teveel verlagen van 
de SBD. Zo zijn er in meerdere cohort studies associaties gevonden tussen een lage SBD, een 
toename in sterfte en versnelde cognitieve achteruitgang, vooral bij 75-plussers. Het advies in 
de huidige internationale hypertensierichtlijnen om bij alle patiënten van 60 jaar en ouder de 
SBD te verlagen, zelfs tot waarden lager dan 130mmHg, voedt de discussie over de voor- en 
nadelen van het te veel verlagen van de SBD in 75-plussers nog meer.
In hoofdstuk 1 is dit dilemma samengevat in een vignet van mevr. S, een kwetsbare 90-plus-
ser met multimorbiditeit en polyfarmacie die bij de huisarts kwam voor een routinecontrole 
van haar bloeddruk. Haar SBD was 154 mmHg bij het gebruik van antihypertensiva. Middels 
deze behandeling tracht de huisarts mevr. S. te beschermen tegen een beroerte en een myo-
cardinfarct. Tegelijkertijd tracht hij haar cognitief en dagelijks functioneren en kwaliteit van 
leven te behouden. Mevr. S. vertegenwoordigt een groep mensen die vaak wordt uitgesloten 
van deelname aan hypertensie trials. Hierdoor kan niet met zekerheid gesteld worden dat de 
resultaten van deze trials ook van toepassing zijn op mevr. S.
Het doel van dit proefschrift is het vergroten van het wetenschappelijk inzicht over de effecten 
van de behandeling van hypertensie bij 75-plussers. De drie doelen van dit proefschrift zijn: 
1) het meten van de prevalentie van polyfarmacie in oudere patiënten; 2) het testen van de 
associatie tussen lage SBD, sterfte, cognitief functioneren, dagelijks functioneren en kwaliteit 
van leven bij oudere patiënten die behandeld worden met antihypertensiva; en 3) het verkrij-
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gen van inzicht in de variatie in behandeling van hypertensie bij ouderen door huisartsen 
uit verschillende landen en wat de invloed van kwetsbaarheid, cardiovasculaire ziektelast en 
levensverwachting hierop is.
Polyfarmacie in relatie tot cardiovasculaire preventieve medicatie
De meeste behandelrichtlijnen voor chronische ziektes zijn gericht op slechts één aandoening. 
Bij de behandeling van patiënten met meerdere chronische aandoeningen zijn huisartsen op 
dit soort ‘enkelvoudige’ richtlijnen aangewezen. In het geval van multimorbiditeit kunnen 
deze ziekte-specifieke richtlijnen de prevalentie van polyfarmacie verhogen en neemt het 
risico op het voorschrijven van potentiële ongepaste medicatie toe. Nog niet alle factoren die 
van invloed zijn op polyfarmacie zijn bekend.
In hoofdstuk 2 werd de prevalentie van polyfarmacie in een willekeurige steekproef van 1.002 
patiënten, tussen de 50 en 80 jaar, in de eerstelijn in Zwitserland bestudeerd. Daarnaast werd 
de associatie tussen polyfarmacie en comorbiditeit (waaronder cardiovasculaire preventie) in 
kaart gebracht om subgroepen met een verhoogd risico op polyfarmacie te identificeren.
We vonden een hoge prevalentie van polyfarmacie. In de totale groep (50-80 jaar) had on-
geveer 40% polyfarmacie, in de oudste leeftijdsgroep (75-80 jaar) zelfs meer dan de helft. 
Sommige ouderen kregen zelfs 10 of meer chronische medicijnen voorgeschreven. Patiënten 
in de oudste leeftijdsgroep met hypertensie hadden een negenvoudig verhoogd risico op 
polyfarmacie.
Deze studie onderstreept het belang om ieder medicatievoorschrift zorgvuldig af te wegen. 
Sleutelfactoren hierbij zijn leeftijd, het aantal chronische aandoeningen en het type aandoe-
ning (bijv. hypertensie). Huisartsen moeten een gedegen klinische inschatting maken en 
vervolgens samen in een proces van gezamenlijke besluitvorming (‘shared decision-making’) 
met de patiënt beslissen welke medicatievoorschriften gestart, gecontinueerd of gestopt kun-
nen worden.
Lage sBD is geassocieerd met sterfte en cognitieve achteruitgang bij kwetsbare 
ouderen met complexe gezondheidsproblemen
Observationele studies hebben aangetoond dat een lage SBD geassocieerd is met cognitieve 
achteruitgang bij oudere en kwetsbare patiënten met multimorbiditeit en polyfarmacie. Er 
wordt aangenomen dat de hemodynamische regulatie van het hart en brein verstoort raakt als 
gevolg van een door intensieve behandeling met antihypertensiva verlaagde bloeddruk en dat 
dit het cognitief functioneren doet verminderen. Deze hypothese wordt ondersteund door een 
studie waar in een geselecteerde groep van 80-jarigen met dementie of milde cognitieve stoor-
nissen een verband gevonden werd tussen een lage SBD en slechter cognitief functioneren bij 
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gebruik van antihypertensiva, terwijl deze associatie zonder het gebruik van antihypertensiva 
niet gevonden werd. Beperkingen van deze studie waren een kleine steekproefgrootte en de 
korte follow-up-periode van minder dan een jaar.
Het doel van hoofdstuk 3 en 4 was het onderzoeken van de associatie tussen SBD en sterfte, 
cognitief en dagelijks functioneren en kwaliteit van leven bij de oudere, met antihypertensiva 
behandelde patiënten. Om de relatie met kwetsbaarheid te onderzoeken werd gestratificeerd 
voor kwetsbaarheid.
In hoofdstuk 3 werd de data van de Leiden 85-plus Studie geanalyseerd, een prospectief 
populatie-gebaseerd cohortonderzoek waarin 85-jarige inwoners van Leiden (n=599) waren 
uitgenodigd om deel te nemen. Een lage SBD bij antihypertensiva gebruikers was geassocieerd 
met een verhoogd risico op sterfte en met versnelde jaarlijkse cognitieve achteruitgang. Ech-
ter, kwetsbaarheid gemeten door handknijpkracht had invloed op de associatie met cognitief 
functioneren. Ouderen met een zwakke handknijpkracht gingen cognitief sneller achteruit, 
maar dit gold niet voor niet-kwetsbare deelnemers en deelnemers die niet voor hypertensie 
werden behandeld.
In ISCOPE, een meer recent observationeel cohortonderzoek van 75-plussers (n=1.266) met 
één jaar follow-up dat beschreven is in hoofdstuk 4, werd dezelfde relatie tussen een lage 
SBD en versnelde cognitieve achteruitgang bij ouderen die met antihypertensiva werden 
behandeld bevestigd. In deze studie werd geen negatief effect op het dagelijks functioneren of 
op de kwaliteit van leven aangetoond. Opnieuw werd de associatie beïnvloed door kwetsbaar-
heid, hier gedefinieerd als het hebben van complexe gezondheidsproblemen. Bij deelnemers 
met complexe gezondheidsproblemen was een lage SBD geassocieerd met cognitieve achter-
uitgang, maar dit gold niet voor deelnemers zonder complexe gezondheidsproblemen. Deze 
bevinden zijn in overeenstemming met de bevindingen uit de Leiden 85-plus Studie.
Aangezien bovenstaande observationele studies hebben laten zien dat een hogere bloeddruk 
tijdens de behandeling van hypertensie beter is voor het cognitief functioneren en voor de 
overleving van oudere patiënten, worden artsen aangemoedigd om een individuele aanpak 
te hanteren bij de behandeling van hypertensie bij 75-plussers met kwetsbaarheid. Voor een 
verdere wetenschappelijke onderbouwing van deze behandeling is het belangrijk om nieuwe 
gerandomiseerde gecontroleerde trials uit te voeren naar de effectiviteit en veiligheid van 
bloeddrukverlaging bij 75-plussers met kwetsbaarheid.
Variatie in behandeling van hypertensie bij ouderen door huisartsen
Omdat het weinige bewijs dat er is voor de optimale behandeling van hypertensie bij 75-plus-
sers niet eenduidig is, luidde onze hypothese dat er verschillen in behandelstrategie tussen 
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huisartsen zouden kunnen zijn. In hoofdstuk 5 en 6 werd getracht deze verschillen in kaart 
te brengen, en werd bestudeerd wat de invloed van kwetsbaarheid op de behandeling van 
hypertensie bij 75-plussers door huisartsen in verschillende landen is. In deze internationale 
studies werd onderzocht of de verschillen verklaard konden worden door de voor het land 
specifieke cardiovasculaire ziektelast en levensverwachting.
In deze studie werden 2.543 huisartsen uit 29 verschillende landen in Europa, Brazilië, Israël 
en New Zeeland met behulp van case-vignetten, allemaal beschreven ze een 80-plusser zoals 
mevr. S. hoofdstuk 5 laat zien dat huisartsen uit verschillende landen hele verschillende be-
slissingen maakten over de behandeling van hypertensie bij deze patiënten. Het advies om te 
behandelen varieerde tussen de 34% en 88% per land. Kwetsbaarheid speelde een belangrijke 
rol in de afweging van huisartsen om met antihypertensiva te starten. In hoofdstuk 6 werden 
de verschillen tussen landen bestudeerd aan de hand van land-specifieke gezondheidsdata, 
waaronder de cardiovasculaire ziektelast en levensverwachting bij een leeftijd van 60 jaar. 
In landen met een hoge cardiovasculaire ziektelast waren huisartsen meer geneigd om te 
starten met antihypertensiva. Deze associatie werd beïnvloed door de land-specifieke levens-
verwachting voor zestigjaren; hoewel er een positieve associatie was in landen met een lage 
levensverwachting bij een leeftijd van 60 jaar, werd er geen associatie in landen met een hoge 
levensverwachting bij een leeftijd van 60 jaar gevonden.
De bevindingen uit hoofdstuk 5 en 6 bevestigden de hypothese dat huisartsen hypertensie 
bij ouderen niet uniform behandelen, en dat patiëntkenmerken, de nationale ziektelast van 
cardiovasculaire ziekten en levensverwachting een rol in de besluitvorming van de huisarts 
spelen. Beide studies hebben implicaties voor verder onderzoek en de klinische praktijk. Er is 
behoefte aan cohortstudies van hoge kwaliteit of (idealiter) nieuwe hypertensie trials waarin 
kwetsbare patiënten worden geïncludeerd om inzicht te krijgen in de rol van kwetsbaarheid bij 
de behandeling van hypertensie onder 75-plussers. Ook kwalitatieve studies zouden kunnen 
helpen om de gevonden variatie beter te begrijpen.
hoofdstuk 7 vat de belangrijkste bevindingen samen: 1) polyfarmacie komt vaak voor onder 
ouderen en hypertensie is een van de belangrijke determinant van polyfarmacie; 2) een lage 
SBD gedurende behandeling met antihypertensiva is geassocieerd met een toename van totale 
sterfte en cognitieve achteruitgang bij ouderen met kwetsbaarheid; 3) er is veel variatie in 
de manier waarop huisartsen uit 29 voornamelijk Europese landen besluiten om bij ouderen 
antihypertensiva te starten. Huisartsen behandelden kwetsbare ouderen minder vaak, maar 
met name in landen met een lage levensverwachting werd hun beslissing ook beïnvloed door 
de mate van cardiovasculaire ziektelast in het land.
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Deze bevindingen zijn besproken in de context van de huidige literatuur en de casus van mevr. 
S. Methodologische beperkingen zijn besproken, waaronder de belangrijkste beperkingen van 
associatie versus causaliteit, omgekeerde causaliteit en “confounding”. Als richting voor verder 
onderzoek worden wetenschappers aangemoedigd om de effectiviteit en veiligheid van het 
stoppen of verminderen van antihypertensiva (‘deprescribing’) om de SBD te verhogen in 
nieuwe trials te onderzoeken bij kwetsbare 75-plussers.
Vanuit een klinisch perspectief wijzen de resultaten van dit proefschrift in de richting van 
het herdefiniëren van de individuele streefwaarden voor SBD voor kwetsbare ouderen die 
antihypertensiva gebruiken.
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DeutsChe ZusAMMenFAssunG
ÄrztInnen stehen vor einem Dilemma, wenn sie den optimalen systolischen Blutdruck (SBD) 
bei älteren PatientInnen über 75-jährig festlegen sollen. Denn diese Menschen zeichnen sich 
durch grosse Unterschiede aus in Bezug auf kognitive und körperliche Funktionen: Einige 
sind sehr gesund, andere haben mehrere chronischen Krankheiten (Multimorbidität) und 
nehmen deswegen regelmässig mehrere Medikamente ein (d.h. haben Polypharmazie) oder 
sind gebrechlich.
Mit zunehmendem Alter steigt der Blutdruck als Folge der Versteifung der Blutgefässe. Es 
wurde viel darüber debattiert, ob eine Blutdrucksenkung auch im hohen Alter vorteilhaft ist. 
Die Meinungen gehen besonders bei über 75-jährigen PatientInnen auseinander, die von Mul-
timorbidität, Polypharmazie und/oder Gebrechlichkeit betroffen sind. Grosse randomisierte 
Studien konnten zwar zeigen, dass eine Blutdrucksenkung bei über 60-jährigen – und selbst 
bei über 80-jährigen - Vorteile bringen, indem Herzinfarkt-, Hirnschlag- und Sterberisiko 
abnahmen. Es gilt jedoch zu beachten, dass solche Studien häufig nicht auf alle PatientInnen 
übertragbar sind, denn typischerweise werden besonders multimorbide oder gebrechlich 
PatientInnen davon ausgeschlossen.
Gleichzeitig zeigen Beobachtungsstudien beunruhigende Folgen eines zu tiefen Blutdrucks: 
Mehrere Kohortenstudien konnten bei über 75-jährigen einen Zusammenhang zwischen 
tiefem Blutdruck und erhöhtem Sterberisiko und rascherer Abnahme der Kognition zeigen. 
Trotzdem halten aktuelle Richtlinien die ÄrztInnen an, den Blutdruck bei allen älteren Pa-
tientInnen auf Werte unter 130mmHg zu senken. Dies schürte Diskussionen über Nutzen 
und Risiken, wenn der Blutdruck bei über 75-jährigen mittels blutdrucksenkenden Medi-
kamenten (Antihypertensiva) gesenkt wird. Besonders bei gebrechlichen PatientInnen mit 
z.B. einem schwachen Händedruck oder komplexen Gesundheitsproblemen, welche in ihrem 
Alltag stark einschränkt leben.
kapitel 1 fasst dieses Dilemma anhand eines Patientenbeispiels zusammen. Frau S., eine 
90-jährige Frau mit Multimorbidität und Polypharmazie suchte ihren Hausarzt auf um 
ihren Blutdruck zu messen. Dieser betrug 154mmHg unter Antihypertensiva. Ihr Hausarzt 
möchte seine PatientInnen durch Antihypertensiva vor Hirnschlag und Herzinfarkt schützen. 
Gleichzeitig möchte er aber auch ihre kognitive und körperliche Leistungsfähigkeit sowie ihre 
Lebensqualität erhalten. Frau S. ist eine typische Patientin, die von Blutdruckstudien ausge-
schlossen wird. Wir wissen also nicht, ob sich die Ergebnisse von solchen randomisierten 
Studien auf sie übertragen lassen oder nicht.
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Diese Arbeit möchte zum Wissen über die Effekte einer Blutdrucksenkung bei gebrechlichen 
über 75-jährigen beizutragen. Sie hat drei Ziele: 1. Die Prävalenz von Polypharmazie bei 
älteren PatientInnen zu bestimmen. 2. Zu testen, ob es einen Zusammenhang gibt zwischen 
tiefem Blutdruck und Sterblichkeit, kognitiven und körperlichen Leistungsfähigkeit sowie der 
Lebensqualität bei PatientInnen unter blutdrucksenkender Therapie. 3. Zu verstehen, welche 
Rolle die Gebrechlichkeit im Entscheid von HausärztInnen aus verschiedenen Ländern spielt, 
wenn sie darüber entscheiden, ob sie ältere PatientInnen mit Antihypertensiva behandeln. 
Auch geht es darum zu untersuchen, ob eine länderspezifische Erhöhung von Herzkreislau-
ferkrankungen und die Lebenserwartung die Unterschiede zwischen den Ländern erklären.
Polypharmazie als Folge der Prävention von herzkreislaufkrankheiten
Die meisten Richtlinien zu chronischen Krankheiten betrachten Krankheiten einzeln und 
nicht im Zusammenhang mit anderen Krankheiten, an denen PatientInnen gleichzeitig lei-
den. HausärztInnen müssen sich aber auf Richtlinien verlassen können, um PatientInnen mit 
mehreren chronischen Krankheiten optimal behandeln zu können. Wenn aber bestehende 
Richtlinien bei diesen multimorbiden PatientInnen zur Anwendung kommen, steigt das Risi-
ko, dass es im Rahmen einer Polypharmazie zu potentiell nicht angebrachten Medikamenten 
kommt. Noch immer sind nicht alle Faktoren bekannt, die zu Polypharmazie führen.
In kapitel 2 beabsichtigten wir die Prävalenz von Polypharmazie in einer Zufallsstichprobe 
von 1002 PatientInnen zwischen 50 und 80 Jahren aus Schweizer Polikliniken zu bestimmen. 
Weiter wollten wir diejenigen PatientInnen identifizieren, die das höchste Risiko für Poly-
pharmazie haben, beispielsweise aufgrund einzelner Krankheiten oder zur Prävention von 
Herzkreislaufkrankheiten.
Wir fanden eine sehr hohe Prävalenz von 40% aller PatientInnen, welche von Polypharmazie 
betroffen waren. In der ältesten Gruppe (75-80-jährig) waren es sogar mehr als jeder zweite. 
Einige PatientInnen nahmen sogar 10 und mehr Medikamente längerfristig ein. Das Risiko 
einer Polypharmazie war sogar 9-fach erhöht bei älteren PatientInnen mit der Diagnose eines 
Bluthochdrucks.
Diese Studie unterstreicht die Wichtigkeit, dass jede medikamentöse Verschreibung kritisch 
hinterfragt werden sollte. Das Alter und die Anzahl chronischer Krankheiten gehören zu den 
Hauptfaktoren für Polypharmazie, aber genauso die Diagnose von Bluthochdruck. Haus-
ärztInnen müssen einen ausgewogenen Entscheid treffen und diesen zusammen mit ihren 
PatientInnen diskutieren, um festzulegen, welche Medikamente gestartet, weitergeführt, 
reduziert oder gestoppt werden.
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tiefer Blutdruck steht im Zusammenhang mit sterblichkeit und Abbau von 
kognition bei gebrechlichen Patientinnen mit komplexen Gesundheitsproblemen
Beobachtungsstudien fanden bereits einen Zusammenhang zwischen tiefem Blutdruck und 
Abbau der Kognition bei älteren, gebrechlichen PatientInnen mit Multimorbidität und Poly-
pharmazie. Es gab Spekulationen darüber ob der tiefe Blutdruck durch Antihypertensiva die 
hämodynamische Regulation zwischen Herz und Hirn stört und so die Kognition nachhaltig 
auch gestört wird. Ein Meilenstein stellte dabei eine Studie bei 80-jährigen mit Demenz oder 
Gedächtnisproblemen. Ein tiefer Blutdruck stand dabei im Zusammenhang mit einem Abbau 
der Kognition aber nur bei PatientInnen die unter Antihypertensiva standen. Bei PatientInnen 
ohne blutdrucksenkende Medikamente bestand kein solcher Zusammenhang. Ein Problem 
der Studie war jedoch, dass sie nur wenige PatientInnen umfasste und diese nur über eine 
kurze Zeit von weniger als ein Jahr verfolgt wurden.
In kapitel 3 und 4 untersuchten wir deswegen ältere PatientInnen mit blutdrucksenkenden 
Medikamenten auf einen Zusammenhang von Blutdruck, Sterblichkeit, geistiger und kör-
perlicher Leistungsfähigkeit sowie Lebensqualität. Wir untersuchten dabei gebrechliche und 
nicht-gebrechliche PatientInnen separat.
In kapitel 3 untersuchen wir Daten von der Leiden-85-plus Studie, einer Bevölkerungsbe-
zogenen prospektiven Kohortenstudie, wo alle 85-jährigen Bewohner aus Leiden eingeladen 
wurden und 599 teilnahmen. Bei Menschen unter blutdrucksenkender Therapie, fanden wir 
einen Zusammenhang zwischen tiefem Blutdruck und erhöhter Sterblichkeit sowie rasche-
rem kognitiven Abbau. Gebrechlichkeit, gemessen mittels Händedruck, veränderte diesen 
Zusammenhang aber: Wer gebrechlich war, zeigte auch einen vermehrten kognitiven Abbau 
bei tieferen Blutdruckwerten. Wer einen stärkeren Händedruck besass oder gar nicht mit 
Antihypertensiva behandelt wurde, zeigte diesen Zusammenhang nicht.
In ISCOPE, einer in kapitel 4 beschriebenen jüngeren Kohortenstudie mit über 75-jährigen 
(n=1266), die über ein ganzes Jahr lang verfolgt wurden, konnten wir erneut dieselben Zu-
sammenhänge bestätigen, jedoch ohne den negativen Effekt auf die Alltagsfunktion und die 
Lebensqualität. Erneut beeinflusste die Gebrechlichkeit die Resultate, diesmal gemessen dar-
an ob Studienteilnehmer komplexe Gesundheitsprobleme hatten oder nicht. Mit komplexen 
Gesundheitsproblemen, zeigten die PatientInnen einen beschleunigten kognitiven Abbau, 
wenn der Blutdruck zu tief war. Wie bei der Leiden-85-plus Studie gab es keinen solchen 
Zusammenhang bei Teilnehmern ohne Antihypertensiva.
Wir konnten also zeigen, dass höher eingestellte Blutdruckwerte unter Antihypertensiva 
einen besseren Effekt hatten auf Sterblichkeit und Kognition. Für Ärzte bedeutet dies, bei 
ihren PatientInnen individuell den Blutdruckzielwert einzustellen. Dies ist besonders wichtig 
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bei älteren PatientInnen, die gebrechlich und über 75-jährig sind. Für Forscher sehen wir den 
Nutzen darin, neue randomisierte Studien durchzuführen, um das Absetzen bzw. das Redu-
zieren (genannt „Deprescribing“) von Antihypertensiva bei gebrechlichen über 75-jährigen 
Menschen auf Nutzen und Sicherheit zu testen.
unterschiede in der Blutdrucksenkung bei älteren Patientinnen durch 
hausärztinnen
Weil das Wissen zur optimalen Blutdruckeinstellung bei über 75-jährigen Menschen mangel-
haft ist und Studien zu unterschiedlichen Resultaten kamen, vermuteten wir, dass dies auch 
zu unterschiedlichen Behandlungsabsichten bei HausärztInnen führen könnte. In kapitel 5 
und 6, untersuchen wir die Rolle von Gebrechlichkeit, wenn sich HausärztInnen aus ver-
schiedenen Ländern für oder gegen eine Blutdrucksenkung bei über 75-Jährigen entscheiden. 
Auch untersuchen wir, ob sich diese Unterschiede durch länderspezifische, unterschiedliche 
Häufigkeiten von Herzkreislauferkrankungen oder Lebenserwartungen erklären liessen.
Die Studie untersuchte 2543 HausärztInnen aus 29 Ländern Europas sowie Brasilien, Israel 
und Neuseeland. Wir entwickelten Fallbeispiele von Menschen wie Frau S., alle über 80 
Jahre alt, und fanden in kapitel 5, dass HausärztInnen bei den gleichen Fallbeispielen je nach 
Herkunftsland sehr unterschiedlich Antihypertensiva einsetzten. Es gab Länder in denen 
34% aller HausärztInnen Blutdrucksenker starten würden und 88% anderen Ländern. Wie 
vermutet spielte die Gebrechlichkeit eine wichtige Rolle in diesem Entscheidungsprozess.
In kapitel 6, untersuchten wir die gefundenen Länderunterschiede in Bezug auf die Häu-
figkeit von Herzkreislaufkrankheiten und Lebenserwartung ab 60 Jahren. Es zeigte sich, 
dass HausärztInnen häufiger eine blutdrucksenkende Therapie starteten in Ländern, wo 
Herzkreislaufkrankheiten häufiger auftraten. Jedoch nur, wenn in diesen Ländern gleichzeitig 
auch die Lebenserwartung tiefer war. In Ländern mit vergleichsweise hoher Lebenserwartung 
behandelten HausärztInnen unabhängig von der Häufigkeit von Herzkreislaufkrankheiten.
Beide Ergebnisse in kapitel 5 und 6 bestätigten die Hypothese, dass HausärztInnen den 
Blutdruck nicht einheitlich im hohen Alter behandeln. Patienteneigenschaften wie auch 
länderspezifische Unterschiede spielen dabei eine grosse Rolle wie auch im obengenannten 
Fall von Frau S. Beide Ergebnisse sind von grosser Bedeutung für die Forschung und die 
Praxis. Wichtig ist es qualitativ hochstehende Kohortenstudien oder (idealerweise) neue 
randomisierte Blutdruckstudien durchzuführen, die bewusst gebrechliche PatientInnen ein-
schliessen. Damit werden wir in Zukunft besser verstehen, welche Rolle die Gebrechlichkeit 
in der Behandlung von über 75-jährigen Menschen spielt. In Zukunft sollten Studien auch 
untersuchen, ob die Anwendung von Richtlinien die gefundenen Unterschiede erklären wie 
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HausärztInnen Blutdrucksenker einsetzen. Dabei können qualitative Studien helfen, diese 
Unterschiede besser zu verstehen.
kapitel 7 fasst die Hauptergebnisse dieser Arbeit zusammen: 1. Polypharmazie ist sehr häufig 
bei älteren Menschen und eine Diagnose von Bluthochdruck erhöht das Risiko dafür noch-
mals deutlich. 2. Tiefer Blutdruck steht im direkten Zusammenhang mit einer erhöhten Sterb-
lichkeit und einem rascheren Abbau der Kognition bei älteren gebrechlichen PatientInnen, 
wenn sie Blutdrucksenker einnehmen. 3. Wie vermutet besteht ein beträchtlicher Unterschied 
darin, wie HausärztInnen in verschiedenen Ländern blutdrucksenkende Medikamente bei 
älteren Menschen einsetzen. Bei gebrechlichen PatientInnen wurde der Blutdruck weniger 
häufig gesenkt. Dieser Entscheid wurde jedoch davon beeinflusst, wie häufig Herzkreislauf-
krankheiten in den entsprechenden 29 Ländern auftraten, besonders dort wo eine tiefere 
Lebenserwartung vorlag.
Weiter diskutierten wir die Resultate unserer Studien im Kontext der bestehenden Literatur 
und dem Fall von Frau S. Ebenso wurden methodologische Einschränkungen diskutiert wie 
z.B. die Problematik wann ein Zusammenhang auch wirklich kausal ist und nicht von umge-
kehrter Kausalität oder „Confounding“ erklärt werden könnte. Diese Arbeit hat weitereichen-
de Folgen auf Forschung und Praxis. Sie soll Forscher dazu ermutigen, neue randomisierte 
Studien durchzuführen, um Nutzen und Sicherheit zu evaluieren, wenn blutdrucksenkende 
Medikamente bei gebrechlichen über 75-jährigen PatientInnen reduziert oder gestoppt 
werden, um den Blutdruck wieder zu erhöhen. Für die Praxis empfiehlt sich besonders bei ge-
brechlichen älteren PatientInnen, die Blutdrucksenker einnehmen ein vorsichtiges Anpassen 
in Richtung höherer Blutdruckzielwerte.
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